Top
Overview
Introduction
Preclinical
Results
RCTs
Form
Bolus
Exclusions
Heterogeneity
Pooled Effects
Discussion
NIH
Perspective
Conclusion
 
Revisions
Methods and Data
Supplementary
References
 
Treatment studies
Treatment RCTs
Treatment form
Bolus treatment
RCT mortality
RCT ICU
Sufficiency studies
Treatment with exclusions
Treatment peer‑reviewed
Treatment mortality
Treatment ventilation
Treatment ICU admission
Treatment hospitalization
Treatment cases
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Vitamin D for COVID-19: real-time meta analysis of 330 studies (122 treatment studies and 208 sufficiency studies)

 
0 0.5 1 1.5+ All studies 37% 122 195,710 Improvement, Studies, Patients Relative Risk Mortality 36% 69 63,650 Ventilation 19% 21 8,642 ICU admission 45% 29 40,888 Hospitalization 19% 24 86,502 Cases 17% 30 145,598 RCTs 32% 30 42,446 RCT mortality 35% 17 2,271 RCT ICU 32% 13 36,438 Cholecalciferol 39% 42 8,259 Calcitriol etc. 69% 8 2,137 Bolus 21% 9 1,660 Ongoing 60% 33 4,573 Sufficiency 52% 208 320,831 Prophylaxis 31% 61 141,727 Early 60% 11 43,587 Late 45% 50 10,396 Vitamin D for COVID-19 c19early.org November 2024 after exclusions Favorsvitamin D Favorscontrol
Abstract
122 treatment studies show statistically significant lower risk for mortality, ICU admission, hospitalization, and cases. 62 studies from 58 independent teams in 22 countries show significantly lower risk.
Random effects meta-analysis with pooled effects using the most serious outcome reported shows 60% [40‑74%] and 37% [31‑42%] lower risk for early treatment and for all studies. Results are similar for higher quality studies, peer-reviewed studies, and mortality: early treatment - 68% [45‑82%], 57% [36‑71%], 68% [39‑84%]; all - 37% [31‑42%], 41% [35‑46%], 36% [28‑43%].
Late stage treatment with calcitriol/calcifediol and analogs is more effective than cholecalciferol: 69% [47‑82%] vs. 39% [27‑49%].
Ongoing treatment with multiple doses is more effective than single bolus doses: 60% [49‑69%] vs. 21% [-13‑45%]
0 0.5 1 1.5+ All studies 37% 122 195,710 Improvement, Studies, Patients Relative Risk Mortality 36% 69 63,650 Ventilation 19% 21 8,642 ICU admission 45% 29 40,888 Hospitalization 19% 24 86,502 Cases 17% 30 145,598 RCTs 32% 30 42,446 RCT mortality 35% 17 2,271 RCT ICU 32% 13 36,438 Cholecalciferol 39% 42 8,259 Calcitriol etc. 69% 8 2,137 Bolus 21% 9 1,660 Ongoing 60% 33 4,573 Sufficiency 52% 208 320,831 Prophylaxis 31% 61 141,727 Early 60% 11 43,587 Late 45% 50 10,396 Vitamin D for COVID-19 c19early.org November 2024 after exclusions Favorsvitamin D Favorscontrol
208 sufficiency studies show a strong association between vitamin D sufficiency and outcomes, with 52% [48‑56%] lower risk for higher levels.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. The quality of non-prescription supplements can vary widely1,2.
All data and sources to reproduce this paper are in the appendix. 19 other meta analyses show significant improvements with vitamin D treatment for mortality3-16, mechanical ventilation3,8,9,14,17,18, ICU admission3,5,8,9,12,14,16-20, hospitalization7,14, severity4,6,8,13,21, and cases10,20,21.
Evolution of COVID-19 clinical evidence Meta analysis results over time Vitamin D p<0.0000000001 early treatment Acetaminophen p=0.00000029 2020 2021 2022 2023 2024 Lowerrisk Higherrisk c19early.org November 2024 100% 50% 0% -50%
Vitamin D for COVID-19 — Highlights
Vitamin D reduces risk with very high confidence for mortality, ICU admission, hospitalization, recovery, cases, viral clearance, and in pooled analysis, high confidence for progression, and low confidence for ventilation.
8th treatment shown effective with ≥3 clinical studies in October 2020, now with p < 0.00000000001 from 122 studies, and recognized in 9 countries.
Outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor.
Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 109 treatments.
A
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Annweiler 89% 0.11 [0.03-0.48] 80,000IU death 10/57 5/9 Improvement, RR [CI] Dose (5d) Treatment Control Annweiler 63% 0.37 [0.06-2.21] 80,000IU death 3/16 10/32 Burahee 93% 0.07 [0.01-0.54] 400,000IU death 0/12 2/2 Asimi 97% 0.03 [0.00-0.44] 10,000IU ventilation 0/270 9/86 CT​1 Sánchez-Zuno (RCT) 89% 0.11 [0.01-0.91] 50,000IU severe case 0/22 4/20 Efird 49% 0.51 [0.23-1.17] varies death 11/544 413/15,794 Valecha 87% 0.13 [0.01-2.43] 5,000IU ICU 0/30 3/25 CT​1 Khan (RCT) 33% 0.67 [0.37-1.19] 1,800IU no recov. 10/25 15/25 CT​1 Hunt 47% 0.53 [0.37-0.77] n/a death 43/1,019 1,569/25,489 Said (RCT) 42% 0.58 [0.09-3.47] 10,000IU recovery 30 (n) 30 (n) Din Ujjan (RCT) 29% 0.71 [0.50-1.03] 1,800IU no recov. 15/25 21/25 CT​1 Tau​2 = 0.21, I​2 = 62.3%, p < 0.0001 Early treatment 60% 0.40 [0.26-0.60] 92/2,050 2,051/41,537 60% lower risk Tan 80% 0.20 [0.04-0.93] 5,000IU oxygen 3/17 16/26 CT​1 Improvement, RR [CI] Dose (5d) Treatment Control Krishnan 19% 0.81 [0.49-1.34] n/a death 8/16 84/136 COVIDIOL Entrenas Ca.. (RCT) 85% 0.15 [0.01-2.93] 0.8mg (c) death 0/50 2/26 SHADE Rastogi (RCT) 53% 0.47 [0.24-0.92] 300,000IU viral+ 6/16 19/24 Murai (DB RCT) -49% 1.49 [0.55-4.05] 200,000IU death 9/119 6/118 Ling 80% 0.20 [0.08-0.48] 40,000IU death 73 (n) 253 (n) Jevalikar 82% 0.18 [0.02-1.69] 60,000IU death 1/128 3/69 Giannini 37% 0.63 [0.35-1.09] 400,000IU death/ICU 14/36 29/55 Nogués (QR) 79% 0.21 [0.10-0.43] 0.8mg (c) death 21/447 62/391 Lohia 11% 0.89 [0.32-1.89] n/a death 26 (n) 69 (n) Mazziotti 19% 0.81 [0.45-1.47] varies death 116 (n) 232 (n) Elhadi (ICU) 23% 0.77 [0.44-1.32] n/a death 7/15 274/450 ICU patients Alcala-Diaz 81% 0.19 [0.04-0.83] 0.8mg (c) death 4/79 90/458 Güven (ICU) 25% 0.75 [0.37-1.24] 300,000IU death 43/113 30/62 ICU patients Assiri (ICU) -66% 1.66 [0.25-7.87] n/a death 12/90 2/28 ICU patients Soliman (RCT) 63% 0.37 [0.09-2.78] 200,000IU death 7/40 3/16 Elamir (RCT) 86% 0.14 [0.01-2.63] 2.5μg (t) death 0/25 3/25 Yildiz 81% 0.19 [0.04-0.91] 300,000IU death 1/37 24/170 Maghbooli (DB RCT) 40% 0.60 [0.15-2.38] 125μg (c) death 3/53 5/53 Leal-Martínez (RCT) 86% 0.14 [0.03-0.80] 20,000IU death 1/40 7/40 CT​1 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] 600,000IU death 0/30 4/30 ICU patients CT​1 Baguma 97% 0.03 [0.00-0.54] n/a death 23 (n) 458 (n) Mahmood 30% 0.70 [0.47-1.04] varies death 45/238 31/114 REsCue Bishop (DB RCT) 85% 0.15 [0.01-2.78] 1020μg (c) progression 0/65 3/69 COVID-VIT-D Cannata-An.. (RCT) -44% 1.44 [0.76-2.72] 100,000IU death 22/274 15/269 Zangeneh (ICU) -26% 1.26 [0.73-2.16] n/a death n/a n/a ICU patients Fiore 93% 0.07 [0.07-0.63] 200,000IU death 3/58 11/58 CARED Mariani (DB RCT) -124% 2.24 [0.44-11.3] 500,000IU death 5/115 2/103 Baykal 22% 0.78 [0.41-1.47] 300,000IU death 7/18 28/56 Shade-S Singh (DB RCT) 45% 0.55 [0.31-0.99] 600,000IU death 11/45 20/45 Shahid 38% 0.62 [0.47-0.82] n/a death 705 (n) 773 (n) Karonova (RCT) 86% 0.14 [0.01-2.66] 50,000IU ICU 0/56 3/54 Zurita-C.. (SB RCT) 79% 0.21 [0.03-1.59] 10,000IU death 1/20 6/25 De Niet (DB RCT) 65% 0.35 [0.04-3.10] 100,000IU death 1/21 3/22 Fairfield -9% 1.09 [1.04-1.12] n/a death population-based cohort Lakkireddy (RCT) 61% 0.39 [0.08-1.91] 300,000IU death 2/44 5/43 see notes Hafez 94% 0.06 [0.00-1.29] 150,000IU death 0/7 12/30 Saheb Shari.. (ICU) 36% 0.64 [0.46-0.90] 50,000IU ICU 20 (n) 25 (n) ICU patients Karimpour-Razke.. 79% 0.21 [0.10-0.45] n/a death 10/124 93/329 Hafezi (ICU) 63% 0.37 [0.14-0.94] 50,000IU death 8/43 12/37 ICU patients COVID-VIT Bychinin (DB RCT) 27% 0.73 [0.47-1.14] 80,000IU death 19/52 27/54 ICU patients Domazet B.. (RCT) 21% 0.79 [0.55-1.13] 50,000IU death 30/75 39/77 ICU patients Salman (RCT) 60% 0.40 [0.16-1.00] 20,000IU death 6/150 15/150 Shamsi 58% 0.42 [0.06-2.95] n/a death 1/17 23/166 Mingiano 39% 0.61 [0.38-0.99] 900μg (c) death 13/56 88/232 Al Sulaiman (ICU) -22% 1.22 [0.87-1.71] n/a death 72/144 62/144 ICU patients Ogasawara 67% 0.33 [0.01-8.01] 5μg (p) death 0/54 1/54 Seely (DB RCT) 48% 0.52 [0.10-2.71] 55,000IU progression 2/42 4/44 CT​1 Milan 47% 0.53 [0.22-1.31] death 9/122 8/58 Sanz (DB RCT) 80% 0.20 [0.01-3.74] 50,000IU death 0/11 2/11 Tau​2 = 0.22, I​2 = 79.5%, p < 0.0001 Late treatment 45% 0.55 [0.46-0.67] 407/4,165 1,176/6,231 45% lower risk All studies 48% 0.52 [0.43-0.62] 499/6,215 3,227/47,768 48% lower risk Vitamin D COVID-19 early and late treatment studies c19early.org November 2024 Tau​2 = 0.24, I​2 = 80.9%, p < 0.0001 Effect extraction pre-specified(most serious outcome, see appendix) 1 CT: study uses combined treatment Favors vitamin D Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Annweiler 89% death Improvement Relative Risk [CI] Annweiler 63% death Burahee 93% death Asimi 97% ventilation CT​1 Sánchez-Zuno (RCT) 89% severe case Efird 49% death Valecha 87% ICU admission CT​1 Khan (RCT) 33% recovery CT​1 Hunt 47% death Said (RCT) 42% recovery Din Ujjan (RCT) 29% recovery CT​1 Tau​2 = 0.21, I​2 = 62.3%, p < 0.0001 Early treatment 60% 60% lower risk Tan 80% oxygen therapy CT​1 Krishnan 19% death COVIDIOL Entrenas C.. (RCT) 85% death SHADE Rastogi (RCT) 53% viral- Murai (DB RCT) -49% death Ling 80% death Jevalikar 82% death Giannini 37% death/ICU Nogués (QR) 79% death Lohia 11% death Mazziotti 19% death Elhadi (ICU) 23% death ICU patients Alcala-Diaz 81% death Güven (ICU) 25% death ICU patients Assiri (ICU) -66% death ICU patients Soliman (RCT) 63% death Elamir (RCT) 86% death Yildiz 81% death Maghbooli (DB RCT) 40% death Leal-Martí.. (RCT) 86% death CT​1 Beigm.. (SB RCT) 89% death ICU patients CT​1 Baguma 97% death Mahmood 30% death REsCue Bishop (DB RCT) 85% progression COVID-VIT-D Cannata-A.. (RCT) -44% death Zangeneh (ICU) -26% death ICU patients Fiore 93% death CARED Mariani (DB RCT) -124% death Baykal 22% death Shade-S Singh (DB RCT) 45% death Shahid 38% death Karonova (RCT) 86% ICU admission Zurita-.. (SB RCT) 79% death De Niet (DB RCT) 65% death Fairfield -9% death Lakkireddy (RCT) 61% death see notes Hafez 94% death Saheb Shar.. (ICU) 36% ICU admission ICU patients Karimpour-Razk.. 79% death Hafezi (ICU) 63% death ICU patients COVID-VIT Bychinin (DB RCT) 27% death ICU patients Domazet .. (RCT) 21% death ICU patients Salman (RCT) 60% death Shamsi 58% death Mingiano 39% death Al Sulaiman (ICU) -22% death ICU patients Ogasawara 67% death Seely (DB RCT) 48% progression CT​1 Milan 47% death Sanz (DB RCT) 80% death Tau​2 = 0.22, I​2 = 79.5%, p < 0.0001 Late treatment 45% 45% lower risk All studies 48% 48% lower risk Vitamin D C19 early and late treatment c19early.org November 2024 Tau​2 = 0.24, I​2 = 80.9%, p < 0.0001 Protocol pre-specified/rotate for details1 CT: study uses combined treatment Favors vitamin D Favors control
B
Loading..
Figure 1. A. Random effects meta-analysis of treatment studies. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. Simplified dosages are shown for comparison, these are the total dose in the first five days for treatment, and the monthly dose for prophylaxis. Calcifediol, calcitriol, and paricalcitol treatment are indicated with (c), (t), and (p). For details of effect extraction and full dosage information see the appendix. B. Timeline of results in vitamin D treatment studies. The marked dates indicate the time when efficacy was known with a statistically significant improvement of ≥10% from ≥3 studies for pooled outcomes, one or more specific outcome, pooled outcomes in RCTs, and one or more specific outcome in RCTs. Efficacy based on RCTs only was delayed by 10.8 months, compared to using all studies. Efficacy based on specific outcomes in RCTs was delayed by 10.6 months, compared to using pooled outcomes in RCTs.
Introduction
SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological injury22-32 and cognitive deficits24,29, cardiovascular complications33-35, organ failure, and death. Minimizing replication as early as possible is recommended.
SARS-CoV-2 infection and replication involves the complex interplay of 50+ host and viral proteins and other factorsA,36-41, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 8,000 compounds may reduce COVID-19 risk42, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.
We analyze all significant controlled studies of vitamin D for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We perform random-effects meta analysis for all treatment studies, Randomized Controlled Trials, peer-reviewed studies, studies using cholecalciferol vs. calcifediol/calcitriol and analogs, studies using large bolus doses vs. ongoing treatment, higher quality studies, and for specific outcomes: mortality, mechanical ventilation, ICU admission, hospitalization, and case results. Results are presented for prophylaxis, early treatment, and late treatment. Separately, we perform random-effects meta analysis for studies that analyze outcomes based on vitamin D sufficiency (non-treatment studies).
Vitamin D has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function43-46. Vitamin D inhibits SARS-CoV-2 replication in vitro47,48, mitigates lung inflammation, damage, and lethality in mice with an MHV-3 model for β-CoV respiratory infections47,48, reduces SARS-CoV-2 replication in nasal epithelial cells via increased type I interferon expression49, downregulates proinflammatory cytokines IL-1β and TNF-α in SARS-CoV-2 spike protein-stimulated cells50, attenuates nucleocapsid protein-induced hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway51, may be neuroprotective by protecting the blood-brain barrier, reducing neuroinflammation, and via immunomodulatory effects52, downregulates ACE2 and TMPRSS2 in human trophoblasts and minimizes spike protein-induced inflammation53, minimizes platelet aggregation mediated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling54, and improves regulatory immune cell levels and control of proinflammatory cytokines in severe COVID-1955. Symptomatic COVID-19 is associated with a lower frequency of natural killer (NK) cells and vitamin D has been shown to improve NK cell activity56,57.
Studies have shown efficacy with vitamin D for influenza58, RSV58, and acute respiratory tract infections59-61.
Vitamin D is a steroid hormone that helps regulate the immune system by binding to specific receptors and activating genes involved in immune defense. It increases the production of antimicrobial proteins, like cathelicidin and defensins, which fight a variety of pathogens, including bacteria, viruses, and fungi. Vitamin D supports the immune system by boosting our natural defenses and promoting healthy cell connections. It helps clear respiratory pathogens through processes like apoptosis and autophagy and regulates toll-like receptors, which play a key role in immunity. Vitamin D also aids in immune cell maturation, balances inflammation, and reduces the production of proinflammatory cytokines. Vitamin D has been shown to downregulate angiotensin-converting enzyme-2 (ACE-2) receptors, which play a role in COVID-19 infection. By suppressing the production of ACE-2 and related molecules, vitamin D increases antioxidant and anti-inflammatory effects, enhances antimicrobial defenses, reduces cytokine storms, and promotes a protective immune response, all of which help decrease the severity of the disease. Vitamin D was first identified in relation to bone health, but is now known to have multiple functions, including an important role in the immune system62,63. For example, Quraishi et al. show a strong association between pre-operative vitamin D levels and hospital-acquired infections, as shown in Figure 2.
Figure 2. Risk of hospital-acquired infections as a function of pre-operative vitamin D levels, from Quraishi et al.
Vitamin D undergoes two conversion steps before reaching the biologically active form as shown in Figure 3. The first step is conversion to calcidiol, or 25(OH)D, in the liver. The second is conversion to calcitriol, or 1,25(OH)2D, which occurs in the kidneys, the immune system, and elsewhere. Calcitriol is the active, steroid-hormone form of vitamin D, which binds with vitamin D receptors found in most cells in the body. There is a significant delay involved in the conversion from cholecalciferol, therefore calcifediol (calcidiol) or calcitriol may be preferable for treatment.
Figure 3. Simplified view of vitamin D sources and conversion.
Many vitamin D studies analyze outcomes based on serum vitamin D levels which may be maintained via sun exposure, diet, or supplementation. We refer to these studies as sufficiency studies, as they typically present outcomes based on vitamin D sufficiency. These studies do not establish a causal link between vitamin D and outcomes. In general, low vitamin D levels are correlated with many other factors that may influence COVID-19 susceptibility and severity. Therefore, beneficial effects found in these studies may be due to factors other than vitamin D. On the other hand, if vitamin D is causally linked to the observed benefits, it is possible that adjustments for correlated factors could obscure this relationship. COVID-19 disease may also affect vitamin D levels65, suggesting additional caution in interpreting results for studies where the vitamin D levels are measured during the disease. For these reasons, we analyze sufficiency studies separately from treatment studies. We include all sufficiency studies that provide a comparison between two groups with low and high levels. Some studies only provide results as a function of change in vitamin D levels66-68, which may not be indicative of results for deficiency/insufficiency versus sufficiency (increasing already sufficient levels may be less useful for example). Some studies only show the average vitamin D level for patients in different groups69-109, most of which show lower D levels for worse outcomes. Other studies analyze vitamin D status and outcomes in geographic regions110-117, all finding worse outcomes to be more likely with lower D levels.
Sufficiency studies vary widely in terms of when vitamin D levels were measured, the cutoff level used, and the population analyzed (for example studies with hospitalized patients exclude the effect of vitamin D on the risk of hospitalization). We do not analyze sufficiency studies in more detail because there are many controlled treatment studies that provide better information on the use of vitamin D as a treatment for COVID-19. A more detailed analysis of sufficiency studies can be found in Chiodini et al. Mishra et al. present a systematic review and meta analysis showing that vitamin D levels are significantly associated with COVID-19 cases.
For studies regarding treatment with vitamin D, we distinguish three stages as shown in Figure 4. Prophylaxis refers to regularly taking vitamin D before being infected in order to minimize the severity of infection. Due to the mechanism of action, vitamin D is unlikely to completely prevent infection, although it may prevent infection from reaching a level detectable by PCR. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.
Figure 4. Treatment stages.
Preclinical Research
Vitamin D inhibits SARS-CoV-2 replication in vitro47,48, mitigates lung inflammation, damage, and lethality in mice with an MHV-3 model for β-CoV respiratory infections47,48, reduces SARS-CoV-2 replication in nasal epithelial cells via increased type I interferon expression49, downregulates proinflammatory cytokines IL-1β and TNF-α in SARS-CoV-2 spike protein-stimulated cells50, attenuates nucleocapsid protein-induced hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway51, may be neuroprotective by protecting the blood-brain barrier, reducing neuroinflammation, and via immunomodulatory effects52, downregulates ACE2 and TMPRSS2 in human trophoblasts and minimizes spike protein-induced inflammation53, and minimizes platelet aggregation mediated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling54.
7 In Silico studies support the efficacy of vitamin D120-126.
11 In Vitro studies support the efficacy of vitamin D47-51,53,54,127-130.
3 In Vivo animal studies support the efficacy of vitamin D48,51,131.
Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.
Results
Table 1 summarizes the results for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, with different exclusions, for specific outcomes, and for sufficiency (non-treatment) studies. Table 2 shows results by treatment stage. Figure 5 and Figure 6 show individual results for treatment studies and sufficiency studies, and by treatment stage. Figure 7, 8, 9, 10, 11, 12, and 13 show forest plots for treatment studies with pooled effects, peer-reviewed studies, cholecalciferol studies, calcifediol/calcitriol studies, and for studies reporting mortality, mechanical ventilation, ICU admission, hospitalization, and case results only. Figure 14 shows a forest plot for random effects meta-analysis of sufficiency (non-treatment) studies.
Table 1. Random effects meta-analysis for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, with different exclusions, for specific outcomes, and for sufficiency (non-treatment) studies. Results show the percentage improvement with treatment and the 95% confidence interval. * p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001.
Improvement Studies Patients Authors
All studies37% [31‑42%] p < 0.0001
****
122 195,710 1,228
Exc. late treatmentExc. late48% [38‑57%] p < 0.0001
****
61 53,983 580
After exclusions41% [35‑46%] p < 0.0001
****
86 171,679 900
Peer-reviewed studiesPeer-reviewed37% [31‑42%] p < 0.0001
****
116 194,092 1,180
Randomized Controlled TrialsRCTs32% [20‑42%] p < 0.0001
****
30 42,446 351
RCTs after exclusionsRCTs w/exc.43% [27‑55%] p < 0.0001
****
21 41,123 263
Cholecalciferol35% [29‑41%] p < 0.0001
****
108 186,371 1,057
Calcifediol/calcitriolCalcifediol52% [32‑66%] p < 0.0001
****
14 9,339 171
Mortality36% [28‑43%] p < 0.0001
****
69 63,650 668
VentilationVent.19% [-3‑36%] p = 0.08921 8,642 228
ICU admissionICU45% [28‑58%] p < 0.0001
****
29 40,888 317
HospitalizationHosp.19% [9‑29%] p = 0.00059
***
24 86,502 243
Recovery26% [16‑34%] p < 0.0001
****
13 1,230 123
Cases17% [9‑24%] p = 0.00016
***
30 145,598 338
Viral52% [30‑67%] p = 0.00014
***
4 200 26
RCT mortality35% [12‑52%] p = 0.0055
**
17 2,271 192
RCT ventilationRCT vent.21% [3‑35%] p = 0.024
*
11 5,684 133
RCT ICU admissionRCT ICU32% [9‑50%] p = 0.01
**
13 36,438 172
RCT hospitalizationRCT hosp.19% [5‑32%] p = 0.012
*
9 40,013 114
Sufficiency52% [48‑56%] p < 0.0001
****
208 320,831 1,760
Table 2. Random effects meta-analysis results by treatment stage. Results show the percentage improvement with treatment, the 95% confidence interval, and the number of studies for the stage.treatment and the 95% confidence interval. * p<0.05  ** p<0.01  *** p<0.001  **** p<0.0001.
Early treatment Late treatment Prophylaxis
All studies60% [40‑74%]
****
45% [33‑54%]
****
31% [24‑38%]
****
Exc. late treatmentExc. late60% [40‑74%]
****
45% [33‑54%]
****
After exclusions68% [45‑82%]
****
63% [52‑72%]
****
30% [22‑36%]
****
Peer-reviewed studiesPeer-reviewed57% [36‑71%]
****
44% [32‑54%]
****
32% [24‑39%]
****
Randomized Controlled TrialsRCTs32% [8‑50%]
*
38% [19‑52%]
***
25% [-9‑48%]
RCTs after exclusionsRCTs w/exc.65% [-65‑92%]53% [34‑66%]
****
25% [-9‑48%]
Cholecalciferol60% [40‑74%]
****
39% [27‑49%]
****
31% [23‑38%]
****
Calcifediol/calcitriolCalcifediol69% [47‑82%]
****
36% [13‑54%]
**
Mortality68% [39‑84%]
***
43% [30‑54%]
****
23% [9‑34%]
**
VentilationVent.97% [56‑100%]
*
11% [-12‑30%]38% [-3‑63%]
ICU admissionICU87% [-143‑99%]45% [24‑60%]
***
46% [22‑63%]
**
HospitalizationHosp.90% [-453‑100%]18% [8‑28%]
***
13% [-4‑27%]
Recovery31% [7‑49%]
*
26% [13‑37%]
***
Cases17% [9‑24%]
***
Viral52% [24‑70%]
**
53% [8‑76%]
*
RCT mortality35% [12‑52%]
**
RCT ventilationRCT vent.23% [4‑39%]
*
-95% [-3010‑88%]
RCT ICU admissionRCT ICU35% [10‑52%]
**
-0% [-301‑75%]
RCT hospitalizationRCT hosp.22% [11‑31%]
***
-26% [-92‑17%]
Loading..
Figure 5. Results for treatment and sufficiency studies.
Loading..
Figure 6. Results by treatment stage.
Loading..
Loading..
Figure 7. Random effects meta-analysis for treatment studies. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.
Loading..
Figure 8. Random effects meta-analysis for peer-reviewed treatment studies. Zeraatkar et al. analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier. Davidson et al. also showed no important difference between meta analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.
Loading..
Loading..
Figure 9. Random effects meta-analysis for treatment mortality results only.
Loading..
Figure 10. Random effects meta-analysis for treatment mechanical ventilation results only.
Loading..
Figure 11. Random effects meta-analysis for treatment ICU admission results only.
Loading..
Figure 12. Random effects meta-analysis for treatment hospitalization results only.
Loading..
Figure 13. Random effects meta-analysis for treatment COVID-19 case results only.
Loading..
Figure 14. Random effects meta-analysis for sufficiency studies. This plot pools studies with different effects, different vitamin D cutoff levels and measurement times, and studies may be within hospitalized patients, excluding the risk of hospitalization. However, the prevalence of positive effects is notable.
Randomized Controlled Trials (RCTs)
Results restricted to Randomized Controlled Trials (RCTs), after exclusions, and for specific outcomes are shown in Figure 15, 16, 17, 18, and 19.
Loading..
Figure 15. Random effects meta-analysis for Randomized Controlled Trials only. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.
Loading..
Figure 16. Random effects meta-analysis for RCTs after exclusions. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.
Loading..
Figure 17. Random effects meta-analysis for RCT mortality results.
Loading..
Figure 18. Random effects meta-analysis for RCT ICU admission results.
Loading..
Figure 19. Random effects meta-analysis for RCT hospitalization results.
RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases134, and analysis of double-blind RCTs has identified extreme levels of bias135. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.
RCTs are expensive and many RCTs are funded by pharmaceutical companies or interests closely aligned with pharmaceutical companies. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example Als-Nielsen et al. analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.
High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 109 treatments we have analyzed, 65% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.
RCTs have a bias against finding an effect for interventions that are widely available — patients that believe they need the intervention are more likely to decline participation and take the intervention. RCTs for vitamin D are more likely to enroll low-risk participants that do not need treatment to recover, making the results less applicable to clinical practice. This bias is likely to be greater for widely known treatments, and may be greater when the risk of a serious outcome is overstated. This bias does not apply to the typical pharmaceutical trial of a new drug that is otherwise unavailable.
For COVID-19, observational study results do not systematically differ from RCTs, RR 1.00 [0.92‑1.08] across 109 treatments137.
Evidence shows that observational studies can also provide reliable results. Concato et al. found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. Anglemyer et al. analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. We performed a similar analysis across the 109 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 1.00 [0.92‑1.08]. Similar results are found for all low-cost treatments, RR 1.02 [0.92‑1.12]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.82‑1.03]. Details can be found in the supplementary data. Lee et al. showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see141,142.
Currently, 48 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. Of these, 60% have been confirmed in RCTs, with a mean delay of 7.1 months (68% with 8.2 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.
We need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta analyses.
Cholecalciferol vs. calcifidiol/calcitriol and analogs
Figure 20 shows the results for studies using cholecalciferol and studies using calcifediol/calcitriol and analogs. This shows late treatment studies as there are currently no early treatment studies using calcifediol/calcitriol and analogs. Calcifediol, calcitriol and analogs show improved results, as expected given the long conversion delays with cholecalciferol. However they were rarely used, despite wide availability.
Loading..
Figure 20. Comparison of cholecalciferol with calcifediol/calcitriol and analogs for late treatment studies, showing improved results with calcifediol/calcitriol and analogs.
Bolus dose vs. multiple doses
Pharmacokinetics and the potential side effects of high bolus doses suggest that ongoing treatment spread over time is more appropriate. One potential advantage of single dose treatment is patient compliance, however this does not apply to COVID-19 trials with ongoing medical care.
Research has shown that lower dose regular treatment with vitamin D is more effective than intermittent high-dose bolus treatment for various conditions, including rickets and acute respiratory infections60,143,144. The biological mechanisms supporting these findings involve the induction of enzymes such as 24-hydroxylase and fibroblast growth factor 23 (FGF23) by high-dose bolus treatments. These enzymes play roles in inactivating vitamin D, which can paradoxically reduce levels of activated vitamin D and suppress its activation for extended periods post-dosage. Evidence indicates that 24-hydroxylase activity may remain elevated for several weeks following a bolus dose, leading to reduced levels of the activated form of vitamin D. Additionally, FGF23 levels can increase for at least three months after a large bolus dose, which also contributes to the suppression of vitamin D activation143.
Figure 21 shows the results for studies using a single bolus dose ≥100,000IU and for studies where treatment continues with multiple doses. Improved results are seen with multiple doses. This analysis is a simplification - for both bolus doses and ongoing treatment, individual trials may use doses that are significantly lower or higher than optimal.
Yang et al. also show improved results with multiple dose treatment.
Loading..
Figure 21. Comparison of bolus vs. multiple dose studies, showing improved results with multiple doses.
Exclusions
To avoid bias in the selection of studies, we include all studies in the main analysis, with the exception of Espitia-Hernandez. This study uses a combined protocol with another medication that shows high effectiveness when used alone. Authors report on viral clearance, showing 100% clearance with treatment and 0% for the control group. Based on the known mechanisms of action, the combined medication is likely to contribute more to the improvement.
Here we show the results after excluding studies with critical issues.
Murai is a very late stage study (mean 10 days from symptom onset, with 90% on oxygen at baseline), with poorly matched arms in terms of gender, ethnicity, hypertension, diabetes, and baseline ventilation, all of which favor the control group. Further, this study uses cholecalciferol, which may be especially poorly suited for such a late stage. Cannata-Andía, Mariani are also very late stage studies using cholecalciferol.
The studies excluded are as follows, and the resulting forest plot is shown in Figure 22.
Abdulateef, unadjusted results with no group details.
Al Sulaiman, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Arboleda, unadjusted results with no group details.
Asimi, excessive unadjusted differences between groups.
Assiri, unadjusted results with no group details.
Aweimer, unadjusted results with no group details.
Baykal, unadjusted results with no group details; significant confounding by time possible due to separation of groups in different time periods.
Beigmohammadi, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Bychinin, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Campi, significant unadjusted differences between groups.
Cannata-Andía, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Din Ujjan, based on dosages and previous research, combined treatments may contribute more to the effect seen.
Domazet Bugarin, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Elhadi, unadjusted results with no group details.
Fairfield, substantial unadjusted confounding by indication likely.
Guldemir, unadjusted results with no group details.
Güven, very late stage, ICU patients.
Hafezi, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Holt, significant unadjusted confounding possible.
Junior, unadjusted results with no group details.
Khan, based on dosages and previous research, combined treatments may contribute more to the effect seen.
Krishnan, unadjusted results with no group details.
Leal-Martínez, combined treatments may contribute more to the effect seen.
Lázaro, very few events; unadjusted results with no group details; minimal details provided.
Mahmood, unadjusted results with no group details; substantial unadjusted confounding by indication likely.
Mahmood, unadjusted results with no group details; substantial unadjusted confounding by indication likely.
Mohseni, unadjusted results with no group details.
Murai, very late stage, >50% on oxygen/ventilation at baseline; very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Pecina, unadjusted results with no group details.
Saheb Sharif-Askari (B), very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Shahid, minimal details provided.
Shamsi, unadjusted results with no group details.
Shehab, unadjusted results with no group details.
Ullah, significant unadjusted confounding possible.
Zangeneh, very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Zurita-Cruz, randomization resulted in significant baseline differences that were not adjusted for.
Loading..
Figure 22. Random effects meta-analysis excluding studies with significant issues. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.
Heterogeneity
Heterogeneity in COVID-19 studies arises from many factors including:
The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours182,183. Baloxavir marboxil studies for influenza also show that treatment delay is critical — Ikematsu et al. report an 86% reduction in cases for post-exposure prophylaxis, Hayden et al. show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and Kumar (B) et al. report only 2.5 hours improvement for inpatient treatment.
Table 3. Studies of baloxavir marboxil for influenza show that early treatment is more effective.
Treatment delayResult
Post-exposure prophylaxis86% fewer cases184
<24 hours-33 hours symptoms185
24-48 hours-13 hours symptoms185
Inpatients-2.5 hours to improvement186
Figure 23 shows a mixed-effects meta-regression of efficacy as a function of treatment delay in COVID-19 vitamin D studies, with group estimates for different stages when a specific value is not provided. For comparison, Figure 24 shows a meta-regression for all studies providing specific values across 109 treatments. Efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.
Loading..
Figure 24. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 vitamin D studies.
Loading..
Figure 24. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 109 treatments.
Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in López-Medina et al.
Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants188, for example the Gamma variant shows significantly different characteristics189-192. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants193,194.
Effectiveness may depend strongly on the dosage, treatment regimen, and the form of vitamin D used (cholecalciferol, calcifediol, or calcitriol).
The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic195-206, therefore efficacy may depend strongly on combined treatments.
The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. Williams et al. analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. Xu et al. analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer. Non-prescription supplements may show very wide variations in quality1,2.
Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.
The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations with a specific form and dosage of vitamin D. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.
Vitamin D studies vary widely in all the factors above, which makes the consistently positive results even more remarkable. A failure to detect an association after combining heterogeneous studies does not mean the treatment is not effective (it may only work in certain cases), however the reverse is not true — an identified association is valid, although the magnitude of the effect may be larger for more optimal cases, and lower for less optimal cases. While we present results for all studies in this paper, the individual outcome, form of vitamin D, and treatment time analyses are more relevant for specific use cases.
Pooled Effects
This section validates the use of pooled effects for COVID-19, which enables earlier detection of efficacy, however note that pooled effects are no longer required for vitamin D as of October 2020. Efficacy is now known for vitamin D based on specific outcomes for all studies and when restricted to RCTs. Efficacy based on specific outcomes in RCTs was delayed by 10.6 months, compared to using pooled outcomes in RCTs.
For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. "The studies reported different outcomes" is not a good reason for disregarding results.
We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.
Another way to view pooled analysis is that we are using more of the available information. Logically we should, and do, use additional information. For example dose-response and treatment delay-response relationships provide significant additional evidence of efficacy that is considered when reviewing the evidence for a treatment.
Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster collection of evidence.
For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.
Analysis of the the association between different outcomes across studies from all 109 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Figure 25 shows that lower hospitalization is very strongly associated with lower mortality (p < 0.000000000001). Similarly, Figure 26 shows that improved recovery is very strongly associated with lower mortality (p < 0.000000000001). Considering the extremes, Singh et al. show an association between viral clearance and hospitalization or death, with p = 0.003 after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Figure 27 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to Singh et al., with higher confidence due to the larger number of studies. As with Singh et al., the confidence increases when excluding the outlier treatment, from p = 0.00000042 to p = 0.00000002.
Loading..
Figure 25. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.
Loading..
Figure 26. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.
Loading..
Figure 25. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.
Currently, 48 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 89% of these have been confirmed with one or more specific outcomes, with a mean delay of 5.1 months. When restricting to RCTs only, 56% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 6.4 months. Figure 28 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.
Loading..
Loading..
Figure 28. The time when studies showed that treatments were effective, defined as statistically significant improvement of ≥10% from ≥3 studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.
Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as difference in treatment delay is more likely to hide efficacy.
Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.
For sufficiency studies, different studies use different levels as the threshold of sufficiency, vitamin D levels were measured at different times, and some studies measure risk only within hospitalized patients, which excludes the risk of a serious enough case to be hospitalized. However, 195 of 208 studies present positive effects.
Sufficiency studies show a strong correlation between low vitamin D levels and worse COVID-19 outcomes, however they do not provide information on vitamin D treatment. Studies with vitamin D levels measured after admission may show lower levels because COVID-19 infection reduces vitamin D levels. Studies with levels measured before infection also show signficant benefit, however the cause could be one or more correlated factors. For example, sunlight exposure increases vitamin D levels, but also increases intracellular melatonin210, and melatonin shows significant benefit for COVID-19211. Sun exposure is also correlated with physical exercise, which also shows benefit for COVID-19212.
105 of 122 treatment studies report positive effects. Studies vary significantly in terms of treatment delay, treatment regimen, patients characteristics, and (for the pooled effects analysis) outcomes, as reflected in the high degree of heterogeneity. However treatment consistently shows a significant benefit. The treatment studies not showing positive effects are mostly prophylaxis studies with unknown dosages. The only non-prophylaxis studies reporting negative effects are a small unadjusted retrospective Assiri, Zangeneh with no details of treatment, and Murai, Cannata-Andía, Mariani which are very late stage studies using cholecalciferol. For Murai, the result also has very low statistical significance due to the small number of events, and the other reported outcomes of ventilation and ICU admission, which have slightly more events and higher confidence, show benefits for vitamin D. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more successful, especially with very late stage usage.
Acute treatment shows greater efficacy than chronic prophylaxis for mortality and in pooled analysis. One hypothesis is that long-term supplementation may affect normal biological processing. A key component of vitamin D processing is regulation via the enzyme CYP24A1, which breaks down active vitamin D. Long-term supplementation may lead to upregulation of CYP24A1, and potentially lower availability of active vitamin D where needed during infection. The prophylaxis RCTs to date Jolliffe, Villasis-Keever are consistent with this possibility, with the shorter-term supplementation in Villasis-Keever showing better results compared to the longer-term high adherence daily supplementation in Jolliffe. For acute respiratory infections, Wang (B) et al. show greater efficacy for prophylaxis trials with shorter durations. Specific forms and administration of vitamin D may minimize upregulation of CYP24A1215. Bader performed an RCT showing high-dose cholecalciferol (50,000 IU/week) significantly increased IL-6, however other studies have shown no significant difference in IL-6217,218 (30,000IU/wk and 100,000IU bolus + 4,000IU/day).
Other factors may be responsible for the observed lower efficacy in prophylaxis studies. For example, analysis of hospitalized patients is subject to selection bias because long-term accurate-dosage supplementing individuals may be significantly less likely to be hospitalized. Studies spanning higher-UV months are subject to confounding. Note that prophylaxis studies include case results, whereas we may expect vitamin D to be more effective against serious outcomes. Comparison of acute treatment versus long-term supplementation should use the specific outcome analyses rather than the pooled outcome analyses.
Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results219-222.
One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.
Figure 29 shows a scatter plot of results for prospective and retrospective treatment studies. Prospective studies show 51% [36‑63%] improvement in meta analysis, compared to 32% [25‑37%] for retrospective studies, suggesting possible negative publication bias, with a non-significant trend towards retrospective studies reporting lower efficacy. This gives us further confidence in the significant efficacy seen in all studies.
Loading..
Figure 29. Prospective vs. retrospective studies. The diamonds show the results of random effects meta-analysis.
Genetic variants have been shown to affect COVID-19 infection, severity, and mortality risk223. Patients with certain vitamin D receptor gene variants may potentially benefit more from vitamin D treatment74,75,223-237.
Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 30 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry (p > 0.05). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, p < 0.0001, with six variants of Egger's test all showing p < 0.05238-245. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.
Figure 30. Example funnel plot analysis for simulated perfect trials.
Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Vitamin D for COVID-19 lacks this because it is an inexpensive and widely available supplement. In contrast, most COVID-19 vitamin D trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all vitamin D trials represent the optimal conditions for efficacy.
19 other meta analyses show significant improvements with vitamin D treatment for mortality3-16, mechanical ventilation3,8,9,14,17,18, ICU admission3,5,8,9,12,14,16-20, hospitalization7,14, severity4,6,8,13,21, and cases10,20,21.
The first version of Lakkireddy was censored based on incorrect claims from an anti-treatment researcher. For example, the author claims that the gender difference between arms (7/44 vs. 15/43 female) indicates randomization failure, however by simulation, using the group sizes and overall gender ratio, the difference between the number of female patients in each arm is expected to be ≥8 6.4% of the time (2.7% with ≥8 in the control arm, and 3.7% with ≥8 in the treatment arm).
Author claims that the difference in CRP would only happen about one in a billion times. This is incorrect. CRP is not normally distributed, and the observed values could be due to a very small number of outliers with very large CRP in one group.
A response from the study authors can be found at c19early.org (E). The study was republished.
Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.
Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.
Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.
Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.
In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.
Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone195-206. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.
This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.
No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.
Many reviews cover vitamin D for COVID-19, presenting additional background on mechanisms and related results, including45,46,52,58,143,248-275.
Table 4 shows the reported results of physicians that use early treatments for COVID-19, compared to the results for a non-treating physician. The treatments used vary. Physicians typically use a combination of treatments, with almost all reporting use of ivermectin and/or HCQ, and most using additional treatments, including vitamin D. These results are subject to selection and ascertainment bias and more accurate analysis requires details of the patient populations and followup, however results are consistently better across many teams, and consistent with the extensive controlled trial evidence that shows a significant reduction in risk with many early treatments, and improved results with the use of multiple treatments in combination.
Table 4. Physician results with early treatment protocols compared to no early treatment. (*) Dr. Uip reportedly prescribed early treatment for himself, but not for patients276.
LATE TREATMENT
Physician / TeamLocationPatients HospitalizationHosp. MortalityDeath
Dr. David Uip (*) Brazil 2,200 38.6% (850) Ref. 2.5% (54) Ref.
EARLY TREATMENT - 40 physicians/teams
Physician / TeamLocationPatients HospitalizationHosp. ImprovementImp. MortalityDeath ImprovementImp.
Dr. Roberto Alfonso Accinelli
0/360 deaths for treatment within 3 days
Peru 1,265 0.6% (7) 77.5%
Dr. Mohammed Tarek Alam
patients up to 84 years old
Bangladesh 100 0.0% (0) 100.0%
Dr. Oluwagbenga Alonge Nigeria 310 0.0% (0) 100.0%
Dr. Raja Bhattacharya
up to 88yo, 81% comorbidities
India 148 1.4% (2) 44.9%
Dr. Flavio Cadegiani Brazil 3,450 0.1% (4) 99.7% 0.0% (0) 100.0%
Dr. Alessandro Capucci Italy 350 4.6% (16) 88.2%
Dr. Shankara Chetty South Africa 8,000 0.0% (0) 100.0%
Dr. Deborah Chisholm USA 100 0.0% (0) 100.0%
Dr. Ryan Cole USA 400 0.0% (0) 100.0% 0.0% (0) 100.0%
Dr. Marco Cosentino
vs. 3-3.8% mortality during period; earlier treatment better
Italy 392 6.4% (25) 83.5% 0.3% (1) 89.6%
Dr. Jeff Davis USA 6,000 0.0% (0) 100.0%
Dr. Dhanajay India 500 0.0% (0) 100.0%
Dr. Bryan Tyson & Dr. George Fareed USA 20,000 0.0% (6) 99.9% 0.0% (4) 99.2%
Dr. Raphael Furtado Brazil 170 0.6% (1) 98.5% 0.0% (0) 100.0%
Rabbi Yehoshua Gerzi Israel 860 0.1% (1) 99.7% 0.0% (0) 100.0%
Dr. Heather Gessling USA 1,500 0.1% (1) 97.3%
Dr. Ellen Guimarães Brazil 500 1.6% (8) 95.9% 0.4% (2) 83.7%
Dr. Syed Haider USA 4,000 0.1% (5) 99.7% 0.0% (0) 100.0%
Dr. Mark Hancock USA 24 0.0% (0) 100.0%
Dr. Sabine Hazan USA 1,000 0.0% (0) 100.0%
Dr. Mollie James USA 3,500 1.1% (40) 97.0% 0.0% (1) 98.8%
Dr. Roberta Lacerda Brazil 550 1.5% (8) 96.2% 0.4% (2) 85.2%
Dr. Katarina Lindley USA 100 5.0% (5) 87.1% 0.0% (0) 100.0%
Dr. Ben Marble USA 150,000 0.0% (4) 99.9%
Dr. Edimilson Migowski Brazil 2,000 0.3% (7) 99.1% 0.1% (2) 95.9%
Dr. Abdulrahman Mohana Saudi Arabia 2,733 0.0% (0) 100.0%
Dr. Carlos Nigro Brazil 5,000 0.9% (45) 97.7% 0.5% (23) 81.3%
Dr. Benoit Ochs Luxembourg 800 0.0% (0) 100.0%
Dr. Ortore Italy 240 1.2% (3) 96.8% 0.0% (0) 100.0%
Dr. Valerio Pascua
one death for a patient presenting on the 5th day in need of supplemental oxygen
Honduras 415 6.3% (26) 83.8% 0.2% (1) 90.2%
Dr. Sebastian Pop Romania 300 0.0% (0) 100.0%
Dr. Brian Proctor USA 869 2.3% (20) 94.0% 0.2% (2) 90.6%
Dr. Anastacio Queiroz Brazil 700 0.0% (0) 100.0%
Dr. Didier Raoult France 8,315 2.6% (214) 93.3% 0.1% (5) 97.6%
Dr. Karin Ried
up to 99yo, 73% comorbidities, av. age 63
Turkey 237 0.4% (1) 82.8%
Dr. Roman Rozencwaig
patients up to 86 years old
Canada 80 0.0% (0) 100.0%
Dr. Vipul Shah India 8,000 0.1% (5) 97.5%
Dr. Silvestre Sobrinho Brazil 116 8.6% (10) 77.7% 0.0% (0) 100.0%
Dr. Unknown Brazil 957 1.7% (16) 95.7% 0.2% (2) 91.5%
Dr. Vladimir Zelenko USA 2,200 0.5% (12) 98.6% 0.1% (2) 96.3%
Mean improvement with early treatment protocols 238,381 HospitalizationHosp. 94.4% MortalityDeath 94.9%
NIH provides an analysis of vitamin D for COVID-19277, concluding that there is insufficient evidence to recommend for or against use. However, they appear not to have looked at the majority of the evidence. For example, considering RCTs providing clinical results for COVID-19 and vitamin D, they reference only146,148,214,278, and appear not to know about 26 other RCTs147,156,157,159,160,168,170,181,203,213,246,279-293 as shown in Figure 31. Notably, the NIH selection does not correspond to the most relevant and highest quality studies, for example including Murai et al., which studies very late treatment (10 days from symptom onset, with 90% on oxygen at baseline) using cholecalciferol. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more appropriate, especially with this very late stage usage. They include none of the early treatment RCTs.
Loading..
Figure 31. Analysis by NIH is missing 26 RCTs.
SARS-CoV-2 infection and replication involves a complex interplay of 50+ host and viral proteins and other factors36-41, providing many therapeutic targets. Over 8,000 compounds have been predicted to reduce COVID-19 risk42, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Figure 32 shows an overview of the results for vitamin D in the context of multiple COVID-19 treatments, and Figure 33 shows a plot of efficacy vs. cost for COVID-19 treatments.
Loading..
Figure 32. Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random effects meta-analysis. 0.6% of 8,000+ proposed treatments show efficacy294.
Loading..
Loading..
Figure 33. Efficacy vs. cost for COVID-19 treatments.
Random effects meta-analysis with pooled effects using the most serious outcome reported shows 60% [40‑74%] and 37% [31‑42%] lower risk for early treatment and for all studies. Results are similar for higher quality studies, peer-reviewed studies, and mortality: early treatment - 68% [45‑82%], 57% [36‑71%], 68% [39‑84%]; all - 37% [31‑42%], 41% [35‑46%], 36% [28‑43%].
122 treatment studies show statistically significant lower risk for mortality, ICU admission, hospitalization, and cases. 62 studies from 58 independent teams in 22 countries show significantly lower risk.
Acute treatment (early 60% [40‑74%], late 45% [33‑54%]) shows greater efficacy than chronic prophylaxis (31% [24‑38%]).
Late stage treatment with calcitriol/calcifediol and analogs is more effective than cholecalciferol: 69% [47‑82%] vs. 39% [27‑49%].
Ongoing treatment with multiple doses is more effective than single bolus doses: 60% [49‑69%] vs. 21% [-13‑45%]
19 other meta analyses show significant improvements with vitamin D treatment for mortality3-16, mechanical ventilation3,8,9,14,17,18, ICU admission3,5,8,9,12,14,16-20, hospitalization7,14, severity4,6,8,13,21, and cases10,20,21.
This paper is data driven, all graphs and numbers are dynamically generated. Please submit updates and corrections at the bottom of this page.Please submit updates and corrections at https://c19early.org/dmeta.html.
11/10: We added Mirkarimi.
11/8: We added Vargas-Castro.
10/23: We added Chan.
10/22: We added Hemdan.
10/14: We added García-Zendejas.
10/6: We added Zhang, Hammam.
9/28: We added references to Wang (B) regarding dosing and trial duration for prophylaxis of acute respiratory infections.
9/22: We updated Wang (C) to the journal version.
9/18: We added Rachman.
8/18: We added Božić.
8/11: We added Pietzner.
8/10: We added Değirmenci.
7/12: We added Węgrzynek-Gallina.
6/22: We added Milan.
6/14: We added Sanz.
6/12: We added Cardoso.
6/10: We added Singhsakul.
5/28: We added Yang.
5/18: We added Wang.
4/26: Updated discussion of bolus treatment.
4/25: We added Chen.
4/8: We added Pavlyshyn.
3/27: We added Arambepola, and updated discussion of pooled outcomes.
3/24: We added Arboleda.
3/13: We added Guðnadóttir.
3/11: We added Devi.
2/28: We added Sartini.
2/24: We added Comunale.
2/23: RCT discussion updates.
2/1: We added Athanassiou.
1/31: We updated Singh (B) to the journal version.
1/24: We added Rozemeijer.
1/24: We updated the introduction.
1/16: We added Choi.
1/9/2024: We added Efe Iris.
12/20: We added Wu.
12/15: Updated discussion of preclinical results.
11/27: We added Renieris.
11/9: We added Akbar.
10/2: We added Bogomaz.
9/24: We added Seely (B).
9/8: We added Ogasawara.
8/29: We added Shamsi.
8/24: We added Al Sulaiman.
8/21: We added Mayurathan.
8/13: We added Mingiano.
8/10: We added Connolly.
8/5: We added analysis for RCT ICU outcomes.
6/24: We added Frish.
6/4: We added Manojlovic.
6/4: We added Jalavu.
6/4: We added Wani.
5/8: We added Hogarth.
5/6: We added Ritsinger.
5/5: We added Regalia.
5/2: We added Sanamandra.
4/25: We added AlKhafaji, Baralić, Hafez.
4/20: We added Allami.
4/19: We added Zafar, Cetin Ozbek.
4/16: We added Rachman (B).
4/12: We added Basińska-Lewandowska.
4/7: We added Protas, Hermawan.
4/6: We added Bayrak.
4/5: We added Aweimer, Wang (C), Khalil.
4/2: We added Gonzalez.
4/1: We added Arabadzhiyska.
3/28: We added Schmidt.
3/28: We added Huang, Nasiri.
3/23: We added Davran.
3/15: We added Bucurica.
3/15: We added Topan.
3/14: We added Domazet Bugarin, Siuka.
3/4: We added Şengül.
3/4: We added Chen (B).
3/2: We added Tan.
2/18: We added Ortatatli.
2/8: We added Arabi.
1/28: We added Batur.
1/20: We added Mostafa.
1/19: We added Din Ujjan.
1/17: We added Valecha.
1/8: We updated van Helmond to the journal version.
1/7/2023: We updated discussion of acute treatment vs. long-term supplementation.
12/31: We added De Nicolò.
12/20: We added Abdrabbo AlYafei.
12/20: We updated the discussion of heterogeneity and RCTs.
12/12: We added Vásquez-Procopio.
12/3: We added Tallon.
11/27: We added Guldemir (B).
11/26: We added Sharif.
11/13: We added Gibbons.
11/8: We added Said.
11/4: We added Bychinin.
10/28: We added Álvarez.
10/26: We added Hafezi.
10/15: We added Charla.
10/8: We added Karimpour-Razkenari.
10/1: We added Singh (B).
9/20: We added Shahid.
9/19: We added van Helmond.
9/15: We added Brunvoll.
9/11: We added Zeidan.
8/25: We added Hafez (B).
8/23: We added Doğan.
8/21: We added Reyes Pérez.
8/19: We added Kalichuran.
8/16: We updated Lakkireddy to the new version (post censorship of the previous version).
8/12: We added Zurita-Cruz, Dana.
8/10: We added Barrett.
8/5: We added Bogliolo.
8/3: We added Alzahrani.
7/27: We added De Niet.
7/26: We added Neves.
7/24: We added Gholi.
7/19: We added Baykal.
7/2: We added Hunt.
6/24: We added Karonova.
5/28: We added Mariani.
5/25: We added Zangeneh, Kazemi.
5/24: We added Ghanei.
5/23: We added Fiore.
5/20: We added Hosseini (C).
5/19: We added Jabeen.
5/19: We added Ozturk.
5/8: We added Charkowick.
5/5: We added Nguyen.
5/1: We added Khan.
4/30: We added Voelkle.
4/24: We added Davoudi.
4/22: We added discussion of Lakkireddy.
4/18: We added Villasis-Keever.
4/17: We added a section on preclinical research.
4/15: We added Parant.
4/12: We added Martínez-Rodríguez.
4/5: We added preprint discussion based on Zeraatkar.
4/2: We added Ferrer-Sánchez.
3/31: We added Ramos.
3/27: We added Pande.
3/25: We added Elhadi.
3/23: We added Jolliffe.
3/20: We added Bushnaq.
3/19: We added Shehab.
3/7: We added Rodríguez-Vidales.
3/5: We added Reis.
3/4: We added Nimer.
3/3: We added Karonova (B).
2/24: We added Zidrou.
2/20: We added Sanson.
2/19: We added Cannata-Andía.
2/18: We added Junior, González-Estevez.
2/17: We added Mahmood.
2/15: We updated Vanegas-Cedillo to the journal version.
2/11: We added Bychinin (B).
2/8: We added Subramanian.
2/8: We added Ranjbar.
2/7: We added Ullah, Tylicki.
2/6: We added Bishop.
2/4: We added Ahmed.
2/4: We updated Dror to the journal version.
1/30: We updated Leal-Martínez to the journal version.
1/29: We added Ansari.
1/28: We added Anjum.
1/25: We added Saponaro.
1/23: We added Smaha.
1/14: We added Baguma.
1/13: We updated Israel to the journal version.
1/8: We added Seal.
1/5: We added Pepkowitz.
1/3/2022: We added Efird.
12/26: We added Abdulateef.
12/21: We added Beigmohammadi, Sainz-Amo.
12/20: We added Galaznik.
12/17: We added Seven.
12/16: We added Parra-Ortega.
12/14: We added Putra.
12/9: We added analysis of the number of independent research groups reporting statistically significant positive results.
12/7: We added Ma.
12/5: We added Asgari.
12/3: We updated Loucera to the journal version.
12/3: We added Fatemi.
12/3: We added Kaur.
11/22: Added discussion related to sufficiency studies.
11/14: We added Gönen.
11/12: We added Asghar.
11/7: We added Holt.
11/3: We added Atanasovska.
11/2: We added Eden, Al-Salman.
11/1: We updated Golabi to the journal version.
10/31: We added Assiri, Leal-Martínez, Bianconi.
10/30: We added Campi, Gaudio.
10/27: We added Lázaro, Hurst.
10/19: We added Jimenez.
10/19: We added Zelzer, Sinaci.
10/18: We added Mohseni.
10/18: We added Basaran, Dudley.
10/16: We added a summary plot for all results.
10/15: We added Ramirez-Sandoval.
10/15: We added Maghbooli.
10/14: We added Burahee, Arroyo-Díaz and analysis of treatment mechanical ventilation, ICU admission, and hospitalization results.
9/28: We added Yildiz.
9/27: We added Derakhshanian.
9/22: We added Bagheri.
9/14: We added Ribeiro.
9/14: We updated Vasheghani to the journal version of the article.
9/14: We added Elamir.
9/10: We added Tomasa-Irriguible.
9/7: We added Pecina, Karonova (C).
9/6: We added Soliman.
9/1: We added Golabi.
8/23: We corrected Jain (B) to include the mortality outcome.
8/15: We added Nimavat.
8/13: We added di Filippo (B) and updated Louca to the journal version of the article.
8/12: We added Alpcan.
8/10: We added discussion of the immune system and vitamin D.
8/2: We added Matin.
8/1: We added Pimental.
7/28: We added Israel (B).
7/27: We added Cozier.
7/26: We added Güven.
7/25: We added Asimi.
7/24: We added Orchard.
7/21: We added Savitri.
7/19: We added Oristrell.
7/11: We added Krishnan.
6/25: We added Cereda.
6/19: We added Jude.
6/16: We added Campi.
6/12: We added Levitus.
6/11: We updated Oristrell (B) to the journal version.
6/9: We added Fasano.
6/8: We updated Nogués to the journal version.
6/7: We added Dror, Diaz-Curiel.
5/29: We added Sánchez-Zuno.
5/22: We added analysis restricted to cholecalciferol studies.
5/21: We added Alcala-Diaz, Li.
5/20: We updated Lakkireddy to the journal version.
5/19: We added AlSafar.
5/10: We added additional information in the abstract.
5/9: We clarified terminology for prophylaxis and added discussion of heterogeneity.
5/8: We added analysis for treatment studies restricted to peer-reviewed articles.
4/30: We added Loucera.
4/29: We corrected the treatment group counts for the early treatment group in Annweiler (there was no change in the relative risk).
4/24: We added analysis restricted to RCT studies and to calcifediol/calcitriol studies. We have excluded Espitia-Hernandez in the treatment analysis because they use a combined protocol with another medication that shows high effectiveness when used alone.
4/14: We added Blanch-Rubió.
4/13: We added Oristrell (B), Lohia.
4/12: We added Barassi.
4/10: We added Szeto.
4/9: We added Ünsal.
4/5: We added Bayramoğlu, Livingston.
4/4: We added event counts to the forest plots.
3/31: We added Mendy.
3/30: We added Macaya.
3/29: We added Im.
3/28: We added Freitas.
3/22: We added Meltzer.
3/15: We added Vanegas-Cedillo.
3/14: We added Cereda (B).
3/12: We added Charoenngam.
3/10: We added Mazziotti.
3/6: We added Ricci.
2/26: We added Lakkireddy.
2/25: We added Sulli.
2/20: We added Gavioli.
2/20: We added Infante.
2/18: Murai was updated to the journal version of the paper.
2/17: We corrected an error in the effect extraction for Angelidi, and we added treatment case and viral clearance forest plots.
2/16: We added Susianti.
2/10: We added Nogués.
2/10: We added Karonova (D).
2/9: We added Karahan.
2/7: We added Li (B).
2/5: We added Yılmaz.
1/31: We added Demir.
1/30: We added Ma (B).
1/22: We added Giannini.
1/21: We added Bennouar.
1/19: We added Amin.
1/18: We added Vasheghani.
1/16: We moved the analysis with exclusions to the main text, and added additional commentary.
1/15: We added the effect measured for each study in the forest plots.
1/10: We added Angelidi.
1/7: We added direct links to the study details in the chronological plots.
1/5: We added direct links to the study details in the forest plots.
1/2/2021: We added dosage information and we added the number of patients to the forest plots.
12/31: We added additional details about the studies in the appendix.
12/28: We added Jevalikar.
12/27: We added the total number of authors and patients.
12/23: We added Cangiano.
12/17/2020: Initial revision.
We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org, which regularly receives submissions of studies upon publication. Search terms are vitamin D, cholecalciferol, or calcitriol, and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of vitamin D for COVID-19 that report a comparison with a control group are included in the main treatment analysis, and all studies comparing COVID-19 outcomes in groups of patients with low and high vitamin D levels are included in the sufficiency analysis. A few studies only provide results as a function of change in vitamin D levels, which may not be indicative of results for deficiency/insufficiency versus sufficiency (if levels are already sufficient then further increase may be less beneficial). Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. This is a living analysis and is updated regularly.
We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are both reported, the effect for mortality is used, this may be different to the effect that a study focused on. If symptomatic results are reported at multiple times, we used the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral test status. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO2 is more important than cough. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to511. Reported confidence intervals and p-values were used when available, using adjusted values when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported p-values and confidence intervals followed Altman, Altman (B), and Fisher's exact test was used to calculate p-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1514. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.13.0) with scipy (1.14.1), pythonmeta (1.26), numpy (1.26.4), statsmodels (0.14.4), and plotly (5.24.1).
Forest plots are computed using PythonMeta515 with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I2 statistic. Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. Forest plots show simplified dosages for comparison, these are the total dose in the first five days for treatment, and the monthly dose for prophylaxis. Calcifediol, calcitriol, and paricalcitol treatment are indicated with (c), (t), and (p). For full dosage details see below. For all statistical tests, a p-value less than 0.05 was considered statistically significant. Grobid 0.8.0 is used to parse PDF documents.
We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients).
We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.
A summary of study results is below. Please submit updates and corrections at the bottom of this page.
A summary of study results is below. Please submit updates and corrections at https://c19early.org/dmeta.html.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. Only the first (most serious) outcome is used in pooled analysis, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
Abdollahi, 12/12/2020, retrospective, Iran, peer-reviewed, 7 authors. risk of case, 53.9% lower, RR 0.46, p = 0.001, high D levels 108, low D levels 294, >30ng/ml.
Abdrabbo AlYafei, 12/5/2022, retrospective, Qatar, peer-reviewed, mean age 19.0, 5 authors. risk of case, 23.2% lower, OR 0.77, p < 0.001, cutoff 10ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥10ng/mL), case control OR, severe deficiency vs. optimal, multivariable.
risk of case, 21.5% lower, OR 0.78, p < 0.001, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), case control OR, mild/moderate deficiency vs. optimal, multivariable.
Abdulrahman, 4/17/2023, retrospective, United Kingdom, peer-reviewed, mean age 69.0, 7 authors, study period April 2020 - May 2021. risk of death, 90.1% lower, OR 0.10, p = 0.048, high D levels (≥25nmol/L) 76, low D levels (<25nmol/L) 5, adjusted per study, inverted to make OR<1 favor high D levels (≥25nmol/L), multivariable, RR approximated with OR.
risk of progression, 82.5% lower, OR 0.18, p = 0.09, high D levels (≥25nmol/L) 76, low D levels (<25nmol/L) 5, adjusted per study, inverted to make OR<1 favor high D levels (≥25nmol/L), hospitalization, ICU, or death, multivariable, RR approximated with OR.
Abrishami, 10/30/2020, retrospective, Iran, peer-reviewed, mean age 55.2, 7 authors. risk of death, 75.9% lower, RR 0.24, p = 0.04, high D levels (≥25ng/mL) 3 of 47 (6.4%), low D levels (<25ng/mL) 9 of 26 (34.6%), NNT 3.5, adjusted per study, inverted to make RR<1 favor high D levels (≥25ng/mL), Cox model 2.
Afaghi, 10/12/2021, retrospective, Iran, peer-reviewed, 7 authors. risk of death, 55.0% lower, RR 0.45, p = 0.002, high D levels 97 of 537 (18.1%), low D levels 51 of 109 (46.8%), NNT 3.5, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, multivariate.
risk of mechanical ventilation, 55.9% lower, RR 0.44, p < 0.001, high D levels 89 of 537 (16.6%), low D levels 41 of 109 (37.6%), NNT 4.8, >20ng/mL, unadjusted.
risk of ICU admission, 34.1% lower, RR 0.66, p < 0.001, high D levels 211 of 537 (39.3%), low D levels 65 of 109 (59.6%), NNT 4.9, >20ng/mL, unadjusted.
Al-Salman, 7/29/2021, retrospective, Bahrain, peer-reviewed, 5 authors. risk of ICU admission, 44.4% lower, OR 0.56, p = 0.03, high D levels (≥50nmol/L) 113, low D levels (<50nmol/L) 337, inverted to make OR<1 favor high D levels (≥50nmol/L), multinomial regression, RR approximated with OR.
Alguwaihes, 12/5/2020, retrospective, Saudi Arabia, peer-reviewed, 10 authors. risk of death, 85.7% lower, RR 0.14, p = 0.007, high D levels 111, low D levels 328, inverted to make RR<1 favor high D levels, >12.5 nmol/L.
AlKhafaji, 1/31/2022, retrospective, Saudi Arabia, peer-reviewed, mean age 56.8, 16 authors, study period January 2021 - August 2021. risk of death, 38.6% lower, RR 0.61, p = 0.50, high D levels (≥20ng/mL) 2 of 76 (2.6%), low D levels (<20ng/mL) 13 of 127 (10.2%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk.
risk of mechanical ventilation, 31.0% lower, RR 0.69, p = 0.51, high D levels (≥20ng/mL) 2 of 76 (2.6%), low D levels (<20ng/mL) 13 of 127 (10.2%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk.
risk of ICU admission, 41.8% lower, RR 0.58, p = 0.20, high D levels (≥20ng/mL) 2 of 76 (2.6%), low D levels (<20ng/mL) 13 of 127 (10.2%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk.
Allami, 11/8/2022, retrospective, Iraq, peer-reviewed, 6 authors. risk of hospitalization, 92.5% lower, OR 0.07, p < 0.001, high D levels (≥10ng/mL) 91, low D levels (<10ng/mL) 80, adjusted per study, inverted to make OR<1 favor high D levels (≥10ng/mL), case control OR, multivariable.
Alpcan, 8/10/2021, retrospective, Turkey, peer-reviewed, 3 authors. risk of case, 73.0% lower, OR 0.27, p < 0.001, high D levels 42 of 75 (56.0%) cases, 66 of 80 (82.5%) controls, NNT 3.2, case control OR, >20ng/mL.
AlSafar, 5/19/2021, retrospective, United Arab Emirates, peer-reviewed, 8 authors. risk of death, 59.3% lower, RR 0.41, p = 0.048, high D levels 16 of 337 (4.7%), low D levels 10 of 127 (7.9%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >=12ng/mL.
risk of severe case, 33.2% lower, RR 0.67, p = 0.005, high D levels 337, low D levels 127, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >=12ng/mL.
Alzahrani, 6/23/2022, retrospective, Saudi Arabia, peer-reviewed, mean age 54.3, 9 authors, study period March 2020 - July 2021. risk of death, 42.5% lower, OR 0.57, p = 0.46, high D levels (≥25ng/mL) 179, low D levels (<25ng/mL) 78, adjusted per study, inverted to make OR<1 favor high D levels (≥25ng/mL), multivariable, RR approximated with OR.
risk of ICU admission, 7.4% lower, OR 0.93, p = 0.80, high D levels (≥25ng/mL) 179, low D levels (<25ng/mL) 78, adjusted per study, inverted to make OR<1 favor high D levels (≥25ng/mL), multivariable, RR approximated with OR.
Al‐Jarallah, 6/20/2021, retrospective, Kuwait, peer-reviewed, 20 authors. risk of death, 88.3% higher, RR 1.88, p = 0.45, high D levels 8 of 120 (6.7%), low D levels 9 of 119 (7.6%), odds ratio converted to relative risk.
Amin, 1/7/2021, retrospective, population-based cohort, United Kingdom, peer-reviewed, 2 authors. COVID-19 severity, 32.3% higher, RR 1.32, p = 0.20, high D levels 140,898, low D levels 35,079, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >=50nmol/L vs. <25nmol/L, MR Egger, baseline risk approximated with overall risk.
risk of case, 7.6% higher, RR 1.08, p = 0.14, high D levels 140,898, low D levels 35,079, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >=50nmol/L vs. <25nmol/L, MR Egger, baseline risk approximated with overall risk.
Angelidi, 1/9/2021, retrospective, USA, peer-reviewed, 8 authors. risk of death, 88.0% lower, RR 0.12, p = 0.01, high D levels 6 of 65 (9.2%), low D levels 20 of 79 (25.3%), NNT 6.2, adjusted per study, >30ng/mL, supplementary table 2, multivariable logistic regression model 5.
Anjum, 7/31/2020, prospective, Pakistan, peer-reviewed, 6 authors, study period March 2020 - June 2020, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 62.5% lower, RR 0.38, p = 0.02, high D levels (≥25nmol/L) 8 of 80 (10.0%), low D levels (<25nmol/L) 16 of 60 (26.7%), NNT 6.0.
Ansari, 12/31/2020, prospective, Pakistan, peer-reviewed, 6 authors, study period 1 March, 2020 - 31 August, 2020, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 86.0% lower, RR 0.14, p = 0.02, high D levels (≥25nmol/L) 2 of 68 (2.9%), low D levels (<25nmol/L) 12 of 57 (21.1%), NNT 5.5.
Arabadzhiyska, 2/28/2023, retrospective, Bulgaria, peer-reviewed, mean age 53.7, 2 authors, study period October 2021 - December 2021. risk of severe case, 29.8% lower, RR 0.70, p = 0.16, high D levels (≥20ng/ml) 16 of 44 (36.4%), low D levels (<20ng/ml) 29 of 56 (51.8%), NNT 6.5.
Arabi, 1/22/2023, retrospective, Iran, peer-reviewed, 7 authors. risk of death, 40.0% lower, RR 0.60, p = 0.28, high D levels (≥20ng/mL) 6 of 30 (20.0%), low D levels (<20ng/mL) 13 of 39 (33.3%), NNT 7.5.
risk of ICU admission, 39.3% lower, RR 0.61, p = 0.20, high D levels (≥20ng/mL) 7 of 30 (23.3%), low D levels (<20ng/mL) 15 of 39 (38.5%), NNT 6.6.
risk of AKI, 42.2% lower, RR 0.58, p = 0.13, high D levels (≥20ng/mL) 8 of 30 (26.7%), low D levels (<20ng/mL) 18 of 39 (46.2%), NNT 5.1.
Arambepola, 3/28/2024, retrospective, India, preprint, 6 authors. risk of case, 47.4% lower, OR 0.53, p = 0.27, high D levels (≥50nmol/L) 17 of 104 (16.3%) cases, 30 of 104 (28.8%) controls, NNT 5.6, adjusted per study, inverted to make OR<1 favor high D levels (≥50nmol/L), case control OR.
Asgari, 11/21/2021, retrospective, Iran, peer-reviewed, 6 authors, study period 21 May, 2020 - 4 September, 2020. risk of death, 72.5% lower, OR 0.27, p = 0.03, cutoff 25ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥25ng/mL), RR approximated with OR.
risk of progression, 65.6% lower, OR 0.34, p = 0.02, cutoff 25ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥25ng/mL), RR approximated with OR.
Asghar, 11/10/2021, retrospective, Pakistan, peer-reviewed, 8 authors. risk of death, 53.1% lower, HR 0.47, p = 0.046, high D levels (≥10ng/mL) 73, low D levels (<10ng/mL) 18, inverted to make HR<1 favor high D levels (≥10ng/mL), multivariate Cox regression.
risk of mechanical ventilation, 19.4% lower, HR 0.81, p = 0.32, high D levels (≥10ng/mL) 5 of 73 (6.8%), low D levels (<10ng/mL) 6 of 18 (33.3%), NNT 3.8, adjusted per study, inverted to make HR<1 favor high D levels (≥10ng/mL), multivariate Cox regression.
risk of ICU admission, 32.9% lower, HR 0.67, p = 0.54, high D levels (≥10ng/mL) 73, low D levels (<10ng/mL) 18, inverted to make HR<1 favor high D levels (≥10ng/mL), multivariate Cox regression.
Atanasovska, 11/2/2021, retrospective, North Macedonia, peer-reviewed, 8 authors. risk of death, 40.7% lower, RR 0.59, p = 0.68, high D levels (≥30ng/mL) 2 of 9 (22.2%), low D levels (<30ng/mL) 9 of 24 (37.5%), NNT 6.5.
risk of severe case, 59.0% lower, RR 0.41, p = 0.13, high D levels (≥30ng/mL) 2 of 9 (22.2%), low D levels (<30ng/mL) 13 of 24 (54.2%), NNT 3.1.
Athanassiou, 9/15/2023, prospective, Greece, peer-reviewed, 9 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 47.9% lower, RR 0.52, p = 0.39, high D levels (≥10ng/mL) 5 of 64 (7.8%), low D levels (<10ng/mL) 3 of 20 (15.0%), NNT 14.
risk of death, 43.0% lower, RR 0.57, p = 0.70, high D levels (≥20ng/mL) 2 of 31 (6.5%), low D levels (<20ng/mL) 6 of 53 (11.3%), NNT 21.
Baktash, 8/27/2020, prospective, United Kingdom, peer-reviewed, 8 authors. risk of death, 28.6% lower, RR 0.71, p = 0.50, high D levels 4 of 31 (12.9%), low D levels 6 of 39 (15.4%), adjusted per study, inverted to make RR<1 favor high D levels, >30nmol/L.
Barassi, 1/25/2021, retrospective, Italy, peer-reviewed, 8 authors. risk of death, 64.9% lower, RR 0.35, p = 0.44, high D levels 1 of 31 (3.2%), low D levels 8 of 87 (9.2%), NNT 17, >20ng/mL.
risk of mechanical ventilation, 64.9% lower, RR 0.35, p = 0.15, high D levels 2 of 31 (6.5%), low D levels 16 of 87 (18.4%), NNT 8.4, >20ng/mL.
Barrett, 8/9/2022, prospective, Ireland, peer-reviewed, mean age 56.0, 19 authors, study period March 2020 - April 2021. risk of death, 78.4% lower, OR 0.22, p = 0.006, high D levels (≥30nmol/L) 144, low D levels (<30nmol/L) 88, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/L), multivariable, RR approximated with OR.
risk of ICU admission, 15.3% lower, OR 0.85, p = 0.63, high D levels (≥30nmol/L) 144, low D levels (<30nmol/L) 88, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/L), multivariable, RR approximated with OR.
risk of progression, 52.6% lower, OR 0.47, p = 0.12, high D levels (≥30nmol/L) 144, low D levels (<30nmol/L) 88, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/L), extended oxygen requirement, multivariable, RR approximated with OR.
Basaran, 2/12/2021, retrospective, Turkey, peer-reviewed, 6 authors. risk of severe case, 68.6% lower, RR 0.31, p = 0.005, high D levels 82 of 119 (68.9%), low D levels 80 of 85 (94.1%), NNT 4.0, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >10μg/L, per standard deviation increase in levels.
Basińska-Lewandowska, 3/24/2023, retrospective, Poland, peer-reviewed, 5 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of case, 58.3% lower, RR 0.42, p = 0.02, high D levels (≥12ng/mL) 20 of 109 (18.3%), low D levels (<12ng/mL) 11 of 25 (44.0%), NNT 3.9.
Batur, 12/26/2022, retrospective, Turkey, peer-reviewed, 2 authors, study period March 2020 - June 2021, excluded in exclusion analyses: unadjusted differences between groups. risk of death, 71.9% lower, RR 0.28, p < 0.001, high D levels (≥20ng/mL) 17 of 76 (22.4%), low D levels (<20ng/mL) 94 of 118 (79.7%), NNT 1.7.
secondary infection, 23.3% lower, RR 0.77, p = 0.03, high D levels (≥20ng/mL) 40 of 76 (52.6%), low D levels (<20ng/mL) 81 of 118 (68.6%), NNT 6.2, growth in culture.
Baykal, 5/30/2022, retrospective, Turkey, peer-reviewed, 2 authors, study period 1 April, 2020 - 1 March, 2021, dosage 300,000IU single dose. risk of death, 8.0% higher, RR 1.08, p = 0.80, high D levels (≥20ng/mL) 11 of 20 (55.0%), low D levels (<20ng/mL) 28 of 55 (50.9%), outcome based on serum levels.
risk of ICU admission, 4.8% lower, RR 0.95, p = 1.00, high D levels (≥20ng/mL) 9 of 20 (45.0%), low D levels (<20ng/mL) 26 of 55 (47.3%), NNT 44, outcome based on serum levels.
risk of progression, 6.1% lower, RR 0.94, p = 0.77, high D levels (≥20ng/mL) 14 of 20 (70.0%), low D levels (<20ng/mL) 41 of 55 (74.5%), NNT 22, severe/critical, outcome based on serum levels.
Bayrak, 4/5/2023, retrospective, Turkey, peer-reviewed, mean age 19.0, 8 authors, study period November 2020 - January 2021. risk of moderate/severe case, 26.5% lower, RR 0.73, p = 1.00, high D levels (≥20ng/mL) 3 of 49 (6.1%), low D levels (<20ng/mL) 2 of 24 (8.3%), NNT 45.
risk of case, 33.4% lower, OR 0.67, p = 0.23, high D levels (≥20ng/mL) 41 of 73 (56.2%) cases, 50 of 76 (65.8%) controls, NNT 9.9, case control OR.
Bayramoğlu, 3/31/2021, retrospective, Turkey, peer-reviewed, 7 authors. risk of moderate/severe case, 69.5% lower, RR 0.30, p = 0.03, high D levels 10 of 60 (16.7%), low D levels 24 of 43 (55.8%), NNT 2.6, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12 ng/mL, multivariate logistic regression.
Bennouar, 1/12/2021, prospective, Algeria, peer-reviewed, 5 authors. risk of death, 85.5% lower, RR 0.14, p = 0.002, high D levels 4 of 30 (13.3%), low D levels 15 of 32 (46.9%), NNT 3.0, adjusted per study, inverted to make RR<1 favor high D levels, >30μg/l vs. <10μg/l, proportional Cox regression.
risk of death, 63.0% lower, RR 0.37, p = 0.10, high D levels 4 of 30 (13.3%), low D levels 14 of 35 (40.0%), NNT 3.7, adjusted per study, inverted to make RR<1 favor high D levels, >30μg/l vs. 10-19μg/l, proportional Cox regression.
risk of death, 23.1% lower, RR 0.77, p = 0.73, high D levels 4 of 30 (13.3%), low D levels 4 of 23 (17.4%), NNT 25, adjusted per study, inverted to make RR<1 favor high D levels, >30μg/l vs. 20-29μg/l, proportional Cox regression.
Bianconi, 7/1/2021, prospective, Italy, peer-reviewed, 12 authors. risk of death, 17.5% lower, HR 0.82, p = 0.58, high D levels (≥12ng/ml) 94, low D levels (<12ng/ml) 106, model 3, Table S2, Cox proportional hazards.
risk of death, 13.9% lower, HR 0.86, p = 0.73, high D levels (≥20ng/ml) 40, low D levels (<20ng/ml) 160, model 3, Table S2, Cox proportional hazards.
risk of death/ICU, 15.9% lower, HR 0.84, p = 0.53, high D levels (≥12ng/ml) 94, low D levels (<12ng/ml) 106, model 3, Cox proportional hazards.
risk of death/ICU, 10.9% lower, HR 0.89, p = 0.73, high D levels (≥20ng/ml) 40, low D levels (<20ng/ml) 160, model 3, Cox proportional hazards.
Bogliolo, 7/5/2022, prospective, Italy, peer-reviewed, median age 73.0, 16 authors, study period March 2020 - August 2020. risk of death, 15.3% lower, HR 0.85, p = 0.29, cutoff 20ng/mL, inverted to make HR<1 favor high D levels (≥20ng/mL).
Bogomaz, 8/24/2023, retrospective, Ukraine, peer-reviewed, median age 62.0, 2 authors. risk of death, 70.0% lower, RR 0.30, p = 0.24, high D levels (≥30ng/ml) 1 of 28 (3.6%), low D levels (<30ng/ml) 5 of 42 (11.9%), NNT 12, inverted to make RR<1 favor high D levels (≥30ng/ml), odds ratio converted to relative risk.
risk of mechanical ventilation, 75.0% lower, RR 0.25, p = 0.23, high D levels (≥30ng/ml) 1 of 28 (3.6%), low D levels (<30ng/ml) 6 of 42 (14.3%), NNT 9.3.
risk of progression, 62.5% lower, RR 0.38, p = 0.30, high D levels (≥30ng/ml) 2 of 28 (7.1%), low D levels (<30ng/ml) 8 of 42 (19.0%), NNT 8.4, critical case.
risk of oxygen therapy, 27.0% lower, RR 0.73, p = 0.24, high D levels (≥30ng/ml) 10 of 28 (35.7%), low D levels (<30ng/ml) 28 of 42 (66.7%), NNT 3.2, adjusted per study, inverted to make RR<1 favor high D levels (≥30ng/ml), odds ratio converted to relative risk, multivariable.
Božić, 6/20/2024, prospective, Serbia, peer-reviewed, median age 69.0, 4 authors, study period October 2021 - December 2021. risk of death, 53.3% lower, OR 0.47, p = 0.007, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
risk of ICU admission, 30.5% lower, OR 0.70, p = 0.21, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
Breslin, 8/17/2021, retrospective, Ireland, peer-reviewed, 4 authors. risk of progression, 55.6% lower, OR 0.44, p = 0.03, high D levels (≥30nmol/l) 106, low D levels (<30nmol/l) 32, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), infiltrates on chest X-ray, multivariable, RR approximated with OR.
Bucurica, 3/6/2023, retrospective, Romania, peer-reviewed, mean age 55.2, 9 authors, study period 1 June, 2020 - 31 May, 2022. risk of case, 27.6% lower, OR 0.72, p < 0.001, high D levels (≥20ng/mL) 7,958, low D levels (<20ng/mL) 3,224, inverted to make OR<1 favor high D levels (≥20ng/mL), RR approximated with OR.
risk of case, 7.4% higher, OR 1.07, p = 0.19, high D levels (≥30ng/mL) 4,367, low D levels (<30ng/mL) 6,815, inverted to make OR<1 favor high D levels (≥30ng/mL), RR approximated with OR.
Bushnaq, 2/8/2022, retrospective, Saudi Arabia, peer-reviewed, 7 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of mechanical ventilation, 32.1% lower, RR 0.68, p = 0.27, high D levels (≥20ng/mL) 10 of 53 (18.9%), low D levels (<20ng/mL) 40 of 144 (27.8%), NNT 11, unadjusted.
risk of ICU admission, 3.9% lower, RR 0.96, p = 0.87, high D levels (≥20ng/mL) 23 of 53 (43.4%), low D levels (<20ng/mL) 65 of 144 (45.1%), NNT 57, unadjusted.
Bychinin (B), 5/7/2021, retrospective, Russia, peer-reviewed, 5 authors, excluded in exclusion analyses: excessive unadjusted differences between groups. risk of death, 36.2% lower, RR 0.64, p = 0.03, high D levels (≥10ng/mL) 16 of 38 (42.1%), low D levels (<10ng/mL) 31 of 47 (66.0%), NNT 4.2.
Campi, 6/14/2021, prospective, Italy, peer-reviewed, 21 authors, dosage not specified. risk of death for severe patients, 24.3% lower, RR 0.76, p = 0.53, high D levels (≥20ng/ml) 6 of 39 (15.4%), low D levels (<20ng/ml) 13 of 64 (20.3%), NNT 20, hospitalized patients, outcome based on serum levels.
risk of ICU for severe patients, 53.1% lower, RR 0.47, p < 0.001, high D levels (≥20ng/ml) 12 of 39 (30.8%), low D levels (<20ng/ml) 42 of 64 (65.6%), NNT 2.9, hospitalized patients, outcome based on serum levels.
Cannata-Andía, 2/18/2022, prospective, multiple countries, peer-reviewed, median age 59.0, 22 authors, study period 4 April, 2020 - 22 April, 2021, dosage 100,000IU single dose, trial NCT04552951 (history) (COVID-VIT-D), excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 117.0% higher, RR 2.17, p = 0.20, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of ICU admission, 65.0% lower, RR 0.35, p = 0.04, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of progression, 79.0% lower, RR 0.21, p = 0.003, high D levels 87, low D levels 96, pulmonary involvment at admission, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
Cardoso, 6/11/2024, prospective, Brazil, preprint, 7 authors, study period April 2020 - February 2022. severe pneumonia, 66.7% lower, OR 0.33, p < 0.001, high D levels (≥30ng/ml) 83 of 145 (57.2%) cases, 147 of 175 (84.0%) controls, NNT 3.0, adjusted per study, inverted to make OR<1 favor high D levels (≥30ng/ml), case control OR, deficient vs. sufficient, multivariable.
severe pneumonia, 50.0% lower, OR 0.50, p < 0.001, high D levels (≥30ng/mL) 83 of 245 (33.9%) cases, 147 of 279 (52.7%) controls, NNT 5.3, adjusted per study, inverted to make OR<1 favor high D levels (≥30ng/mL), case control OR, insufficient vs. sufficient, multivariable.
Carpagnano, 8/9/2020, retrospective, Italy, peer-reviewed, 10 authors. risk of death at day 26, 70.6% lower, RR 0.29, p = 0.0499, high D levels 5 of 34 (14.7%), low D levels 4 of 8 (50.0%), NNT 2.8, >30 ng/mL.
risk of death at day 10, 90.0% lower, RR 0.10, p = 0.02, high D levels 2 of 34 (5.9%), low D levels 4 of 8 (50.0%), NNT 2.3, adjusted per study, >30 ng/mL.
Cereda (B), 11/1/2020, prospective, Italy, peer-reviewed, 13 authors. risk of death, 120.0% higher, RR 2.20, p = 0.04, high D levels 10 of 30 (33.3%), low D levels 24 of 99 (24.2%), inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL.
risk of ICU admission, 86.7% lower, RR 0.13, p = 0.59, high D levels 0 of 30 (0.0%), low D levels 5 of 99 (5.1%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Cetin Ozbek, 3/24/2023, retrospective, Turkey, peer-reviewed, mean age 63.4, 6 authors, study period 1 August, 2021 - 31 October, 2021. risk of death, 50.9% lower, RR 0.49, p = 0.07, high D levels (≥20ng/mL) 7 of 61 (11.5%), low D levels (<20ng/mL) 25 of 107 (23.4%), NNT 8.4.
risk of death, 3.0% lower, OR 0.97, p = 0.32, adjusted per study, continuous values, multivariable, RR approximated with OR.
Chan, 10/20/2024, retrospective, multiple countries, peer-reviewed, 3 authors, study period January 2022 - September 2024. risk of death, 5.7% lower, HR 0.94, p = 0.42, high D levels (≥20ng/mL) 365 of 34,407 (1.1%), low D levels (<20ng/mL) 382 of 34,407 (1.1%), NNT 2024, inverted to make HR<1 favor high D levels (≥20ng/mL), Cox proportional hazards.
risk of progression, 4.8% lower, HR 0.95, p = 0.02, high D levels (≥20ng/mL) 4,181 of 34,407 (12.2%), low D levels (<20ng/mL) 4,345 of 34,407 (12.6%), NNT 210, inverted to make HR<1 favor high D levels (≥20ng/mL), death, hospitalization, critical care, Cox proportional hazards.
risk of progression, 21.9% lower, HR 0.78, p < 0.001, high D levels (≥20ng/mL) 702 of 34,407 (2.0%), low D levels (<20ng/mL) 885 of 34,407 (2.6%), NNT 188, inverted to make HR<1 favor high D levels (≥20ng/mL), critical care, Cox proportional hazards.
risk of hospitalization, 1.0% lower, HR 0.99, p = 0.80, high D levels (≥20ng/mL) 3,812 of 34,407 (11.1%), low D levels (<20ng/mL) 3,803 of 34,407 (11.1%), inverted to make HR<1 favor high D levels (≥20ng/mL), Cox proportional hazards.
Chang, 7/4/2020, retrospective, USA, preprint, 13 authors, study period 9 March, 2020 - 14 June, 2020. risk of case, 43.2% lower, OR 0.57, p < 0.001, cutoff 20ng/mL, inverted to make OR<1 favor high D levels (≥20ng/mL), Table S4, RR approximated with OR.
Charkowick, 5/5/2022, retrospective, USA, peer-reviewed, 10 authors, study period 1 January, 2020 - 5 February, 2021. risk of death, 73.4% lower, OR 0.27, p = 0.02, high D levels 140, low D levels 68, adjusted per study, inverted to make OR<1 favor high D levels, multivariable, RR approximated with OR.
risk of ICU admission, 67.2% lower, OR 0.33, p = 0.001, high D levels 140, low D levels 68, adjusted per study, inverted to make OR<1 favor high D levels, multivariable, RR approximated with OR.
Charla, 7/13/2022, retrospective, India, preprint, 8 authors, study period 1 April, 2020 - 30 April, 2021, excluded in exclusion analyses: excessive unadjusted differences between groups. risk of death, 10.7% lower, RR 0.89, p = 0.74, high D levels (≥20ng/ml) 24 of 91 (26.4%), low D levels (<20ng/ml) 26 of 88 (29.5%), NNT 32.
Charoenngam, 3/8/2021, retrospective, USA, peer-reviewed, 6 authors. risk of death, 34.1% lower, RR 0.66, p = 0.26, high D levels 12 of 100 (12.0%), low D levels 29 of 187 (15.5%), adjusted per study, odds ratio converted to relative risk, >=30ng/mL.
risk of mechanical ventilation, 37.2% lower, RR 0.63, p = 0.17, high D levels 14 of 100 (14.0%), low D levels 34 of 187 (18.2%), adjusted per study, odds ratio converted to relative risk, >=30ng/mL.
risk of ICU admission, 23.1% lower, RR 0.77, p = 0.28, high D levels 25 of 100 (25.0%), low D levels 56 of 187 (29.9%), NNT 20, adjusted per study, odds ratio converted to relative risk, >=30ng/mL.
risk of death, 58.1% lower, RR 0.42, p = 0.05, high D levels 7 of 57 (12.3%), low D levels 25 of 79 (31.6%), NNT 5.2, adjusted per study, odds ratio converted to relative risk, >65 years old, >=30ng/mL.
Chen (B), 2/28/2023, retrospective, China, peer-reviewed, 9 authors, study period 1 June, 2022 - 5 July, 2022. viral clearance, 40.0% improved, HR 0.60, p = 0.01, high D levels (≥41.07ng/mL) 52, low D levels (<27.5ng/mL) 53, adjusted per study, tertile 3 vs. tertile 1, multivariable, Cox proportional hazards.
Choi, 1/2/2024, retrospective, South Korea, peer-reviewed, mean age 55.7, 6 authors, study period April 2022 - December 2022. risk of no recovery, 48.9% lower, HR 0.51, p = 0.002, high D levels (≥20ng/mL) 99, low D levels (<20ng/mL) 67, adjusted per study, multivariable.
risk of PASC, 68.4% lower, HR 0.32, p = 0.001, high D levels (≥20ng/mL) 99, low D levels (<20ng/mL) 67, adjusted per study, inverted to make HR<1 favor high D levels (≥20ng/mL), multivariable.
risk of hospitalization, 25.6% lower, RR 0.74, p = 0.48, high D levels (≥20ng/mL) 11 of 99 (11.1%), low D levels (<20ng/mL) 10 of 67 (14.9%), NNT 26, unadjusted.
Connolly, 8/17/2021, retrospective, Ireland, peer-reviewed, 8 authors, study period March 2020 - May 2020. risk of death, 90.4% lower, OR 0.10, p = 0.06, high D levels (≥30nmol/l) 65, low D levels (<30nmol/l) 49, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), multivariable, RR approximated with OR.
risk of oxygen therapy, 73.3% lower, OR 0.27, p = 0.048, high D levels (≥30nmol/l) 65, low D levels (<30nmol/l) 49, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), multivariable, RR approximated with OR.
Cozier, 7/27/2021, prospective, USA, peer-reviewed, 6 authors. risk of case, 38.6% lower, RR 0.61, p = 0.04, high D levels 94 of 1,601 (5.9%), low D levels 33 of 373 (8.8%), NNT 34, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, multivariable.
Dana, 8/11/2022, retrospective, Iran, peer-reviewed, 16 authors, study period March 2020 - November 2020. risk of death, 33.1% lower, RR 0.67, p = 0.29, high D levels (≥10ng/mL) 49 of 376 (13.0%), low D levels (<10ng/mL) 8 of 46 (17.4%), NNT 23, adjusted per study, inverted to make RR<1 favor high D levels (≥10ng/mL), odds ratio converted to relative risk, sufficiency vs. severe deficiency, multivariable.
risk of death, 15.7% lower, RR 0.84, p = 0.44, high D levels (≥20ng/mL) 49 of 376 (13.0%), low D levels (<20ng/mL) 30 of 197 (15.2%), NNT 46, adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, sufficiency vs. deficiency, multivariable.
risk of severe case, no change, RR 1.00, p = 1.00, high D levels (≥10ng/mL) 59 of 376 (15.7%), low D levels (<10ng/mL) 7 of 46 (15.2%), adjusted per study, inverted to make RR<1 favor high D levels (≥10ng/mL), odds ratio converted to relative risk, sufficiency vs. severe deficiency, multivariable.
risk of severe case, 11.6% lower, RR 0.88, p = 0.45, high D levels (≥20ng/mL) 59 of 376 (15.7%), low D levels (<20ng/mL) 35 of 197 (17.8%), NNT 48, adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, sufficiency vs. deficiency, multivariable.
Davoudi, 5/18/2021, retrospective, Iran, peer-reviewed, 11 authors, study period February 2020 - March 2020, excluded in exclusion analyses: excessive unadjusted differences between groups. risk of death, 12.3% higher, RR 1.12, p = 1.00, high D levels (≥30ng/mL) 2 of 57 (3.5%), low D levels (<30ng/mL) 3 of 96 (3.1%).
risk of mechanical ventilation, 15.8% lower, RR 0.84, p = 1.00, high D levels (≥30ng/mL) 1 of 57 (1.8%), low D levels (<30ng/mL) 2 of 96 (2.1%), NNT 304.
risk of ICU admission, 27.8% lower, RR 0.72, p = 0.74, high D levels (≥30ng/mL) 3 of 57 (5.3%), low D levels (<30ng/mL) 7 of 96 (7.3%), NNT 49.
risk of severe case, 68.4% higher, RR 1.68, p = 0.30, high D levels (≥30ng/mL) 9 of 57 (15.8%), low D levels (<30ng/mL) 9 of 96 (9.4%).
Davran, 3/15/2023, retrospective, Turkey, peer-reviewed, mean age 53.6, 9 authors. risk of death, 75.4% lower, RR 0.25, p = 0.02, high D levels (≥10ng/ml) 4 of 63 (6.3%), low D levels (<10ng/ml) 8 of 31 (25.8%), NNT 5.1.
De Smet, 11/25/2020, retrospective, Belgium, peer-reviewed, 5 authors. risk of death, 70.1% lower, RR 0.30, p = 0.02, high D levels 7 of 77 (9.1%), low D levels 20 of 109 (18.3%), adjusted per study, odds ratio converted to relative risk, >20ng/mL.
Demir, 1/29/2021, retrospective, Turkey, peer-reviewed, 3 authors. risk of severe case, 89.3% lower, RR 0.11, p < 0.001, high D levels 13, low D levels 99, ratio of the mean number of affected lung segments, >30ng/ml vs. <=10ng/mL.
hospitalization time, 87.1% lower, relative time 0.13, p < 0.001, high D levels 13, low D levels 99, >30ng/ml vs. <=10ng/mL.
risk of case, 24.2% lower, RR 0.76, p = 0.18, high D levels 13 of 31 (41.9%), low D levels 99 of 179 (55.3%), NNT 7.5, >30ng/ml vs. <=10ng/mL.
Derakhshanian, 9/19/2021, retrospective, Iran, peer-reviewed, 11 authors. risk of death, 44.8% lower, RR 0.55, p = 0.046, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
risk of mechanical ventilation, 41.7% lower, RR 0.58, p = 0.09, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
risk of ICU admission, 37.3% lower, RR 0.63, p = 0.04, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
Devi, 4/15/2023, retrospective, India, peer-reviewed, mean age 47.0, 4 authors, study period August 2020 - August 2022. risk of case, 98.0% lower, OR 0.02, p = 0.007, high D levels (≥10ng/mL) 69 of 88 (78.4%) cases, 88 of 88 (100.0%) controls, NNT 1.8, case control OR.
risk of case, 88.4% lower, OR 0.12, p < 0.001, high D levels (≥20ng/mL) 54 of 88 (61.4%) cases, 82 of 88 (93.2%) controls, NNT 2.2, case control OR.
Değirmenci, 7/30/2024, retrospective, Turkey, peer-reviewed, mean age 29.3, 7 authors, study period March 2020 - January 2021. risk of ICU admission, 50.6% lower, RR 0.49, p = 0.27, high D levels (≥20ng/ml) 3 of 36 (8.3%), low D levels (<20ng/ml) 15 of 89 (16.9%), NNT 12.
severe CT finding, 36.0% lower, RR 0.64, p = 0.53, high D levels (≥20ng/ml) 3 of 16 (18.8%), low D levels (<20ng/ml) 17 of 58 (29.3%), NNT 9.5.
moderate/severe CT finding, 25.6% lower, RR 0.74, p = 0.25, high D levels (≥20ng/ml) 8 of 16 (50.0%), low D levels (<20ng/ml) 39 of 58 (67.2%), NNT 5.8.
hospitalization time, 16.7% lower, relative time 0.83, p = 0.48, high D levels (≥20ng/ml) 36, low D levels (<20ng/ml) 89.
di Filippo (B), 8/12/2021, retrospective, Italy, peer-reviewed, 8 authors. risk of death, 10.7% lower, RR 0.89, p = 1.00, high D levels 5 of 28 (17.9%), low D levels 12 of 60 (20.0%), NNT 47, >20ng/mL.
risk of ICU admission, 41.6% lower, RR 0.58, p = 0.22, high D levels 6 of 28 (21.4%), low D levels 22 of 60 (36.7%), NNT 6.6, >20ng/mL.
risk of severe case, 39.6% lower, RR 0.60, p = 0.04, high D levels 11 of 28 (39.3%), low D levels 39 of 60 (65.0%), NNT 3.9, >20ng/mL.
Diaz-Curiel, 6/6/2021, retrospective, Spain, peer-reviewed, 8 authors. risk of ICU admission, 73.2% lower, RR 0.27, p = 0.02, high D levels 3 of 214 (1.4%), low D levels 91 of 1,017 (8.9%), odds ratio converted to relative risk, >30ng/mL vs. <20ng/mL.
Doğan, 8/4/2022, prospective, Turkey, peer-reviewed, 5 authors, study period 1 July, 2021 - 30 October, 2021. risk of case, 63.7% lower, OR 0.36, p = 0.003, high D levels (≥10ng/ml) 53 of 88 (60.2%) cases, 71 of 88 (80.7%) controls, NNT 4.1, case control OR.
Dror, 6/7/2021, retrospective, Israel, peer-reviewed, 18 authors. risk of severe or critical case, 84.8% lower, RR 0.15, p = 0.001, high D levels 109 of 120 (90.8%), low D levels 76 of 133 (57.1%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >40ng/mL vs. <20ng/mL, multivariable.
Eden, 8/5/2021, retrospective, United Kingdom, peer-reviewed, 5 authors. risk of death, 63.9% lower, RR 0.36, p = 0.10, high D levels (≥25nmol/L) 3 of 26 (11.5%), low D levels (<25nmol/L) 8 of 25 (32.0%), NNT 4.9.
risk of death, 92.9% lower, RR 0.07, p = 0.18, high D levels (≥50nmol/L) 0 of 8 (0.0%), low D levels (<50nmol/L) 11 of 43 (25.6%), NNT 3.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Efe Iris, 12/30/2023, retrospective, Turkey, peer-reviewed, mean age 46.9, 8 authors. risk of case, 59.2% lower, OR 0.41, p < 0.001, cutoff 18.4ng/mL, inverted to make OR<1 favor high D levels (≥18.4ng/mL), RR approximated with OR.
Faniyi, 10/6/2020, prospective, United Kingdom, preprint, 10 authors. risk of seropositive, 28.8% lower, RR 0.71, p = 0.003, high D levels 170 of 331 (51.4%), low D levels 44 of 61 (72.1%), NNT 4.8, >30nmol/L.
Fatemi, 11/30/2021, prospective, Iran, peer-reviewed, 5 authors, study period 1 October, 2020 - 31 May, 2021. risk of death, 42.0% lower, RR 0.58, p = 0.07, high D levels 18 of 139 (12.9%), low D levels 25 of 109 (22.9%), NNT 10, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, vitamin D measured prior to COVID-19, multivariate.
risk of death, 51.1% lower, RR 0.49, p = 0.02, high D levels 13 of 115 (11.3%), low D levels 30 of 133 (22.6%), NNT 8.9, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, vitamin D measured on admission, multivariate.
risk of severe case, 37.9% lower, RR 0.62, p = 0.007, high D levels 38 of 139 (27.3%), low D levels 48 of 109 (44.0%), NNT 6.0, vitamin D measured prior to COVID-19.
risk of severe case, 34.8% lower, RR 0.65, p = 0.02, high D levels 31 of 115 (27.0%), low D levels 55 of 133 (41.4%), NNT 6.9, vitamin D measured on admission.
Faul, 6/30/2020, retrospective, Ireland, peer-reviewed, 9 authors. risk of mechanical ventilation, 69.0% lower, RR 0.31, p = 0.03, high D levels 4 of 21 (19.0%), low D levels 8 of 12 (66.7%), NNT 2.1, adjusted per study, >30nmol/L.
Ferrer-Sánchez, 3/26/2022, retrospective, Spain, peer-reviewed, 7 authors. risk of ICU admission, 81.8% lower, RR 0.18, p = 1.00, high D levels (≥20ng/mL) 0 of 9 (0.0%), low D levels (<20ng/mL) 4 of 73 (5.5%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), excluded in exclusion analyses: unadjusted results with no group details.
risk of moderate/severe case, 88.7% lower, RR 0.11, p = 1.00, high D levels (≥20ng/mL) 0 of 9 (0.0%), low D levels (<20ng/mL) 7 of 73 (9.6%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), excluded in exclusion analyses: unadjusted results with no group details.
risk of case, 62.7% lower, OR 0.37, p = 0.01, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
Freitas, 3/27/2021, retrospective, Portugal, preprint, 36 authors. risk of death, 41.2% lower, RR 0.59, p = 0.02, high D levels 23 of 179 (12.8%), low D levels 68 of 311 (21.9%), NNT 11, >20ng/mL.
Frish, 6/15/2023, retrospective, Israel, peer-reviewed, 7 authors, study period 1 February, 2020 - 31 December, 2020. risk of case, 35.5% lower, OR 0.65, p = 0.001, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
Galaznik, 5/28/2021, retrospective, USA, preprint, 6 authors. risk of case, 35.1% lower, OR 0.65, p = 0.01, high D levels 13,903, low D levels 2,384, adjusted per study, inverted to make OR<1 favor high D levels, breast cancer patients, logistic regression, RR approximated with OR.
risk of case, 32.4% lower, OR 0.68, p = 0.045, high D levels 13,601, low D levels 1,318, adjusted per study, inverted to make OR<1 favor high D levels, prostate cancer patients, logistic regression, RR approximated with OR.
García-Zendejas, 9/16/2024, retrospective, Mexico, peer-reviewed, mean age 53.4, 3 authors. risk of death, 65.2% lower, OR 0.35, p = 0.18, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
risk of ICU admission, 64.2% lower, OR 0.36, p = 0.15, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
risk of hospitalization, 83.7% lower, OR 0.16, p = 0.02, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
risk of case, 57.6% lower, OR 0.42, p = 0.26, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
Gaudio, 3/27/2021, retrospective, Italy, peer-reviewed, 6 authors. risk of case, 79.3% lower, OR 0.21, p < 0.001, high D levels 27 of 50 (54.0%) cases, 85 of 100 (85.0%) controls, NNT 2.7, case control OR.
Gavioli, 2/19/2021, retrospective, USA, peer-reviewed, 4 authors. risk of death, 4.7% higher, RR 1.05, p = 0.83, high D levels 80 of 260 (30.8%), low D levels 52 of 177 (29.4%), >20ng/ml.
risk of death, 44.8% lower, RR 0.55, p < 0.001, high D levels 102 of 376 (27.1%), low D levels 30 of 61 (49.2%), NNT 4.5, >10ng/ml.
risk of oxygen therapy, 55.2% lower, RR 0.45, p < 0.001, high D levels 127 of 260 (48.8%), low D levels 116 of 177 (65.5%), NNT 6.0, adjusted per study, inverted to make RR<1 favor high D levels, >20ng/ml, multivariate.
risk of hospitalization, 3.6% lower, RR 0.96, p = 0.41, high D levels 218 of 260 (83.8%), low D levels 154 of 177 (87.0%), NNT 32, >20ng/ml.
Ghanei, 3/23/2022, prospective, Iran, peer-reviewed, 6 authors, study period 20 March, 2020 - 20 January, 2021. risk of case, 42.1% lower, OR 0.58, p = 0.09, high D levels (≥20ng/ml) 58 of 90 (64.4%) cases, 72 of 95 (75.8%) controls, NNT 7.4, case control OR.
Gholi, 7/19/2022, prospective, Iran, peer-reviewed, 4 authors. risk of death, 74.7% lower, HR 0.25, p < 0.001, high D levels 157, low D levels 38, inverted to make HR<1 favor high D levels, >30ng/mL vs. <20ng/mL, model 2, day 45.
risk of death, 39.8% lower, HR 0.60, p = 0.05, high D levels 157, low D levels 38, inverted to make HR<1 favor high D levels, >30ng/mL vs. <20ng/mL, ICU mortality, model 2.
risk of mechanical ventilation, 44.9% higher, HR 1.45, p = 0.27, high D levels 157, low D levels 38, inverted to make HR<1 favor high D levels, >30ng/mL vs. <20ng/mL, model 2, day 45.
Golabi, 8/26/2021, retrospective, Iran, peer-reviewed, 10 authors. odds of symptoms, 90.0% lower, OR 0.10, p < 0.001, high D levels 34, low D levels 10, >30ng/mL vs. <20ng/mL, GEE regression, RR approximated with OR.
odds of symptoms, 81.0% lower, OR 0.19, p = 0.006, high D levels 34, low D levels 9, 20-30ng/mL vs. <20ng/mL, GEE regression, RR approximated with OR.
risk of case, 71.7% lower, OR 0.28, p = 0.07, high D levels 34 of 44 (77.3%) cases, 36 of 39 (92.3%) controls, NNT 3.5, case control OR, >30ng/mL vs. <20ng/mL.
Gonzalez, 3/13/2023, retrospective, Argentina, peer-reviewed, 10 authors. risk of death, 66.1% lower, OR 0.34, p = 0.046, high D levels (≥12ng/ml) 129, low D levels (<12ng/ml) 35, adjusted per study, inverted to make OR<1 favor high D levels (≥12ng/ml), multivariable, RR approximated with OR.
González-Estevez, 7/7/2021, retrospective, Mexico, peer-reviewed, 6 authors. risk of symptomatic case, 25.0% lower, RR 0.75, p = 0.04, high D levels (≥30ng/mL) 6 of 8 (75.0%), low D levels (<30ng/mL) 32 of 32 (100.0%), NNT 4.0.
Green, 11/7/2022, retrospective, Israel, peer-reviewed, 9 authors, study period 1 February, 2020 - 31 December, 2020. risk of case, 18.7% lower, OR 0.81, p < 0.001, cutoff 30ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥30ng/mL), multivariable, RR approximated with OR.
Guðnadóttir, 3/4/2024, retrospective, Iceland, peer-reviewed, 4 authors, study period February 2020 - March 2021. risk of death, 54.3% lower, OR 0.46, p = 0.15, high D levels (≥50nmol/L) 221, low D levels (<50nmol/L) 52, adjusted per study, inverted to make OR<1 favor high D levels (≥50nmol/L), multivariable, RR approximated with OR.
risk of mechanical ventilation, 8.3% lower, OR 0.92, p = 0.86, high D levels (≥50nmol/L) 221, low D levels (<50nmol/L) 52, adjusted per study, inverted to make OR<1 favor high D levels (≥50nmol/L), multivariable, RR approximated with OR.
risk of ICU admission, 28.1% lower, OR 0.72, p = 0.43, high D levels (≥50nmol/L) 221, low D levels (<50nmol/L) 52, adjusted per study, inverted to make OR<1 favor high D levels (≥50nmol/L), multivariable, RR approximated with OR.
Gönen, 11/12/2021, retrospective, Turkey, peer-reviewed, 20 authors, dosage varies. risk of death, 65.8% lower, RR 0.34, p = 0.62, high D levels (≥12ng/mL) 1 of 80 (1.2%), low D levels (<12ng/mL) 3 of 82 (3.7%), NNT 42, retrospective study.
risk of ICU admission, 16.9% lower, RR 0.83, p = 1.00, high D levels (≥12ng/mL) 4 of 77 (5.2%), low D levels (<12ng/mL) 5 of 80 (6.2%), NNT 95, retrospective study.
hospital stay >8 days, 21.1% lower, RR 0.79, p = 0.11, high D levels (≥12ng/mL) 40 of 78 (51.3%), low D levels (<12ng/mL) 52 of 80 (65.0%), NNT 7.3, retrospective study.
Hafez, 3/29/2022, retrospective, United Arab Emirates, peer-reviewed, mean age 43.0, 11 authors. risk of death, 97.7% lower, RR 0.02, p = 0.02, high D levels (≥12ng/mL) 6 of 116 (5.2%), low D levels (<12ng/mL) 3 of 10 (30.0%), NNT 4.0, adjusted per study, inverted to make RR<1 favor high D levels (≥12ng/mL), odds ratio converted to relative risk, multivariable, model 2.
risk of death, 96.3% lower, RR 0.04, p = 0.04, high D levels (≥20ng/mL) 4 of 64 (6.2%), low D levels (<20ng/mL) 5 of 62 (8.1%), adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable, model 3.
Hammam, 8/16/2024, retrospective, Egypt, peer-reviewed, 7 authors, study period December 2021 - April 2022. risk of severe case, 51.6% lower, RR 0.48, p = 0.02, high D levels (≥25ng/mL) 11 of 49 (22.4%), low D levels (<25ng/mL) 19 of 41 (46.3%), NNT 4.2, excluded in exclusion analyses: unadjusted results with no group details.
risk of case, 95.5% lower, OR 0.04, p < 0.001, cutoff 14.8ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥14.8ng/mL), multivariable, RR approximated with OR.
Hastie, 8/26/2020, retrospective, population-based cohort, database analysis, United Kingdom, peer-reviewed, 14 authors. risk of death, 17.4% lower, RR 0.83, p = 0.31, cutoff 25nmol/L, adjusted per study, inverted to make RR<1 favor high D levels (≥25nmol/L), multivariable Cox.
risk of hospitalization, 9.1% lower, RR 0.91, p = 0.40, cutoff 25nmol/L, adjusted per study, inverted to make RR<1 favor high D levels (≥25nmol/L), multivariable Cox.
Hemdan, 3/1/2022, retrospective, Saudi Arabia, peer-reviewed, 1 author, study period March 2020 - February 2021. risk of death, 30.7% lower, RR 0.69, p = 0.02, high D levels 36 of 92 (39.1%), low D levels 57 of 101 (56.4%), NNT 5.8.
Hermawan, 3/28/2023, retrospective, Indonesia, peer-reviewed, survey, 5 authors, study period March 2022 - July 2022. risk of symptomatic case, 70.6% lower, RR 0.29, p < 0.001, high D levels (≥10ng/ml) 10 of 34 (29.4%), low D levels (<10ng/ml) 13 of 13 (100.0%), NNT 1.4.
risk of symptomatic case, 45.6% lower, RR 0.54, p = 0.42, high D levels (≥20ng/ml) 2 of 7 (28.6%), low D levels (<20ng/ml) 21 of 40 (52.5%), NNT 4.2.
Hernández, 10/27/2020, retrospective, Spain, peer-reviewed, mean age 60.9, 12 authors. risk of combined death/ICU/ventilation, 83.0% lower, RR 0.17, p < 0.001, high D levels 35, low D levels 162, >= 20ng/mL risk of hospitalization * risk of death/ICU/ventilation | hospitalization.
risk of combined death/ICU/ventilation if hospitalized, 12.0% lower, RR 0.88, p = 0.86, high D levels 35, low D levels 162, >= 20ng/mL risk of death/ICU/ventilation | hospitalization.
risk of hospitalization, 80.6% lower, RR 0.19, p < 0.001, >= 20ng/mL.
Hogarth, 5/3/2023, retrospective, USA, peer-reviewed, median age 56.0, 9 authors, study period 1 January, 2021 - 8 November, 2021. risk of case, 46.5% lower, OR 0.53, p < 0.001, high D levels (≥20ng/mL) 96,894, low D levels (<20ng/mL) 13,486, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), breakthrough case, multivariable, RR approximated with OR.
Huang, 3/24/2023, retrospective, China, peer-reviewed, 5 authors, study period 14 June, 2021 - 1 April, 2022. recovery time, 25.0% lower, relative time 0.75, p = 0.02, high D levels (≥20ng/ml) 28, low D levels (<20ng/ml) 18, relative time until resolution of pneumonia.
Hurst, 10/22/2021, prospective, United Kingdom, peer-reviewed, 23 authors. risk of death, 68.4% lower, RR 0.32, p = 0.005, high D levels 68, low D levels 191, odds ratio converted to relative risk, >50nmol/l, multivariable, Supplementary Table 2, control prevalance approximated with overall prevalence.
risk of mechanical ventilation, 66.0% lower, RR 0.34, p = 0.004, high D levels 6 of 68 (8.8%), low D levels 61 of 191 (31.9%), NNT 4.3, odds ratio converted to relative risk, >50nmol/l, multivariable, Supplementary Table 2.
Im, 8/11/2020, retrospective, South Korea, peer-reviewed, 6 authors. risk of case, 73.1% lower, OR 0.27, p < 0.001, high D levels 13 of 50 (26.0%) cases, 85 of 150 (56.7%) controls, NNT 4.3, case control OR.
Infante, 2/18/2021, retrospective, Italy, peer-reviewed, 11 authors. risk of death, 54.8% lower, RR 0.45, p = 0.046, high D levels 4 of 19 (21.1%), low D levels 55 of 118 (46.6%), NNT 3.9, >20ng/mL.
Israel, 9/20/2021, retrospective, population-based cohort, Israel, peer-reviewed, 9 authors, study period 1 March, 2020 - 31 October, 2020. risk of severe case, 33.9% lower, OR 0.66, p < 0.001, high D levels 423 of 1,036 (40.8%) cases, 509 of 934 (54.5%) controls, NNT 7.3, adjusted per study, inverted to make OR<1 favor high D levels, case control OR, >75 nmol/L vs. <30 nmol/L, multivariable.
risk of case, 19.7% lower, OR 0.80, p < 0.001, high D levels 6,152 of 15,892 (38.7%) cases, 73,810 of 159,193 (46.4%) controls, NNT 39, adjusted per study, inverted to make OR<1 favor high D levels, case control OR, >75 nmol/L vs. <30 nmol/L, among COVID+ cases, multivariable.
Jain (B), 11/19/2020, prospective, India, peer-reviewed, 6 authors. risk of death, 85.2% lower, RR 0.15, p = 0.001, high D levels 2 of 64 (3.1%), low D levels 19 of 90 (21.1%), NNT 5.6, >20ng/mL.
risk of ICU admission, 95.4% lower, RR 0.05, p < 0.001, high D levels 2 of 64 (3.1%), low D levels 61 of 90 (67.8%), NNT 1.5, >20ng/mL.
Jalavu, 6/1/2023, prospective, South Africa, peer-reviewed, 16 authors, study period 29 October, 2020 - 10 February, 2021. risk of death, 1.0% lower, HR 0.99, p = 0.97, high D levels (≥50nmol/L) 16 of 31 (51.6%), low D levels (<50nmol/L) 38 of 55 (69.1%), NNT 5.7, Kaplan–Meier.
Jimenez, 7/26/2021, retrospective, Spain, peer-reviewed, 21 authors, study period 12 March, 2020 - 21 May, 2020, dosage paricalcitol 0.9μg weekly, excluded in exclusion analyses: many patients received vitamin D treatment. risk of death, 7.7% higher, OR 1.08, p = 0.81, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels.
risk of mechanical ventilation, 47.5% lower, OR 0.53, p = 0.56, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels.
risk of ICU admission, 12.2% lower, OR 0.88, p = 0.87, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels.
risk of hospitalization, 0.8% lower, OR 0.99, p = 0.98, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels.
Jude, 6/17/2021, retrospective, United Kingdom, peer-reviewed, 5 authors. risk of hospitalization, 71.6% lower, RR 0.28, p < 0.001, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >25 nmol/L, control prevalence approximated with overall prevalence.
risk of hospitalization, 57.9% lower, RR 0.42, p < 0.001, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >50 nmol/L, control prevalence approximated with overall prevalence.
Junior, 2/17/2022, prospective, Brazil, peer-reviewed, 6 authors, dosage not specified. risk of mechanical ventilation, 84.4% lower, OR 0.16, p = 0.03, cutoff 40ng/dl, inverted to make OR<1 favor high D levels (≥40ng/dl), risk of mechanical ventilation for vitamin D levels >40ng/ml, RR approximated with OR, outcome based on serum levels.
Kalichuran, 4/26/2022, prospective, South Africa, peer-reviewed, survey, 4 authors, study period September 2020 - February 2021. risk of symptomatic case, 60.0% lower, RR 0.40, p < 0.001, high D levels (≥20ng/mL) 56, low D levels (<20ng/mL) 44, inverted to make RR<1 favor high D levels (≥20ng/mL).
risk of symptomatic case, 58.2% lower, RR 0.42, p = 0.004, inverted to make RR<1 favor high D levels, higher sunlight exposure vs. lower sunlight exposure.
Karahan, 10/5/2020, retrospective, Turkey, peer-reviewed, 2 authors. risk of death, 82.5% lower, RR 0.17, p < 0.001, high D levels 5 of 46 (10.9%), low D levels 64 of 103 (62.1%), NNT 2.0, >20nmol/L.
Karonova (B), 3/2/2022, retrospective, Russia, peer-reviewed, 11 authors, study period 30 November, 2020 - 20 March, 2021. risk of severe case, 22.5% lower, OR 0.78, p = 0.01, cutoff 11.4ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥11.4ng/mL), multivariable, RR approximated with OR.
Karonova (C), 8/29/2021, retrospective, Russia, peer-reviewed, 8 authors, study period April 2020 - December 2020. risk of death, 77.8% lower, RR 0.22, p = 0.006, high D levels 8 of 96 (8.3%), low D levels 10 of 37 (27.0%), NNT 5.3, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >10ng/mL, logistic regression model 2.
risk of death, 84.8% lower, RR 0.15, p = 0.06, high D levels 1 of 43 (2.3%), low D levels 17 of 90 (18.9%), NNT 6.0, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, logistic regression model 2.
risk of severe case, 67.3% lower, RR 0.33, p = 0.005, high D levels 12 of 96 (12.5%), low D levels 13 of 37 (35.1%), NNT 4.4, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >10ng/mL, logistic regression model 2.
risk of severe case, 53.2% lower, RR 0.47, p = 0.13, high D levels 4 of 43 (9.3%), low D levels 21 of 90 (23.3%), NNT 7.1, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, logistic regression model 2.
Karonova (D), 12/31/2020, retrospective, Russia, peer-reviewed, 3 authors. risk of death, 79.4% lower, RR 0.21, p = 0.11, high D levels 1 of 23 (4.3%), low D levels 12 of 57 (21.1%), NNT 6.0, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/ml.
risk of severe case, 71.1% lower, RR 0.29, p = 0.05, high D levels 3 of 23 (13.0%), low D levels 22 of 57 (38.6%), NNT 3.9, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/ml.
Katz, 12/4/2020, retrospective, population-based cohort, USA, peer-reviewed, 3 authors. risk of case, 78.4% lower, RR 0.22, p < 0.001, high D levels 85 of 101,175 (0.1%), low D levels 87 of 31,950 (0.3%), NNT 531, adjusted per study, inverted to make RR<1 favor high D levels.
Kaufman, 9/17/2020, retrospective, population-based cohort, USA, peer-reviewed, median age 54.0, 5 authors. risk of case, 53.0% lower, RR 0.47, p < 0.001, high D levels 12,321, low D levels 39,190, >55 ng/mL vs. <20 ng/mL.
Kaur, 11/30/2021, prospective, India, peer-reviewed, 5 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 89.8% lower, RR 0.10, p < 0.001, high D levels (≥10ng/mL) 5 of 64 (7.8%), low D levels (<10ng/mL) 13 of 17 (76.5%), NNT 1.5.
risk of mechanical ventilation, 90.3% lower, RR 0.10, p < 0.001, high D levels (≥10ng/mL) 4 of 64 (6.2%), low D levels (<10ng/mL) 11 of 17 (64.7%), NNT 1.7.
Kazemi, 5/7/2022, retrospective, Iran, peer-reviewed, mean age 56.0, 4 authors. risk of death, 75.8% lower, RR 0.24, p = 0.26, high D levels (≥30ng/mL) 1 of 75 (1.3%), low D levels (<30ng/mL) 7 of 127 (5.5%), NNT 24.
risk of severe case, 4.8% higher, RR 1.05, p = 1.00, high D levels (≥30ng/mL) 13 of 75 (17.3%), low D levels (<30ng/mL) 21 of 127 (16.5%).
Khalil, 11/8/2022, retrospective, Iraq, peer-reviewed, 3 authors. risk of case, 41.6% lower, OR 0.58, p = 0.27, high D levels (≥10ng/ml) 30 of 52 (57.7%) cases, 21 of 30 (70.0%) controls, NNT 8.2, case control OR.
Lau, 4/28/2020, retrospective, USA, preprint, 7 authors. risk of ICU admission, 45.0% lower, RR 0.55, p = 0.29, high D levels 2 of 5 (40.0%), low D levels 11 of 15 (73.3%), NNT 3.0, >30ng/mL.
Li, 5/19/2021, retrospective, USA, peer-reviewed, 4 authors. risk of case, 8.6% lower, RR 0.91, p = 0.24, high D levels 610 of 13,650 (4.5%), low D levels 290 of 4,498 (6.4%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, Figure 2.
risk of case, 12.4% lower, RR 0.88, p = 0.07, high D levels 289 of 7,272 (4.0%), low D levels 611 of 10,876 (5.6%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >30ng/mL, Figure 2.
Li (B), 1/11/2021, retrospective, population-based cohort, United Kingdom, peer-reviewed, 6 authors. risk of hospitalization, 36.2% lower, RR 0.64, p < 0.001, NNT 932, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >25nmol/L.
risk of case, 29.5% lower, RR 0.71, p < 0.001, NNT 823, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >25nmol/L.
Livingston, 4/2/2021, retrospective, United Kingdom, peer-reviewed, 7 authors. risk of case, 50.9% lower, RR 0.49, p = 0.02, high D levels 16 of 52 (30.8%), low D levels 31 of 52 (59.6%), NNT 3.5, odds ratio converted to relative risk, >34.4nmol/L.
Lohia, 3/4/2021, retrospective, USA, peer-reviewed, 4 authors. risk of death, 14.7% lower, RR 0.85, p = 0.56, high D levels 88, low D levels 95, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, >30 ng/mL vs. <20 ng/mL, >30 ng/mL group size approximated.
risk of mechanical ventilation, 18.9% lower, RR 0.81, p = 0.48, high D levels 88, low D levels 95, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, >30 ng/mL vs. <20 ng/mL, >30 ng/mL group size approximated.
risk of ICU admission, 28.5% lower, RR 0.72, p = 0.17, high D levels 88, low D levels 95, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, >30 ng/mL vs. <20 ng/mL, >30 ng/mL group size approximated.
Luo, 11/13/2020, retrospective, China, peer-reviewed, median age 56.0, 5 authors. risk of progression, 63.0% lower, RR 0.37, p = 0.01, high D levels 335, low D levels 560, >30nmol/L.
Ma, 12/3/2021, retrospective, USA, peer-reviewed, 16 authors, study period May 2020 - March 2021, dosage varies. risk of hospitalization, 67.0% lower, OR 0.33, p = 0.15, high D levels 7,893, low D levels 7,823, adjusted per study, highest quintile vs. lowest quintile predicted vitamin D levels, model 3, supplemental table 3, multivariable, RR approximated with OR, outcome based on serum levels.
risk of symptomatic case, 9.0% lower, OR 0.91, p = 0.52, high D levels 7,893, low D levels 7,823, adjusted per study, highest quintile vs. lowest quintile predicted vitamin D levels, model 3, supplemental table 3, multivariable, RR approximated with OR, outcome based on serum levels.
risk of case, 52.0% lower, OR 0.48, p = 0.01, high D levels 7,893, low D levels 7,823, adjusted per study, highest quintile vs. lowest quintile predicted vitamin D levels, model 3, supplemental table 3, multivariable, RR approximated with OR, outcome based on serum levels.
Macaya, 10/21/2020, retrospective, Spain, peer-reviewed, 8 authors. risk of severe case, 55.0% lower, RR 0.45, p = 0.07, high D levels 11 of 35 (31.4%), low D levels 20 of 45 (44.4%), NNT 7.7, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL.
Manojlovic, 6/15/2023, retrospective, Serbia, peer-reviewed, mean age 57.6, 11 authors, excluded in exclusion analyses: unadjusted differences between groups. risk of death, 89.9% lower, RR 0.10, p = 0.009, high D levels (≥30nmol/l) 1 of 41 (2.4%), low D levels (<30nmol/l) 8 of 33 (24.2%), NNT 4.6.
Martínez-Rodríguez, 3/31/2022, retrospective, Mexico, peer-reviewed, 5 authors. risk of death, 52.2% lower, OR 0.48, p = 0.04, cutoff 20ng/mL, adjusted per study, multivariable, RR approximated with OR.
Matin, 7/30/2021, retrospective, case control, Iran, peer-reviewed, 8 authors. risk of case, 66.1% lower, OR 0.34, p < 0.001, inverted to make OR<1 favor high D levels, case control OR, >20ng/mL.
Mayurathan, 8/8/2023, retrospective, Sri Lanka, peer-reviewed, 11 authors. risk of death, 98.2% higher, RR 1.98, p = 0.69, high D levels (≥20ng/mL) 8 of 113 (7.1%), low D levels (<20ng/mL) 1 of 28 (3.6%).
risk of severe case, 67.3% higher, RR 1.67, p = 0.32, high D levels (≥20ng/mL) 27 of 113 (23.9%), low D levels (<20ng/mL) 4 of 28 (14.3%).
Mazziotti, 3/5/2021, retrospective, Italy, peer-reviewed, 11 authors, dosage varies. risk of death, 2.4% lower, RR 0.98, p = 0.91, high D levels 187, low D levels 161, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, control prevalance approximated with overall prevalence, outcome based on serum levels.
risk of acute hypoxemic respiratory failure, 37.0% lower, RR 0.63, p = 0.006, high D levels 72 of 187 (38.5%), low D levels 97 of 161 (60.2%), NNT 4.6, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, outcome based on serum levels.
Meltzer, 3/19/2021, retrospective, database analysis, USA, peer-reviewed, 6 authors. risk of case, 34.6% lower, RR 0.65, p = 0.11, high D levels 61 of 1,097 (5.6%), low D levels 118 of 1,251 (9.4%), NNT 26, adjusted per study, inverted to make RR<1 favor high D levels, >40ng/mL vs. <20ng/mL, Table 2, Model 2.
Meltzer (B), 9/3/2020, retrospective, USA, peer-reviewed, 6 authors. risk of case, 43.5% lower, RR 0.56, p = 0.02, high D levels 39 of 317 (12.3%), low D levels 32 of 172 (18.6%), NNT 16, adjusted per study, inverted to make RR<1 favor high D levels, >20ng/mL.
Mendy, 6/27/2020, retrospective, USA, preprint, 4 authors. risk of death, 7.0% lower, RR 0.93, p = 0.89, high D levels 21 of 600 (3.5%), low D levels 5 of 89 (5.6%), inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
risk of death/ICU, 16.7% lower, RR 0.83, p < 0.001, high D levels 68 of 600 (11.3%), low D levels 23 of 89 (25.8%), NNT 6.9, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
risk of ICU admission, 55.3% lower, RR 0.45, p = 0.008, high D levels 47 of 600 (7.8%), low D levels 18 of 89 (20.2%), NNT 8.1, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
risk of hospitalization, 15.1% lower, RR 0.85, p < 0.001, high D levels 171 of 600 (28.5%), low D levels 45 of 89 (50.6%), NNT 4.5, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
Merzon, 7/23/2020, retrospective, Israel, peer-reviewed, 7 authors. risk of hospitalization, 46.4% lower, RR 0.54, p = 0.06, high D levels 79, low D levels 703, odds ratio converted to relative risk, >30ng/mL.
risk of case, 28.4% lower, RR 0.72, p < 0.001, high D levels 1,139, low D levels 6,668, odds ratio converted to relative risk, >30ng/mL.
Mingiano, 7/30/2023, retrospective, Italy, peer-reviewed, 11 authors, study period November 2020 - February 2021, dosage calcifediol 450μg days 1-2, patients with deficiency only. risk of death, 49.8% lower, RR 0.50, p = 0.005, cutoff 10ng/mL, outcome based on serum levels.
risk of death, 35.9% lower, RR 0.64, p = 0.04, cutoff 20ng/mL, outcome based on serum levels.
Mirkarimi, 11/6/2024, retrospective, Iran, peer-reviewed, 7 authors, study period May 2022 - May 2023. risk of moderate/severe case, 62.9% lower, RR 0.37, p < 0.001, high D levels (≥20 ng/mL) 117 of 345 (33.9%), low D levels (<20 ng/mL) 233 of 255 (91.4%), NNT 1.7, moderate/severe vs. mild.
Mostafa, 11/30/2022, retrospective, Egypt, peer-reviewed, 10 authors, study period November 2020 - December 2021, excluded in exclusion analyses: categorical results are unadjusted with significant differences between groups. risk of death, 92.8% lower, RR 0.07, p < 0.001, high D levels (≥20ng/mL) 4 of 135 (3.0%), low D levels (<20ng/mL) 21 of 51 (41.2%), NNT 2.6, unadjusted, normal vs. deficiency.
risk of mechanical ventilation, 95.0% lower, RR 0.05, p < 0.001, high D levels (≥20ng/mL) 4 of 135 (3.0%), low D levels (<20ng/mL) 30 of 51 (58.8%), NNT 1.8, unadjusted, normal vs. deficiency.
risk of ICU admission, 90.6% lower, RR 0.09, p < 0.001, high D levels (≥20ng/mL) 9 of 135 (6.7%), low D levels (<20ng/mL) 36 of 51 (70.6%), NNT 1.6, unadjusted, normal vs. deficiency.
Nasiri, 6/30/2021, retrospective, Iran, peer-reviewed, 3 authors. risk of death, 8.9% higher, OR 1.09, p = 0.89, high D levels (≥30ng/mL) 238, low D levels (<20ng/mL) 43, inverted to make OR<1 favor high D levels (≥30ng/mL), RR approximated with OR.
Neves, 6/14/2022, retrospective, Brazil, peer-reviewed, mean age 62.1, 7 authors, study period July 2020 - December 2020, excluded in exclusion analyses: excessive unadjusted differences between groups. risk of death, 57.1% lower, RR 0.43, p = 0.046, high D levels (≥50nmol/L) 12 of 87 (13.8%), low D levels (<50nmol/L) 9 of 28 (32.1%), NNT 5.4.
risk of ICU admission, 19.5% higher, RR 1.20, p = 0.81, high D levels (≥50nmol/L) 26 of 87 (29.9%), low D levels (<50nmol/L) 7 of 28 (25.0%).
Nguyen, 5/3/2022, retrospective, USA, peer-reviewed, 11 authors, study period 15 July, 2020 - 15 October, 2020. risk of death, 81.1% lower, OR 0.19, p = 0.008, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), 25-OH-D3, multivariable, RR approximated with OR.
risk of mechanical ventilation, 52.8% lower, OR 0.47, p = 0.13, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), 25-OH-D3, multivariable, RR approximated with OR.
risk of no hospital discharge, 74.0% lower, HR 0.26, p < 0.001, cutoff 20ng/mL, 25-OH-D3, Cox proportional hazards.
Nimavat, 8/5/2021, retrospective, India, peer-reviewed, 5 authors. risk of death, 50.4% lower, RR 0.50, p = 0.17, high D levels 13 of 131 (9.9%), low D levels 5 of 25 (20.0%), NNT 9.9, >10ng/mL, within cases.
risk of severe case, 67.6% lower, RR 0.32, p = 0.003, high D levels 17 of 131 (13.0%), low D levels 10 of 25 (40.0%), NNT 3.7, >10ng/mL, within cases.
Orchard, 1/19/2021, retrospective, United Kingdom, peer-reviewed, 7 authors. risk of ICU admission, 58.8% lower, RR 0.41, p = 0.001, high D levels 9 of 40 (22.5%), low D levels 41 of 75 (54.7%), NNT 3.1, all hospitalized patients, >50 nmol/L.
risk of death, 24.1% lower, RR 0.76, p = 1.00, high D levels 1 of 9 (11.1%), low D levels 6 of 41 (14.6%), NNT 28, ICU patients only, >50 nmol/L.
risk of mechanical ventilation, 8.9% lower, RR 0.91, p = 0.70, high D levels 6 of 9 (66.7%), low D levels 30 of 41 (73.2%), NNT 15, ICU patients only, >50 nmol/L.
Ortatatli, 2/14/2023, prospective, Turkey, peer-reviewed, 9 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 82.1% lower, RR 0.18, p = 0.09, cutoff 20ng/mL, inverted to make RR<1 favor high D levels (≥20ng/mL), 25(OH)D.
risk of death, 73.7% lower, RR 0.26, p = 0.04, cutoff 1ng/mL, inverted to make RR<1 favor high D levels (≥1ng/mL), 1,25(OH)2D.
Ozturk, 5/16/2022, retrospective, Turkey, peer-reviewed, 6 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of severe case, 46.4% lower, RR 0.54, p = 0.10, high D levels (≥20ng/mL) 9 of 110 (8.2%), low D levels (<20ng/mL) 29 of 190 (15.3%), NNT 14.
Panagiotou, 6/30/2020, retrospective, United Kingdom, preprint, 12 authors. risk of ICU admission, 52.0% lower, RR 0.48, p = 0.02, high D levels 8 of 44 (18.2%), low D levels 34 of 90 (37.8%), NNT 5.1, >50nmol/L.
Pande, 3/16/2022, retrospective, India, peer-reviewed, 7 authors, study period October 2020 - October 2021, excluded in exclusion analyses: unadjusted results with no group details. risk of severe case, 93.4% lower, RR 0.07, p < 0.001, high D levels (≥20ng/ml) 7 of 116 (6.0%), low D levels (<20ng/ml) 85 of 93 (91.4%), NNT 1.2.
Parra-Ortega, 8/24/2021, prospective, Mexico, peer-reviewed, 9 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 98.7% lower, RR 0.01, p < 0.001, high D levels (≥20ng/dL) 0 of 15 (0.0%), low D levels (<20ng/dL) 63 of 79 (79.7%), NNT 1.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), unadjusted.
Pavlyshyn, 4/5/2024, retrospective, Ukraine, peer-reviewed, 3 authors. risk of severe case, 59.7% lower, RR 0.40, p = 0.13, high D levels (≥20ng/ml) 7 of 59 (11.9%), low D levels (<20ng/ml) 5 of 17 (29.4%), NNT 5.7, deficiency vs. other.
risk of case, 89.0% lower, OR 0.11, p = 0.13, high D levels (≥20ng/ml) 59 of 76 (77.6%) cases, 15 of 15 (100.0%) controls, NNT 4.9, case control OR.
Pecina, 8/27/2021, retrospective, USA, peer-reviewed, 4 authors, dosage not specified. risk of death, 35.9% lower, RR 0.64, p = 0.74, high D levels (≥20ng/mL) 6 of 77 (7.8%), low D levels (<20ng/mL) 1 of 15 (6.7%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
risk of mechanical ventilation, 56.9% lower, RR 0.43, p = 0.22, high D levels (≥20ng/mL) 8 of 15 (53.3%), low D levels (<20ng/mL) 4 of 15 (26.7%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
risk of ICU admission, 13.1% higher, RR 1.13, p = 0.57, high D levels (≥20ng/mL) 54 of 77 (70.1%), low D levels (<20ng/mL) 9 of 15 (60.0%), inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable logistic regression, outcome based on serum levels.
Pepkowitz, 9/29/2020, retrospective, USA, preprint, 7 authors. risk of ICU admission, 55.8% lower, RR 0.44, p = 0.01, high D levels (≥20ng/mL) 9 of 24 (37.5%), low D levels (<20ng/mL) 11 of 13 (84.6%), NNT 2.1, inverted to make RR<1 favor high D levels (≥20ng/mL).
Pietzner, 7/8/2024, retrospective, United Kingdom, peer-reviewed, 9 authors. risk of death, 55.4% lower, HR 0.45, p < 0.001, cutoff 25nmol/L, inverted to make HR<1 favor high D levels (≥25nmol/L), Cox proportional hazards.
risk of hospitalization, 52.6% lower, HR 0.47, p < 0.001, cutoff 25nmol/L, inverted to make HR<1 favor high D levels (≥25nmol/L), Cox proportional hazards.
severe respiratory failure, 24.8% lower, HR 0.75, p = 0.05, cutoff 25nmol/L, inverted to make HR<1 favor high D levels (≥25nmol/L), Cox proportional hazards.
risk of PASC, 56.1% lower, HR 0.44, p < 0.001, cutoff 25nmol/L, inverted to make HR<1 favor high D levels (≥25nmol/L), Cox proportional hazards.
Pimental, 5/31/2021, retrospective, Brazil, peer-reviewed, 3 authors. risk of death, 29.4% lower, RR 0.71, p = 1.00, high D levels 3 of 17 (17.6%), low D levels 2 of 8 (25.0%), NNT 14, >20ng/mL.
Protas, 4/6/2023, retrospective, Kazakhstan, peer-reviewed, survey, 6 authors, study period October 2022 - November 2022. risk of case, 76.6% lower, OR 0.23, p = 0.06, high D levels (≥10ng/ml) 68 of 88 (77.3%) cases, 29 of 31 (93.5%) controls, NNT 4.8, case control OR.
risk of case, 46.2% lower, OR 0.54, p = 0.17, high D levels (≥20ng/ml) 50 of 88 (56.8%) cases, 22 of 31 (71.0%) controls, NNT 8.8, case control OR.
Putra, 12/10/2021, retrospective, Indonesia, peer-reviewed, 3 authors, study period February 2020 - September 2020. risk of hospitalization, 25.6% lower, OR 0.74, p = 0.59, high D levels 9 of 31 (29.0%) cases, 11 of 31 (35.5%) controls, NNT 14, case control OR.
Rachman, 9/13/2024, retrospective, Indonesia, peer-reviewed, mean age 42.8, 5 authors, study period October 2021 - January 2022. risk of severe case, 51.5% lower, RR 0.48, p = 0.37, high D levels (≥20ng/mL) 2 of 28 (7.1%), low D levels (<20ng/mL) 19 of 129 (14.7%), NNT 13.
Rachman (B), 4/13/2023, prospective, Indonesia, peer-reviewed, 4 authors, study period October 2021 - February 2022. risk of death, 94.8% lower, RR 0.05, p = 0.04, high D levels (≥20ng/mL) 0 of 45 (0.0%), low D levels (<20ng/mL) 14 of 146 (9.6%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of severe case, 77.6% lower, RR 0.22, p = 0.01, high D levels (≥20ng/mL) 2 of 45 (4.4%), low D levels (<20ng/mL) 29 of 146 (19.9%), NNT 6.5.
Radujkovic, 9/10/2020, prospective, Germany, peer-reviewed, 6 authors. risk of death, 93.2% lower, HR 0.07, p = 0.001, high D levels 144, low D levels 12, >30nmol/L.
risk of death/intubation, 84.0% lower, HR 0.16, p < 0.001, high D levels 144, low D levels 12, >30nmol/L.
Ramirez-Sandoval, 10/15/2021, retrospective, Mexico, peer-reviewed, 7 authors. risk of death, 31.5% lower, HR 0.68, p < 0.001, high D levels 2,337, low D levels 571, adjusted per study, inverted to make HR<1 favor high D levels, >12.5ng/mL, 30 day in-hospital mortality.
hospitalization time, 22.2% lower, relative time 0.78, p < 0.001, high D levels 2,337, low D levels 571.
Ramos, 11/15/2021, retrospective, Brazil, peer-reviewed, 11 authors. risk of case, 45.7% lower, RR 0.54, p = 0.16, high D levels (≥20ng/mL) 4 of 9 (44.4%), low D levels (<20ng/mL) 9 of 11 (81.8%), NNT 2.7.
Ranjbar, 11/29/2021, retrospective, Iran, peer-reviewed, 27 authors, study period 16 February, 2020 - 21 March, 2020. risk of death, 41.9% lower, RR 0.58, p = 0.07, high D levels (≥20ng/mL) 16 of 163 (9.8%), low D levels (<20ng/mL) 26 of 154 (16.9%), NNT 14.
Reis, 5/21/2021, prospective, Brazil, peer-reviewed, 19 authors. risk of death, 23.0% lower, HR 0.77, p = 0.82, high D levels (≥10ng/mL) 198, low D levels (<10ng/mL) 16, model 2, Cox proportional hazards.
risk of mechanical ventilation, 45.0% higher, HR 1.45, p = 0.77, high D levels (≥10ng/mL) 198, low D levels (<10ng/mL) 16, adjusted per study, model 2, multivariable, Cox proportional hazards.
risk of no hospital discharge, 33.3% lower, HR 0.67, p = 0.18, high D levels (≥10ng/mL) 198, low D levels (<10ng/mL) 16, adjusted per study, inverted to make HR<1 favor high D levels (≥10ng/mL), model 2, multivariable, Cox proportional hazards.
hospitalization time, 22.2% lower, relative time 0.78, p = 0.06, high D levels (≥10ng/mL) 191, low D levels (<10ng/mL) 15, model 2.
Renieris, 11/26/2023, retrospective, Greece, peer-reviewed, 10 authors, trial NCT04357366 (history). risk of death, 52.4% lower, HR 0.48, p = 0.04, high D levels (≥20ng/mL) 17 of 130 (13.1%), low D levels (<20ng/mL) 17 of 60 (28.3%), NNT 6.6, inverted to make HR<1 favor high D levels (≥20ng/mL).
Reyes Pérez, 4/30/2020, retrospective, Mexico, peer-reviewed, 5 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 61.7% lower, RR 0.38, p = 0.006, high D levels (≥8ng/mL) 21 of 137 (15.3%), low D levels (<8ng/mL) 14 of 35 (40.0%), NNT 4.1, inverted to make RR<1 favor high D levels (≥8ng/mL), odds ratio converted to relative risk.
Ribeiro, 8/5/2021, retrospective, Brazil, peer-reviewed, 8 authors. risk of case, 50.5% lower, OR 0.50, p = 0.01, inverted to make OR<1 favor high D levels, >30ng/mL, multivariate, RR approximated with OR.
Ricci, 3/3/2021, retrospective, Italy, peer-reviewed, 15 authors. risk of death, 87.6% lower, RR 0.12, p = 0.07, high D levels 0 of 30 (0.0%), low D levels 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >10 ng/mL.
Ritsinger, 4/28/2023, retrospective, Sweden, peer-reviewed, mean age 79.8, 8 authors, study period 1 January, 2020 - 9 September, 2021. risk of death, 9.1% lower, HR 0.91, p < 0.001, high D levels (≥50nmol/L) 37,972, low D levels (<50nmol/L) 6,894, inverted to make HR<1 favor high D levels (≥50nmol/L).
Rodríguez-Vidales, 2/24/2022, retrospective, Mexico, peer-reviewed, 8 authors, study period March 2020 - September 2020. risk of severe case, 38.9% lower, RR 0.61, p = 0.05, high D levels (≥10ng/mL) 89 of 265 (33.6%), low D levels (<10ng/mL) 27 of 32 (84.4%), NNT 2.0, adjusted per study, inverted to make RR<1 favor high D levels (≥10ng/mL), odds ratio converted to relative risk, multivariable.
Rozemeijer, 1/29/2024, prospective, Netherlands, peer-reviewed, 9 authors. risk of ICU admission, 35.7% lower, OR 0.64, p = 0.67, high D levels (≥50nmol/L) 6 of 20 (30.0%) cases, 2 of 5 (40.0%) controls, NNT 14, case control OR.
Sanamandra, 4/30/2023, prospective, India, peer-reviewed, 6 authors, study period August 2020 - March 2021. risk of death, 20.9% lower, OR 0.79, p = 0.67, high D levels (≥10ng/mL) 155, low D levels (<10ng/mL) 45, inverted to make OR<1 favor high D levels (≥10ng/mL), RR approximated with OR.
risk of mechanical ventilation, 15.3% lower, OR 0.85, p = 0.73, high D levels (≥10ng/mL) 155, low D levels (<10ng/mL) 45, inverted to make OR<1 favor high D levels (≥10ng/mL), RR approximated with OR.
risk of severe case, 434.8% higher, OR 5.35, p = 0.12, high D levels (≥10ng/mL) 155, low D levels (<10ng/mL) 45, inverted to make OR<1 favor high D levels (≥10ng/mL), RR approximated with OR.
Sanson, 2/19/2022, prospective, Italy, peer-reviewed, 13 authors, study period March 2020 - September 2020, excluded in exclusion analyses: unadjusted results with no group details. NIV/IMV/death, 64.0% lower, RR 0.36, p = 0.03, high D levels (≥30ng/mL) 2 of 9 (22.2%), low D levels (<30ng/mL) 37 of 60 (61.7%), NNT 2.5.
Saponaro, 1/24/2022, retrospective, Italy, peer-reviewed, 13 authors, study period March 2020 - May 2020. risk of ARDS, 36.5% lower, RR 0.64, p = 0.43, high D levels (≥20ng/ml) 5 of 32 (15.6%), low D levels (<20ng/ml) 15 of 61 (24.6%), NNT 11, severe ARDS.
Savitri, 5/8/2021, retrospective, Indonesia, peer-reviewed, 5 authors. risk of symptomatic case, 88.0% lower, RR 0.12, p < 0.001, high D levels 3 of 25 (12.0%), low D levels 17 of 17 (100.0%), NNT 1.1, >20ng/ml.
Schmidt, 3/22/2023, prospective, Poland, peer-reviewed, 4 authors, study period 4 February, 2021 - 31 December, 2021. risk of death, 85.5% lower, OR 0.14, p = 0.003, cutoff 27ng/mL, inverted to make OR<1 favor high D levels (≥27ng/mL), RR approximated with OR.
Seal, 1/1/2022, retrospective, USA, peer-reviewed, 6 authors. risk of death, 45.1% lower, RR 0.55, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 60ng/mL vs. 15 ng/mL.
risk of death, 40.5% lower, RR 0.60, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 50ng/mL vs. 15 ng/mL.
risk of death, 34.6% lower, RR 0.65, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 40ng/mL vs. 15 ng/mL.
risk of death, 25.9% lower, RR 0.74, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 30ng/mL vs. 15 ng/mL.
risk of death, 20.0% lower, RR 0.80, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 25ng/mL vs. 15 ng/mL.
risk of death, 11.5% lower, RR 0.88, p = 0.001, adjusted per study, inverted to make RR<1 favor high D levels, 20ng/mL vs. 15 ng/mL.
risk of hospitalization, 22.5% lower, RR 0.78, p = 0.01, adjusted per study, inverted to make RR<1 favor high D levels, 60ng/mL vs. 15 ng/mL.
risk of hospitalization, 20.0% lower, RR 0.80, p = 0.009, adjusted per study, inverted to make RR<1 favor high D levels, 50ng/mL vs. 15 ng/mL.
risk of hospitalization, 16.7% lower, RR 0.83, p = 0.007, adjusted per study, inverted to make RR<1 favor high D levels, 40ng/mL vs. 15 ng/mL.
risk of hospitalization, 12.3% lower, RR 0.88, p = 0.008, adjusted per study, inverted to make RR<1 favor high D levels, 30ng/mL vs. 15 ng/mL.
risk of hospitalization, 9.1% lower, RR 0.91, p = 0.01, adjusted per study, inverted to make RR<1 favor high D levels, 25ng/mL vs. 15 ng/mL.
risk of hospitalization, 4.8% lower, RR 0.95, p = 0.02, adjusted per study, inverted to make RR<1 favor high D levels, 20ng/mL vs. 15 ng/mL.
Seven, 11/23/2021, prospective, Turkey, peer-reviewed, 6 authors, study period September 2020 - November 2020. risk of severe disease or poor prognostic factor, 46.5% lower, RR 0.53, p = 0.006, cutoff 14.5ng/ml, inverted to make RR<1 favor high D levels (≥14.5ng/ml).
Sinaci, 8/11/2021, retrospective, Turkey, peer-reviewed, 10 authors, dosage not specified. risk of moderate/severe case, 79.5% lower, RR 0.21, p < 0.001, high D levels (≥10ng/mL) 8 of 100 (8.0%), low D levels (<10ng/mL) 23 of 59 (39.0%), NNT 3.2, outcome based on serum levels.
risk of case, 59.9% lower, RR 0.40, p < 0.001, high D levels (≥10ng/mL) 100 of 397 (25.2%), low D levels (<10ng/mL) 59 of 94 (62.8%), NNT 2.7, outcome based on serum levels.
Singhsakul, 6/9/2024, retrospective, Thailand, peer-reviewed, mean age 50.8, 6 authors, study period 1 September, 2021 - 30 November, 2021. risk of severe case, 51.2% lower, RR 0.49, p = 0.02, high D levels (≥20ng/mL) 16 of 52 (30.8%), low D levels (<20ng/mL) 28 of 45 (62.2%), NNT 3.2, adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable.
moderate case, 67.3% lower, RR 0.33, p = 0.34, high D levels (≥20ng/mL) 2 of 52 (3.8%), low D levels (<20ng/mL) 2 of 45 (4.4%), adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable.
Siuka, 3/9/2023, prospective, Slovenia, peer-reviewed, 7 authors, study period December 2020 - December 2021. risk of death, 55.9% lower, RR 0.44, p = 0.24, high D levels (≥30nmol/L) 10 of 255 (3.9%), low D levels (<30nmol/L) 4 of 45 (8.9%), NNT 20.
risk of ICU admission, 58.8% higher, RR 1.59, p = 0.59, high D levels (≥30nmol/L) 27 of 255 (10.6%), low D levels (<30nmol/L) 3 of 45 (6.7%).
risk of severe case, 61.0% higher, RR 1.61, p = 0.009, high D levels (≥30nmol/L) 146 of 255 (57.3%), low D levels (<30nmol/L) 16 of 45 (35.6%).
Smaha, 1/22/2022, retrospective, Slovakia, peer-reviewed, 13 authors, study period 1 November, 2020 - 30 April, 2021. risk of death, 19.0% lower, RR 0.81, p = 0.05, high D levels (≥12ng/mL) 127 of 283 (44.9%), low D levels (<12ng/mL) 41 of 74 (55.4%), NNT 9.5.
Subramanian, 1/31/2022, prospective, United Kingdom, peer-reviewed, 16 authors, dosage not specified. risk of death, 49.7% lower, RR 0.50, p = 0.02, high D levels 16 of 115 (13.9%), low D levels 33 of 118 (28.0%), NNT 7.1, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. <25nmol/L, multivariable, outcome based on serum levels.
risk of death, 39.7% lower, RR 0.60, p = 0.07, high D levels 16 of 115 (13.9%), low D levels 38 of 157 (24.2%), NNT 9.7, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. 25-49nmol/L, multivariable, outcome based on serum levels.
Sulli (B), 2/24/2021, retrospective, Italy, peer-reviewed, 10 authors, dosage not specified. risk of case, 79.2% lower, OR 0.21, p < 0.001, high D levels 28 of 65 (43.1%) cases, 51 of 65 (78.5%) controls, NNT 2.7, case control OR, >10ng/mL.
Susianti, 2/12/2021, retrospective, Indonesia, peer-reviewed, 8 authors. risk of death, 91.5% lower, RR 0.09, p = 0.32, high D levels 0 of 8 (0.0%), low D levels 9 of 42 (21.4%), NNT 4.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >49.92 nmol/L.
risk of ICU admission, 90.5% lower, RR 0.10, p = 0.32, high D levels 0 of 8 (0.0%), low D levels 8 of 42 (19.0%), NNT 5.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >49.92 nmol/L.
risk of progression, 81.5% lower, OR 0.19, p = 0.04, high D levels 8, low D levels 42, inverted to make OR<1 favor high D levels, ISTH DIC>=5, >49.92 nmol/L, bivariate, RR approximated with OR.
risk of progression, 44.4% lower, OR 0.56, p = 0.03, high D levels 8, low D levels 42, inverted to make OR<1 favor high D levels, increased D-dimer >2 mg/L, >49.92 nmol/L, multivariate, RR approximated with OR.
Szeto, 12/30/2020, retrospective, USA, peer-reviewed, 7 authors. risk of death, 5.6% higher, RR 1.06, p = 1.00, high D levels 14 of 58 (24.1%), low D levels 8 of 35 (22.9%).
risk of mechanical ventilation, 39.7% lower, RR 0.60, p = 0.21, high D levels 10 of 58 (17.2%), low D levels 10 of 35 (28.6%), NNT 8.8.
risk of no hospital discharge, 26.7% higher, RR 1.27, p = 0.50, high D levels 21 of 58 (36.2%), low D levels 10 of 35 (28.6%).
Sánchez-Zuno (B), 5/28/2021, prospective, Mexico, peer-reviewed, 12 authors, dosage 10,000IU days 1-14. risk of severe case, 5.6% lower, RR 0.94, p = 1.00, high D levels 4 of 8 (50.0%), low D levels 18 of 34 (52.9%), NNT 34, >30ng/mL, >4 symptoms.
Tallon, 11/15/2022, retrospective, USA, peer-reviewed, 17 authors. risk of hospitalization, 41.5% lower, OR 0.58, p < 0.001, high D levels (≥30ng/mL) 113,143, low D levels (<30ng/mL) 3,227, adjusted per study, inverted to make OR<1 favor high D levels (≥30ng/mL), RR approximated with OR.
Tan, 2/27/2023, retrospective, Philippines, peer-reviewed, 3 authors. risk of progression, 71.5% lower, RR 0.29, p = 0.04, high D levels (≥30ng/mL) 7 of 38 (18.4%), low D levels (<20ng/mL) 18 of 34 (52.9%), NNT 2.9, adjusted per study, inverted to make RR<1 favor high D levels (≥30ng/mL), odds ratio converted to relative risk, combined mortality and morbidity, multivariable.
risk of death, 91.1% lower, RR 0.09, p = 0.002, high D levels (≥30ng/mL) 1 of 38 (2.6%), low D levels (<20ng/mL) 10 of 34 (29.4%), NNT 3.7, unadjusted.
risk of ICU admission, 82.1% lower, RR 0.18, p = 0.010, high D levels (≥30ng/mL) 2 of 38 (5.3%), low D levels (<20ng/mL) 10 of 34 (29.4%), NNT 4.1, unadjusted.
Tehrani, 1/25/2021, retrospective, Iran, peer-reviewed, 5 authors. risk of death, 47.5% lower, RR 0.52, p = 0.07, high D levels 34 of 180 (18.9%), low D levels 9 of 25 (36.0%), NNT 5.8, >10ng/ml.
Tomasa-Irriguible, 10/26/2020, retrospective, Spain, peer-reviewed, 7 authors, study period March 2020 - May 2020. risk of mechanical ventilation, 35.0% lower, RR 0.65, p = 0.21, high D levels 15 of 27 (55.6%), low D levels 18 of 78 (23.1%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, ≥20 ng/mL, bivariate logistic regression.
risk of ICU admission, 16.9% lower, RR 0.83, p = 0.58, high D levels 11 of 27 (40.7%), low D levels 17 of 78 (21.8%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, ≥20 ng/mL, bivariate logistic regression.
Topan, 2/28/2023, retrospective, Romania, peer-reviewed, survey, 6 authors, study period April 2020 - May 2022. risk of death, 30.6% lower, RR 0.69, p = 0.02, high D levels (≥20ng/mL) 61 of 1,148 (5.3%), low D levels (<20ng/mL) 118 of 1,194 (9.9%), adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, multivariable.
risk of severe case, 10.9% lower, RR 0.89, p = 0.02, high D levels (≥20ng/mL) 432 of 1,148 (37.6%), low D levels (<20ng/mL) 560 of 1,194 (46.9%), NNT 11, adjusted per study, inverted to make RR<1 favor high D levels (≥20ng/mL), odds ratio converted to relative risk, severe/critical case, multivariable.
Umay, 7/26/2023, retrospective, Turkey, peer-reviewed, 4 authors, study period 1 March, 2020 - 31 January, 2021. hospitalization time, 13.5% lower, relative time 0.87, p = 0.33, high D levels 374, low D levels 39.
Vanegas-Cedillo, 3/14/2021, retrospective, Mexico, peer-reviewed, 15 authors. risk of death, 52.6% lower, RR 0.47, p = 0.006, high D levels (≥12ng/mL) 95 of 494 (19.2%), low D levels (<12ng/mL) 21 of 57 (36.8%), NNT 5.7, adjusted per study, inverted to make RR<1 favor high D levels (≥12ng/mL).
Vasheghani (B), 1/18/2021, retrospective, Iran, preprint, 6 authors, dosage not specified. risk of ICU admission, 63.8% lower, RR 0.36, p = 0.009, high D levels 13 of 185 (7.0%), low D levels 53 of 323 (16.4%), NNT 11, adjusted per study, inverted to make RR<1 favor high D levels, vitamin D levels >30ng/mL.
Vassiliou (B), 12/9/2020, prospective, Greece, peer-reviewed, 6 authors. risk of death, 90.9% lower, RR 0.09, p = 0.04, high D levels 0 of 15 (0.0%), low D levels 5 of 15 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >15.2ng/mL.
Voelkle, 4/30/2022, prospective, Switzerland, peer-reviewed, median age 67.0, 9 authors, study period 17 March, 2020 - 30 April, 2020. risk of death/ICU, 23.4% lower, RR 0.77, p = 0.55, high D levels 8 of 34 (23.5%), low D levels 7 of 23 (30.4%), NNT 14, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
Vásquez-Procopio, 12/2/2022, retrospective, Mexico, peer-reviewed, 12 authors. risk of severe case, 82.8% lower, OR 0.17, p = 0.04, high D levels (≥20ng/mL) 111, low D levels (<20ng/mL) 54, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), multivariable, RR approximated with OR.
Walk, 11/9/2020, retrospective, Netherlands, preprint, 5 authors. risk of death/intubation, 0.4% higher, RR 1.00, p = 1.00, high D levels 48 of 110 (43.6%), low D levels 10 of 23 (43.5%), >25nmol/L.
Wang (C), 3/29/2023, prospective, China, peer-reviewed, median age 36.5, 23 authors, study period 18 December, 2022 - 20 February, 2023, dosage 200,000IU days 1, 14, trial NCT05673980 (history). risk of case, 22.7% lower, RR 0.77, p = 0.19, high D levels (≥30ng/ml) 20 of 44 (45.5%), low D levels (<20ng/ml) 50 of 85 (58.8%), NNT 7.5, outcome based on serum levels.
Wani, 6/1/2023, retrospective, India, peer-reviewed, 5 authors, excluded in exclusion analyses: unadjusted results with no group details. risk of severe case, 72.2% lower, OR 0.28, p = 0.007, high D levels (≥28ng/mL) 66, low D levels (<28ng/mL) 170, inverted to make OR<1 favor high D levels (≥28ng/mL), RR approximated with OR.
Wu, 12/19/2023, retrospective, multiple countries, peer-reviewed, 9 authors, study period 1 January, 2022 - 30 November, 2022. risk of death, 42.8% lower, HR 0.57, p = 0.005, high D levels (≥20 ng/mL) 8,300, low D levels (<20 ng/mL) 8,300, inverted to make HR<1 favor high D levels (≥20 ng/mL), propensity score matching.
risk of hospitalization, 18.7% lower, HR 0.81, p < 0.001, high D levels (≥20 ng/mL) 8,300, low D levels (<20 ng/mL) 8,300, inverted to make HR<1 favor high D levels (≥20 ng/mL), propensity score matching.
ER visit, 10.2% lower, HR 0.90, p = 0.03, high D levels (≥20 ng/mL) 8,300, low D levels (<20 ng/mL) 8,300, inverted to make HR<1 favor high D levels (≥20 ng/mL), propensity score matching.
risk of PASC, 2.0% higher, HR 1.02, p = 0.93, high D levels (≥20 ng/mL) 8,300, low D levels (<20 ng/mL) 8,300, inverted to make HR<1 favor high D levels (≥20 ng/mL), propensity score matching.
Węgrzynek-Gallina, 1/31/2024, retrospective, Poland, peer-reviewed, mean age 66.5, 6 authors, study period November 2020 - June 2021. hospitalization time, 33.3% lower, relative time 0.67, p < 0.001, high D levels (≥50nmol/L) 169, low D levels (<50nmol/L) 63.
Ye, 10/13/2020, retrospective, China, peer-reviewed, 18 authors. risk of severe/critical COVID-19, 93.4% lower, RR 0.07, p = 0.03, high D levels 2 of 36 (5.6%), low D levels 8 of 26 (30.8%), NNT 4.0, adjusted per study, inverted to make RR<1 favor high D levels, >50nmol/L.
Yılmaz, 10/5/2020, retrospective, Turkey, peer-reviewed, 2 authors. risk of severe case, 73.4% lower, RR 0.27, p = 1.00, high D levels 0 of 11 (0.0%), low D levels 2 of 29 (6.9%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >20ng/ml.
risk of moderate or severe case, 41.4% lower, RR 0.59, p = 0.69, high D levels 2 of 11 (18.2%), low D levels 9 of 29 (31.0%), NNT 7.8, >20ng/ml.
Zafar, 9/6/2021, retrospective, United Kingdom, peer-reviewed, median age 68.0, 37 authors. risk of death, 42.9% higher, RR 1.43, p = 0.71, high D levels (≥25nmol/L) 12 of 42 (28.6%), low D levels (<25nmol/L) 2 of 10 (20.0%), COVID+ patients.
risk of death, 6.0% lower, OR 0.94, p = 0.68, high D levels 42, low D levels 10, COVID+ patients, RR approximated with OR.
Zeidan, 9/9/2022, prospective, Egypt, peer-reviewed, median age 11.4, 38 authors. risk of hospitalization, 61.5% lower, OR 0.38, p = 0.002, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), case control OR, multivariable.
Zelzer, 6/22/2021, retrospective, Austria, peer-reviewed, 7 authors. risk of death, 46.4% lower, RR 0.54, p = 0.08, high D levels 24 of 121 (19.8%), low D levels 10 of 27 (37.0%), NNT 5.8, >30nmol/L.
Zidrou, 2/19/2022, retrospective, Greece, peer-reviewed, 6 authors, study period August 2020 - October 2020. risk of death, 26.4% lower, RR 0.74, p = 1.00, high D levels (≥20ng/ml) 2 of 25 (8.0%), low D levels (<20ng/ml) 5 of 46 (10.9%), NNT 35.
radiographic changes, 18.2% lower, RR 0.82, p = 0.26, high D levels (≥20ng/ml) 16 of 25 (64.0%), low D levels (<20ng/ml) 36 of 46 (78.3%), NNT 7.0.
hospitalization time, 37.7% lower, relative time 0.62, p = 0.16, high D levels (≥20ng/ml) 25, low D levels (<20ng/ml) 46.
Álvarez, 10/28/2022, retrospective, Spain, preprint, 1 author, study period March 2020 - March 2021, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 38.8% lower, RR 0.61, p < 0.001, high D levels 4,871 of 33,673 (14.5%), low D levels 611 of 2,588 (23.6%), NNT 11, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
risk of ICU admission, 54.7% lower, RR 0.45, p < 0.001, high D levels 289 of 33,673 (0.9%), low D levels 49 of 2,588 (1.9%), NNT 97, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
risk of hospitalization, 43.0% lower, RR 0.57, p < 0.001, high D levels 8,905 of 33,673 (26.4%), low D levels 1,202 of 2,588 (46.4%), NNT 5.0, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk.
Ünsal, 4/5/2021, retrospective, Turkey, peer-reviewed, 10 authors. risk of death, 80.6% lower, RR 0.19, p = 0.23, high D levels 0 of 29 (0.0%), low D levels 2 of 27 (7.4%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >=20ng/mL.
risk of oxygen therapy, 73.4% lower, RR 0.27, p = 0.07, high D levels 2 of 29 (6.9%), low D levels 7 of 27 (25.9%), NNT 5.3, >=20ng/mL.
Şengül, 12/31/2022, retrospective, Turkey, peer-reviewed, 4 authors, study period March 2020 - December 2021, dosage not specified. risk of case, 75.6% lower, OR 0.24, p < 0.001, high D levels (≥20ng/mL) 7 of 54 (13.0%) cases, 100 of 264 (37.9%) controls, NNT 6.4, case control OR, outcome based on serum levels.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. Only the first (most serious) outcome is used in pooled analysis, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
Annweiler, 11/2/2020, retrospective, France, peer-reviewed, 7 authors, dosage 80,000IU single dose. risk of death, 63.0% lower, RR 0.37, p = 0.28, treatment 3 of 16 (18.8%), control 10 of 32 (31.2%), NNT 8.0, adjusted per study, supplementation after diagnosis.
Annweiler (B), 10/13/2020, retrospective, France, peer-reviewed, mean age 87.7, 6 authors, dosage 80,000IU single dose, 80,000IU either in the week following the suspicion or diagnosis of COVID-19, or during the previous month. risk of death, 89.0% lower, RR 0.11, p = 0.002, treatment 10 of 57 (17.5%), control 5 of 9 (55.6%), NNT 2.6, adjusted per study.
Asimi, 5/22/2021, retrospective, Bosnia and Herzegovina, preprint, 3 authors, dosage 2,000IU daily, this trial uses multiple treatments in the treatment arm (combined with zinc and selenium) - results of individual treatments may vary, excluded in exclusion analyses: excessive unadjusted differences between groups. risk of mechanical ventilation, 97.4% lower, RR 0.03, p < 0.001, treatment 0 of 270 (0.0%), control 9 of 86 (10.5%), NNT 9.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), unadjusted.
risk of hospitalization, 99.0% lower, RR 0.010, p < 0.001, treatment 0 of 270 (0.0%), control 24 of 86 (27.9%), NNT 3.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), unadjusted.
risk of severe case, 99.5% lower, RR 0.005, p < 0.001, treatment 0 of 270 (0.0%), control 51 of 86 (59.3%), NNT 1.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), unadjusted.
Boukef, 2/28/2023, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, trial NCT05670444 (history). 150 patient RCT with results unknown and over 1.5 years late.
Burahee, 2/17/2021, retrospective, United Kingdom, peer-reviewed, 4 authors, dosage 100,000IU days 1-4, additional 200000IU over four weeks if serum level insufficient. risk of death, 93.3% lower, RR 0.07, p = 0.01, treatment 0 of 12 (0.0%), control 2 of 2 (100.0%), NNT 1.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Din Ujjan, 1/18/2023, Randomized Controlled Trial, Pakistan, peer-reviewed, 6 authors, study period 21 September, 2021 - 21 January, 2022, dosage 360IU days 1-14, this trial uses multiple treatments in the treatment arm (combined with curcumin and quercetin) - results of individual treatments may vary, trial NCT04603690 (history), excluded in exclusion analyses: based on dosages and previous research, combined treatments may contribute more to the effect seen. risk of no recovery, 28.6% lower, RR 0.71, p = 0.11, treatment 15 of 25 (60.0%), control 21 of 25 (84.0%), NNT 4.2, no symptoms, day 7.
risk of no recovery, 71.4% lower, RR 0.29, p < 0.001, treatment 6 of 25 (24.0%), control 21 of 25 (84.0%), NNT 1.7, <= 1 symptom, day 7.
risk of no recovery, 76.9% lower, RR 0.23, p = 0.005, treatment 3 of 25 (12.0%), control 13 of 25 (52.0%), NNT 2.5, <= 2 symptoms, day 7.
risk of no recovery, 85.7% lower, RR 0.14, p = 0.23, treatment 0 of 25 (0.0%), control 3 of 25 (12.0%), NNT 8.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), <= 3 symptoms, day 7.
risk of no viral clearance, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
risk of no viral clearance, 73.7% lower, RR 0.26, p < 0.001, treatment 5 of 25 (20.0%), control 19 of 25 (76.0%), NNT 1.8, day 7.
Efird, 12/31/2021, retrospective, USA, peer-reviewed, 10 authors, study period 1 March, 2020 - 10 September, 2020, dosage varies. risk of death, 48.9% lower, RR 0.51, p = 0.10, treatment 11 of 544 (2.0%), control 413 of 15,794 (2.6%), adjusted per study, non-hospitalized patients, vitamin D + no corticosteroids vs. no vitamin D + no corticosteroids.
risk of death, 54.5% lower, RR 0.45, p = 0.02, treatment 11 of 192 (5.7%), control 553 of 4,340 (12.7%), NNT 14, adjusted per study, hospitalized patients, vitamin D + no corticosteroids vs. no vitamin D + no corticosteroids.
Hunt, 6/29/2022, retrospective, USA, peer-reviewed, 8 authors, study period 1 March, 2020 - 10 September, 2020, dosage not specified. risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 43 of 1,019 (4.2%), control 1,569 of 25,489 (6.2%), adjusted per study, day 30.
Khan, 5/1/2022, Randomized Controlled Trial, Pakistan, peer-reviewed, 7 authors, study period 2 September, 2021 - 28 November, 2021, dosage 360IU days 1-14, this trial uses multiple treatments in the treatment arm (combined with curcumin and quercetin) - results of individual treatments may vary, trial NCT05130671 (history), excluded in exclusion analyses: based on dosages and previous research, combined treatments may contribute more to the effect seen. risk of no recovery, 33.3% lower, RR 0.67, p = 0.15, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
Said, 11/8/2022, Randomized Controlled Trial, Egypt, peer-reviewed, 5 authors, study period 21 July, 2021 - 30 December, 2021, dosage 2,000IU daily, trial NCT04981743 (history). risk of no recovery, 42.0% lower, OR 0.58, p = 0.57, treatment 30, control 30, adjusted per study, multivariable, dyspnea, RR approximated with OR.
risk of no recovery, 89.0% lower, OR 0.11, p = 0.01, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, dyspnea, RR approximated with OR.
risk of no recovery, 52.0% lower, OR 0.48, p = 0.16, treatment 30, control 30, adjusted per study, multivariable, cough, RR approximated with OR.
risk of no recovery, 77.0% lower, OR 0.23, p = 0.01, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, cough, RR approximated with OR.
risk of no recovery, 56.0% lower, OR 0.44, p = 0.20, treatment 30, control 30, adjusted per study, multivariable, fatigue, RR approximated with OR.
risk of no recovery, 90.0% lower, OR 0.10, p < 0.001, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, fatigue, RR approximated with OR.
risk of no recovery, 33.0% lower, OR 0.67, p = 0.67, treatment 30, control 30, adjusted per study, multivariable, smell, RR approximated with OR.
risk of no recovery, 67.0% lower, OR 0.33, p = 0.23, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, smell, RR approximated with OR.
risk of no recovery, 25.0% higher, OR 1.25, p = 0.79, treatment 30, control 30, adjusted per study, multivariable, taste, RR approximated with OR.
risk of no recovery, 58.0% lower, OR 0.42, p = 0.28, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, taste, RR approximated with OR.
risk of no recovery, 56.0% lower, OR 0.44, p = 0.36, treatment 30, control 30, adjusted per study, multivariable, sore throat, RR approximated with OR.
risk of no recovery, 86.0% lower, OR 0.14, p = 0.03, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, sore throat, RR approximated with OR.
risk of no recovery, 175.0% higher, OR 2.75, p = 0.13, treatment 30, control 30, adjusted per study, multivariable, headache, RR approximated with OR.
risk of no recovery, 56.0% lower, OR 0.44, p = 0.21, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, headache, RR approximated with OR.
risk of no recovery, 87.0% lower, OR 0.13, p = 0.05, treatment 30, control 30, adjusted per study, multivariable, diarrhea, RR approximated with OR.
risk of no recovery, 90.0% lower, OR 0.10, p = 0.03, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, diarrhea, RR approximated with OR.
risk of no viral clearance, 49.0% lower, OR 0.51, p = 0.20, treatment 30, control 30, day 14, RR approximated with OR.
risk of no viral clearance, 23.0% lower, OR 0.77, p = 0.74, treatment 30, control 30, day 7, RR approximated with OR.
risk of no viral clearance, 91.0% lower, OR 0.09, p < 0.001, treatment 30, control 30, vitamin D and nigella sativa, day 14, RR approximated with OR.
risk of no viral clearance, 87.0% lower, OR 0.13, p = 0.003, treatment 30, control 30, vitamin D and nigella sativa, day 7, RR approximated with OR.
Sánchez-Zuno, 5/28/2021, Randomized Controlled Trial, Mexico, peer-reviewed, 12 authors, dosage 10,000IU days 1-14. risk of severe case, 89.4% lower, RR 0.11, p = 0.04, treatment 0 of 22 (0.0%), control 4 of 20 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), risk of >3 symptoms at day 14.
risk of no recovery, 80.8% lower, RR 0.19, p = 0.22, treatment 0 of 22 (0.0%), control 2 of 20 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), risk of fever at day 14, Table S1.
Valecha, 4/26/2022, prospective, India, peer-reviewed, 1 author, average treatment delay 3.7 days, dosage 1,000IU daily, this trial uses multiple treatments in the treatment arm (combined with magnesium and vitamin B12) - results of individual treatments may vary. risk of ICU admission, 86.8% lower, RR 0.13, p = 0.09, treatment 0 of 30 (0.0%), control 3 of 25 (12.0%), NNT 8.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 38.5% lower, relative time 0.62, p < 0.001, treatment mean 11.2 (±2.8) n=30, control mean 18.2 (±1.21) n=25.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. Only the first (most serious) outcome is used in pooled analysis, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
Al Sulaiman, 8/14/2023, retrospective, Saudi Arabia, peer-reviewed, 25 authors, study period March 2020 - July 2021, dosage not specified, excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 22.0% higher, HR 1.22, p = 0.25, treatment 72 of 144 (50.0%), control 62 of 144 (43.1%).
risk of mechanical ventilation, 27.0% higher, OR 1.27, p = 0.046, treatment 144, control 144, RR approximated with OR.
risk of ICU admission, 17.0% higher, OR 1.17, p = 0.07, treatment 144, control 144, RR approximated with OR.
risk of hospitalization, no change, OR 1.00, p = 1.00, treatment 144, control 144, RR approximated with OR.
Alcala-Diaz, 5/21/2021, retrospective, Spain, peer-reviewed, 17 authors, dosage calcifediol 0.5mg day 1, 0.27mg day 3, 0.27mg day 7, 0.27mg day 14, 0.27mg day 21, 0.27mg day 28. risk of death, 80.8% lower, RR 0.19, p = 0.04, treatment 4 of 79 (5.1%), control 90 of 458 (19.7%), NNT 6.9, adjusted per study, odds ratio converted to relative risk, day 30, multivariate logistic regression.
Assiri, 8/28/2021, retrospective, Saudi Arabia, peer-reviewed, 8 authors, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 66.5% higher, RR 1.66, p = 0.60, treatment 12 of 90 (13.3%), control 2 of 28 (7.1%), inverted to make RR<1 favor treatment, odds ratio converted to relative risk.
Baguma (B), 12/28/2021, retrospective, Uganda, preprint, 16 authors, study period March 2020 - October 2021, dosage not specified. risk of death, 96.7% lower, RR 0.03, p = 0.02, treatment 23, control 458, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
Baykal, 5/30/2022, retrospective, Turkey, peer-reviewed, 2 authors, study period 1 April, 2020 - 1 March, 2021, dosage 300,000IU single dose, excluded in exclusion analyses: unadjusted results with no group details; significant confounding by time possible due to separation of groups in different time periods. risk of death, 22.2% lower, RR 0.78, p = 0.43, treatment 7 of 18 (38.9%), control 28 of 56 (50.0%), NNT 9.0.
risk of ICU admission, 59.4% lower, RR 0.41, p = 0.005, treatment 5 of 18 (27.8%), control 39 of 57 (68.4%), NNT 2.5.
Beigmohammadi, 11/14/2021, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 6 authors, study period April 2020 - July 2020, dosage 600,000IU single dose, this trial uses multiple treatments in the treatment arm (combined with vitamins A, B, C, E) - results of individual treatments may vary, trial IRCT20200319046819N1, excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 88.9% lower, RR 0.11, p = 0.11, treatment 0 of 30 (0.0%), control 4 of 30 (13.3%), NNT 7.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization >7 days, 41.0% lower, RR 0.59, p = 0.25, treatment 4 of 30 (13.3%), control 16 of 30 (53.3%), NNT 2.5, adjusted per study, odds ratio converted to relative risk.
relative SOFA score @day 7, 45.5% better, RR 0.55, p < 0.001, treatment 30, control 30.
Bishop, 2/5/2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, survey, 11 authors, study period 2 November, 2020 - 8 October, 2021, dosage calcifediol 300μg days 1-3, 60μg days 4-27, trial NCT04551911 (history) (REsCue). ER/urgent care visits, 85.4% lower, RR 0.15, p = 0.25, treatment 0 of 65 (0.0%), control 3 of 69 (4.3%), NNT 23, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no recovery, 33.7% lower, RR 0.66, p = 0.56, treatment 5 of 65 (7.7%), control 8 of 69 (11.6%), NNT 26, day 21, mid-trial.
risk of no recovery, 73.5% lower, RR 0.27, p = 0.37, treatment 1 of 65 (1.5%), control 4 of 69 (5.8%), NNT 23, day 35.
risk of no recovery, 57.5% lower, RR 0.42, p = 0.44, treatment 2 of 65 (3.1%), control 5 of 69 (7.2%), NNT 24, day 28.
risk of no recovery, 6.2% higher, RR 1.06, p = 0.85, treatment 17 of 65 (26.2%), control 17 of 69 (24.6%), day 14.
risk of no recovery, 3.0% higher, RR 1.03, p = 1.00, treatment 33 of 65 (50.8%), control 34 of 69 (49.3%), day 7.
resolution of 5 aggregated symptoms, 9.3% lower, relative time 0.91, p = 0.52, treatment mean 9.8 (±8.15) n=65, control mean 10.8 (±9.54) n=69.
Bychinin, 11/3/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Russia, peer-reviewed, 7 authors, study period 1 May, 2020 - 31 January, 2022, average treatment delay 9.0 days, dosage 60,000IU day 1, 5,000IU days 2-7, 8, 5,000IU days 9-14, 15, 5,000IU days 16-21, 22, 5,000IU days 23-28, trial NCT05092698 (history) (COVID-VIT), excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 26.9% lower, RR 0.73, p = 0.18, treatment 19 of 52 (36.5%), control 27 of 54 (50.0%), NNT 7.4.
risk of mechanical ventilation, 7.4% lower, RR 0.93, p = 0.68, treatment 33 of 52 (63.5%), control 37 of 54 (68.5%), NNT 20.
Cannata-Andía, 2/18/2022, Randomized Controlled Trial, multiple countries, peer-reviewed, median age 59.0, 22 authors, study period 4 April, 2020 - 22 April, 2021, dosage 100,000IU single dose, trial NCT04552951 (history) (COVID-VIT-D), excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 44.0% higher, RR 1.44, p = 0.31, treatment 22 of 274 (8.0%), control 15 of 269 (5.6%).
risk of ICU admission, 4.9% higher, RR 1.05, p = 0.82, treatment 47 of 274 (17.2%), control 44 of 269 (16.4%).
De Niet, 7/26/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Belgium, peer-reviewed, 16 authors, study period August 2020 - August 2021, dosage 25,000IU days 1-4, 11, 18, 25, trial NCT04636086 (history). risk of death, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, COVID-19 mortality.
risk of death, 39.7% higher, RR 1.40, p = 0.70, treatment 4 of 21 (19.0%), control 3 of 22 (13.6%), all cause including after discharge and non-COVID-19.
risk of ICU admission, 58.1% lower, RR 0.42, p = 0.41, treatment 2 of 21 (9.5%), control 5 of 22 (22.7%), NNT 7.6.
ICU time, 67.7% lower, relative time 0.32, p = 0.47, treatment 21, control 22.
risk of no hospital discharge, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 36.
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 21.
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, day 14.
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.03, treatment 4 of 21 (19.0%), control 12 of 22 (54.5%), NNT 2.8, day 7.
recovery time, 45.4% lower, relative time 0.55, p = 0.06, treatment 21, control 22, fever.
hospitalization time, 50.0% lower, relative time 0.50, p = 0.003, treatment 21, control 22.
Domazet Bugarin, 2/28/2023, Randomized Controlled Trial, Croatia, peer-reviewed, 9 authors, study period November 2021 - May 2022, dosage 10,000IU days 1-14, trial NCT05384574 (history), excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 21.0% lower, RR 0.79, p = 0.20, treatment 30 of 75 (40.0%), control 39 of 77 (50.6%), NNT 9.4, day 60.
risk of death, 12.5% lower, RR 0.87, p = 0.61, treatment 23 of 75 (30.7%), control 27 of 77 (35.1%), NNT 23, day 28.
risk of death, 28.9% lower, RR 0.71, p = 0.49, treatment 9 of 75 (12.0%), control 13 of 77 (16.9%), NNT 20, day 14.
Elamir, 9/8/2021, Randomized Controlled Trial, USA, peer-reviewed, 9 authors, study period September 2020 - December 2020, dosage calcitriol 0.5μg days 1-14. risk of death, 85.7% lower, RR 0.14, p = 0.23, treatment 0 of 25 (0.0%), control 3 of 25 (12.0%), NNT 8.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 80.0% lower, RR 0.20, p = 0.48, treatment 0 of 25 (0.0%), control 2 of 25 (8.0%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 37.5% lower, RR 0.62, p = 0.33, treatment 5 of 25 (20.0%), control 8 of 25 (32.0%), NNT 8.3.
hospitalization time, 40.5% lower, relative time 0.60, p = 0.14, treatment 25, control 25.
relative Δ SaO2/FiO2, RR 0.14, p = 0.03, treatment 25, control 25, primary outcome.
Elhadi, 4/30/2021, prospective, Libya, peer-reviewed, 21 authors, study period 29 May, 2020 - 30 December, 2020, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 23.4% lower, RR 0.77, p = 0.29, treatment 7 of 15 (46.7%), control 274 of 450 (60.9%), NNT 7.0.
Entrenas Castillo, 8/29/2020, Randomized Controlled Trial, Spain, peer-reviewed, 7 authors, study period May 2020 - June 2020, dosage calcifediol 0.5mg day 1, 0.27mg day 3, 0.27mg day 7, and then weekly until discharge or ICU admission, trial NCT04366908 (history) (COVIDIOL). risk of death, 85.4% lower, RR 0.15, p = 0.11, treatment 0 of 50 (0.0%), control 2 of 26 (7.7%), NNT 13, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 94.2% lower, RR 0.06, p = 0.008, treatment 1 of 50 (2.0%), control 13 of 26 (50.0%), NNT 2.1, odds ratio converted to relative risk.
Fairfield, 7/26/2022, retrospective, USA, peer-reviewed, 10 authors, study period 1 January, 2020 - 31 July, 2021, dosage not specified, excluded in exclusion analyses: substantial unadjusted confounding by indication likely. risk of death, 8.9% higher, RR 1.09, p < 0.001, treatment 3,653 of 28,993 (12.6%), control 13,185 of 129,842 (10.2%), odds ratio converted to relative risk.
risk of mechanical ventilation, 40.8% higher, RR 1.41, p < 0.001, treatment 4,897 of 28,993 (16.9%), control 15,520 of 129,842 (12.0%), odds ratio converted to relative risk.
Fiore, 5/22/2022, retrospective, matched cohort, Italy, peer-reviewed, mean age 62.5, 10 authors, dosage 100,000IU days 1-2. risk of death, 92.7% lower, RR 0.07, p = 0.01, treatment 3 of 58 (5.2%), control 11 of 58 (19.0%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
NIV, 47.8% lower, RR 0.52, p = 0.04, treatment 12 of 58 (20.7%), control 23 of 58 (39.7%), NNT 5.3.
Giannini, 1/14/2021, retrospective, Italy, peer-reviewed, 21 authors, dosage 200,000IU days 1-2. risk of death/ICU, 36.6% lower, RR 0.63, p = 0.13, treatment 14 of 36 (38.9%), control 29 of 55 (52.7%), NNT 7.2, odds ratio converted to relative risk.
Güven, 7/23/2021, retrospective, Turkey, peer-reviewed, 2 authors, dosage 300,000IU single dose, excluded in exclusion analyses: very late stage, ICU patients. risk of death, 24.8% lower, RR 0.75, p = 0.32, treatment 43 of 113 (38.1%), control 30 of 62 (48.4%), NNT 9.7, odds ratio converted to relative risk.
Hafez (B), 8/9/2022, retrospective, Egypt, peer-reviewed, 2 authors, study period April 2020 - June 2020, dosage 50,000IU days 1, 3, 5, 7, 9, 11, 13, 50,000IU every other day for two weeks or one intramuscular shot of 300,000IU. risk of death, 93.7% lower, RR 0.06, p = 0.07, treatment 0 of 7 (0.0%), control 12 of 30 (40.0%), NNT 2.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), high dose, 50,000IU every other day for two weeks or one intramuscular shot of 300,000IU.
risk of death, 58.3% lower, RR 0.42, p = 0.28, treatment 2 of 12 (16.7%), control 12 of 30 (40.0%), NNT 4.3, low dose, ≤10,000IU/day.
Hafezi, 10/22/2022, retrospective, United Arab Emirates, peer-reviewed, 8 authors, study period September 2020 - January 2021, dosage 50,000IU days 1, 8, 15, excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 63.0% lower, HR 0.37, p = 0.04, treatment 8 of 43 (18.6%), control 12 of 37 (32.4%), NNT 7.2, Cox proportional hazards, day 29.
Jevalikar, 12/28/2020, prospective, India, peer-reviewed, 8 authors, dosage 60,000IU single dose, median total dose. risk of death, 82.0% lower, RR 0.18, p = 0.12, treatment 1 of 128 (0.8%), control 3 of 69 (4.3%), NNT 28.
risk of ICU admission, 33.7% lower, RR 0.66, p = 0.29, treatment 16 of 128 (12.5%), control 13 of 69 (18.8%), NNT 16.
risk of oxygen therapy, 31.7% lower, RR 0.68, p = 0.06, treatment 38 of 128 (29.7%), control 30 of 69 (43.5%), NNT 7.3.
Karimpour-Razkenari, 10/3/2022, retrospective, Iran, peer-reviewed, median age 58.5, 9 authors, study period 23 February, 2020 - 23 May, 2020, dosage not specified. risk of death, 79.0% lower, RR 0.21, p < 0.001, treatment 10 of 124 (8.1%), control 93 of 329 (28.3%), NNT 4.9, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Karonova, 6/23/2022, Randomized Controlled Trial, Russia, peer-reviewed, 12 authors, study period 30 November, 2020 - 20 March, 2021, dosage 50,000IU days 1, 8, trial NCT05166005 (history). risk of ICU admission, 85.9% lower, RR 0.14, p = 0.11, treatment 0 of 56 (0.0%), control 3 of 54 (5.6%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 9.
risk of oxygen therapy, 7.0% lower, RR 0.93, p = 0.85, treatment 27 of 56 (48.2%), control 28 of 54 (51.9%), NNT 27, baseline oxygen supplementation was higher in the treatment group, 38 vs. 32, day 9.
Krishnan, 7/20/2020, retrospective, USA, peer-reviewed, 13 authors, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 19.0% lower, RR 0.81, p = 0.42, treatment 8 of 16 (50.0%), control 84 of 136 (61.8%), NNT 8.5.
Lakkireddy, 7/27/2022, Randomized Controlled Trial, India, peer-reviewed, mean age 45.5, 9 authors, dosage 60,000IU days 1-8, 8 or 10 days depending on BMI. risk of death, 60.9% lower, RR 0.39, p = 0.27, treatment 2 of 44 (4.5%), control 5 of 43 (11.6%), NNT 14.
risk of ICU admission, 21.8% lower, RR 0.78, p = 0.74, treatment 4 of 44 (9.1%), control 5 of 43 (11.6%), NNT 39.
hospitalization time, 7.1% lower, relative time 0.93, p = 0.90, treatment 44, control 43.
Leal-Martínez, 10/25/2021, Randomized Controlled Trial, Mexico, peer-reviewed, 7 authors, study period 1 September, 2020 - 28 February, 2021, dosage 4,000IU days 1-21, this trial uses multiple treatments in the treatment arm (combined with comprehensive nutritional support) - results of individual treatments may vary, trial NCT04507867 (history), excluded in exclusion analyses: combined treatments may contribute more to the effect seen. risk of death, 85.7% lower, RR 0.14, p = 0.03, treatment 1 of 40 (2.5%), control 7 of 40 (17.5%), NNT 6.7.
risk of mechanical ventilation, 57.1% lower, RR 0.43, p = 0.31, treatment 3 of 40 (7.5%), control 7 of 40 (17.5%), NNT 10.0.
Ling, 12/11/2020, retrospective, United Kingdom, peer-reviewed, 7 authors, dosage 40,000IU weekly, regimen varied with 77% receiving a total of 40,000IU/week. risk of death, 79.8% lower, RR 0.20, p < 0.001, treatment 73, control 253, odds ratio converted to relative risk, primary cohort.
risk of death, 55.5% lower, RR 0.44, p = 0.02, treatment 80, control 443, odds ratio converted to relative risk, validation cohort.
Lohia (B), 3/4/2021, retrospective, USA, peer-reviewed, 4 authors, dosage not specified. risk of death, 10.7% lower, RR 0.89, p = 0.80, treatment 26, control 69, odds ratio converted to relative risk, <20 ng/mL, control prevalence approximated with overall prevalence.
risk of mechanical ventilation, 26.9% lower, RR 0.73, p = 0.51, treatment 26, control 69, odds ratio converted to relative risk, <20 ng/mL, control prevalence approximated with overall prevalence.
risk of ICU admission, 2.7% lower, RR 0.97, p = 0.93, treatment 26, control 69, odds ratio converted to relative risk, <20 ng/mL, control prevalence approximated with overall prevalence.
Maghbooli, 10/13/2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors, dosage calcifediol 25μg daily, mean daily dose. risk of death, 40.0% lower, RR 0.60, p = 0.72, treatment 3 of 53 (5.7%), control 5 of 53 (9.4%), NNT 26.
risk of mechanical ventilation, 60.0% lower, RR 0.40, p = 0.44, treatment 2 of 53 (3.8%), control 5 of 53 (9.4%), NNT 18.
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.42, treatment 6 of 53 (11.3%), control 10 of 53 (18.9%), NNT 13.
ICU time, 36.4% lower, relative time 0.64, p = 0.20, treatment 53, control 53.
hospitalization time, 16.7% lower, relative time 0.83, p = 0.10, treatment 53, control 53.
Mahmood, 12/29/2021, retrospective, United Kingdom, peer-reviewed, 4 authors, study period 23 March, 2020 - 31 December, 2020, dosage varies, excluded in exclusion analyses: unadjusted results with no group details; substantial unadjusted confounding by indication likely. risk of death, 30.5% lower, RR 0.70, p = 0.10, treatment 45 of 238 (18.9%), control 31 of 114 (27.2%), NNT 12, started after admission, late treatment result.
Mariani, 5/27/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Argentina, peer-reviewed, mean age 59.1, 33 authors, study period 14 August, 2020 - 22 June, 2021, average treatment delay 7.0 days, dosage 500,000IU single dose, trial NCT04411446 (history) (CARED). risk of death, 124.0% higher, RR 2.24, p = 0.45, treatment 5 of 115 (4.3%), control 2 of 103 (1.9%).
risk of mechanical ventilation, 25.0% lower, RR 0.75, p = 0.85, treatment 5 of 115 (4.3%), control 6 of 103 (5.8%), NNT 68.
risk of ICU admission, 27.0% lower, RR 0.73, p = 0.62, treatment 9 of 115 (7.8%), control 11 of 103 (10.7%), NNT 35.
risk of progression, 3.0% lower, OR 0.97, p = 0.82, treatment 115, control 103, Wilcoxon-Mann-Whitney, primary outcome, RR approximated with OR.
risk of progression, 32.8% lower, RR 0.67, p = 0.71, treatment 3 of 115 (2.6%), control 4 of 103 (3.9%), NNT 78, Δ rSOFA 4.
risk of progression, 79.1% higher, RR 1.79, p = 0.30, treatment 10 of 115 (8.7%), control 5 of 103 (4.9%), Δ rSOFA 3.
risk of progression, 25.4% lower, RR 0.75, p = 0.76, treatment 5 of 115 (4.3%), control 6 of 103 (5.8%), NNT 68, Δ rSOFA 2.
risk of progression, 16.0% lower, RR 0.84, p = 0.70, treatment 15 of 115 (13.0%), control 16 of 103 (15.5%), NNT 40, Δ rSOFA 1.
Mazziotti, 3/5/2021, retrospective, Italy, peer-reviewed, 11 authors, dosage varies. risk of death, 19.0% lower, OR 0.81, p = 0.49, treatment 116, control 232, supplementation, RR approximated with OR.
risk of mechanical ventilation, 67.0% higher, OR 1.67, p = 0.08, treatment 116, control 232, supplementation, RR approximated with OR.
Milan, 4/30/2024, retrospective, Philippines, peer-reviewed, median age 11.0, 5 authors, study period 1 April, 2020 - 31 August, 2021. risk of death, 46.5% lower, RR 0.53, p = 0.18, treatment 9 of 122 (7.4%), control 8 of 58 (13.8%), NNT 16, day 45.
risk of mechanical ventilation, 20.8% lower, RR 0.79, p = 0.53, treatment 20 of 122 (16.4%), control 12 of 58 (20.7%), NNT 23, day 45.
risk of ICU admission, 15.9% lower, RR 0.84, p = 0.69, treatment 23 of 122 (18.9%), control 13 of 58 (22.4%), NNT 28, day 45.
Mingiano, 7/30/2023, retrospective, Italy, peer-reviewed, 11 authors, study period November 2020 - February 2021, dosage calcifediol 450μg days 1-2, patients with deficiency only. risk of death, 38.8% lower, RR 0.61, p = 0.04, treatment 13 of 56 (23.2%), control 88 of 232 (37.9%), NNT 6.8.
risk of oxygen therapy, 23.1% lower, RR 0.77, p = 0.22, treatment 18 of 56 (32.1%), control 97 of 232 (41.8%), NNT 10.
hospitalization time, 34.6% lower, relative time 0.65, p = 0.01, treatment 56, control 232.
Murai, 11/17/2020, Double Blind Randomized Controlled Trial, Brazil, peer-reviewed, 17 authors, study period 2 June, 2020 - 27 August, 2020, average treatment delay 10.2 days, dosage 200,000IU single dose, trial NCT04449718 (history), excluded in exclusion analyses: very late stage, >50% on oxygen/ventilation at baseline; very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 48.7% higher, RR 1.49, p = 0.43, treatment 9 of 119 (7.6%), control 6 of 118 (5.1%).
risk of mechanical ventilation, 47.5% lower, RR 0.52, p = 0.09, treatment 9 of 119 (7.6%), control 17 of 118 (14.4%), NNT 15.
risk of ICU admission, 24.6% lower, RR 0.75, p = 0.30, treatment 19 of 119 (16.0%), control 25 of 118 (21.2%), NNT 19.
risk of no hospital discharge, 6.5% lower, HR 0.93, p = 0.63, treatment 119, control 118, inverted to make HR<1 favor treatment.
Nogués, 1/22/2021, prospective quasi-randomized (ward), Spain, peer-reviewed, 16 authors, dosage calcifediol 0.5mg day 1, 0.27mg day 3, 0.27mg day 7, 0.27mg day 15, 0.27mg day 30. risk of death, 79.0% lower, RR 0.21, p = 0.001, treatment 21 of 447 (4.7%), control 62 of 391 (15.9%), NNT 9.0, adjusted per study, ITT.
risk of death, 48.0% lower, RR 0.52, p = 0.001, treatment 500, control 338, adjusted per study, including patients treated later.
risk of ICU admission, 87.0% lower, RR 0.13, p < 0.001, treatment 20 of 447 (4.5%), control 82 of 391 (21.0%), NNT 6.1, adjusted per study, ITT.
Ogasawara, 9/1/2023, retrospective, Japan, peer-reviewed, 10 authors, study period April 2021 - September 2022, dosage alfacalcidol 1μg days 1-8, median duration, alfacalcidol and eldecalcitol used. risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 54 (0.0%), control 1 of 54 (1.9%), NNT 54, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 77.8% lower, RR 0.22, p = 0.05, treatment 2 of 54 (3.7%), control 9 of 54 (16.7%), NNT 7.7, high-flow oxygen, mechanical ventilation, or mortality, primary outcome.
risk of oxygen therapy, 75.0% lower, RR 0.25, p = 0.09, treatment 2 of 54 (3.7%), control 8 of 54 (14.8%), NNT 9.0.
Rastogi, 11/12/2020, Randomized Controlled Trial, India, peer-reviewed, 8 authors, dosage 60,000IU days 1-7, trial NCT04459247 (history) (SHADE). risk of no viral clearance, 52.6% lower, RR 0.47, p = 0.02, treatment 6 of 16 (37.5%), control 19 of 24 (79.2%), NNT 2.4.
Saheb Sharif-Askari (B), 8/24/2022, retrospective, USA, peer-reviewed, 10 authors, dosage 50,000IU days 1, 8, 15, excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. ICU time, 35.7% lower, relative time 0.64, p = 0.01, treatment 20, control 25.
Salman, 6/16/2023, Randomized Controlled Trial, Pakistan, peer-reviewed, 6 authors, study period January 2021 - May 2021, dosage 4,000IU days 1-14. risk of death, 60.0% lower, RR 0.40, p = 0.07, treatment 6 of 150 (4.0%), control 15 of 150 (10.0%), NNT 17.
risk of mechanical ventilation, 16.7% lower, RR 0.83, p = 0.55, treatment 25 of 150 (16.7%), control 30 of 150 (20.0%), NNT 30.
risk of ICU admission, 12.5% lower, RR 0.88, p = 0.85, treatment 14 of 150 (9.3%), control 16 of 150 (10.7%), NNT 75.
hospitalization time, 18.2% lower, relative time 0.82, p = 0.001, treatment 150, control 150.
recovery time, 22.2% lower, relative time 0.78, p = 0.001, treatment 150, control 150.
Sanz, 6/12/2024, Double Blind Randomized Controlled Trial, placebo-controlled, Argentina, peer-reviewed, mean age 59.0, 7 authors, study period August 2021 - June 2022, dosage 10,000IU days 1-10. risk of death, 80.0% lower, RR 0.20, p = 0.48, treatment 0 of 11 (0.0%), control 2 of 11 (18.2%), NNT 5.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 83.3% lower, RR 0.17, p = 0.06, treatment 1 of 11 (9.1%), control 6 of 11 (54.5%), NNT 2.2.
risk of ICU admission, 60.0% lower, RR 0.40, p = 0.36, treatment 2 of 11 (18.2%), control 5 of 11 (45.5%), NNT 3.7.
Seely, 9/22/2023, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, peer-reviewed, mean age 39.9, 10 authors, study period September 2021 - April 2022, dosage 51,000IU day 1, 1,000IU days 2-21, this trial uses multiple treatments in the treatment arm (combined with vitamin C, D, K2, and zinc) - results of individual treatments may vary, trial NCT04780061 (history). ER visit, 47.6% lower, RR 0.52, p = 0.68, treatment 2 of 42 (4.8%), control 4 of 44 (9.1%), NNT 23.
relative mean cumulative symptom score, 13.8% better, RR 0.86, p = 0.41, treatment mean 166.3 (±92.3) n=34, control mean 192.9 (±153.6) n=24.
EQ-VAS average score <80, 29.4% lower, RR 0.71, p = 0.54, treatment 7 of 34 (20.6%), control 7 of 24 (29.2%), NNT 12, average daily EQ-VAS score <80.
relative EQ5D improvement, 28.6% better, RR 0.71, p = 0.44, treatment 32, control 31, relative improvement in EQ5D, week 1.
relative EQ5D improvement, 14.3% better, RR 0.86, p = 0.73, treatment 33, control 30, relative improvement in EQ5D, week 2.
relative EQ5D improvement, 50.0% better, RR 0.50, p = 0.17, treatment 32, control 33, relative improvement in EQ5D, week 3.
relative EQ5D improvement, 12.5% worse, RR 1.12, p = 0.47, treatment 30, control 25, relative improvement in EQ5D, week 4.
recovery time, 4.0% higher, relative time 1.04, p = 0.81, treatment 34, control 24.
risk of PASC, 12.1% lower, RR 0.88, p = 1.00, treatment 3 of 33 (9.1%), control 3 of 29 (10.3%), NNT 80, 12 weeks.
risk of PASC, 35.7% lower, RR 0.64, p = 0.69, treatment 3 of 35 (8.6%), control 4 of 30 (13.3%), NNT 21, 8 weeks.
risk of PASC, 0.6% lower, RR 0.99, p = 1.00, treatment 6 of 35 (17.1%), control 5 of 29 (17.2%), NNT 1015, 4 weeks.
Shahid, 6/17/2022, retrospective, USA, peer-reviewed, 2 authors, dosage not specified, excluded in exclusion analyses: minimal details provided. risk of death, 38.0% lower, RR 0.62, p < 0.001, treatment 705, control 773.
Shamsi, 7/17/2023, retrospective, Iran, peer-reviewed, 4 authors, study period 1 March, 2020 - 1 August, 2021, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 57.5% lower, RR 0.42, p = 0.70, treatment 1 of 17 (5.9%), control 23 of 166 (13.9%), NNT 13.
Singh (B), 6/1/2022, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 15 authors, study period 1 August, 2021 - 10 December, 2021, dosage 600,000IU single dose, trial NCT04952857 (history) (Shade-S). risk of death, 45.0% lower, RR 0.55, p = 0.046, treatment 11 of 45 (24.4%), control 20 of 45 (44.4%), NNT 5.0.
risk of no recovery, 40.0% lower, RR 0.60, p = 0.01, treatment 45, control 45.
Soliman, 9/1/2021, Randomized Controlled Trial, placebo-controlled, Egypt, peer-reviewed, 3 authors, dosage 200,000IU single dose. risk of death, 63.4% lower, RR 0.37, p = 0.21, treatment 7 of 40 (17.5%), control 3 of 16 (18.8%), adjusted per study, odds ratio converted to relative risk, logistic regression.
risk of mechanical ventilation, 20.0% lower, RR 0.80, p = 0.56, treatment 14 of 40 (35.0%), control 7 of 16 (43.8%), NNT 11, unadjusted.
risk of no recovery, 20.0% lower, RR 0.80, p = 0.56, treatment 14 of 40 (35.0%), control 7 of 16 (43.8%), NNT 11, unadjusted.
Tan (B), 6/10/2020, retrospective, Singapore, peer-reviewed, 14 authors, dosage 1,000IU daily, this trial uses multiple treatments in the treatment arm (combined with magnesium and vitamin B12) - results of individual treatments may vary. risk of oxygen therapy, 80.5% lower, RR 0.20, p = 0.04, treatment 3 of 17 (17.6%), control 16 of 26 (61.5%), NNT 2.3, adjusted per study, multivariate.
risk of ICU admission, 80.9% lower, RR 0.19, p = 0.07, treatment 1 of 17 (5.9%), control 8 of 26 (30.8%), NNT 4.0, no adjusted result available.
Yildiz, 9/27/2021, retrospective, Turkey, peer-reviewed, 5 authors, dosage 300,000IU single dose. risk of death, 80.9% lower, RR 0.19, p = 0.04, treatment 1 of 37 (2.7%), control 24 of 170 (14.1%), NNT 8.8.
risk of ICU admission, 94.5% lower, RR 0.06, p = 0.13, treatment 0 of 37 (0.0%), control 14 of 170 (8.2%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 9.6% lower, relative time 0.90, p = 0.32, treatment 37, control 170.
Zangeneh, 5/13/2022, retrospective, Iran, peer-reviewed, 3 authors, dosage not specified, excluded in exclusion analyses: very late stage study using cholecalciferol instead of calcifediol or calcitriol. risk of death, 26.0% higher, HR 1.26, p = 0.40, Cox proportional hazards.
Zurita-Cruz, 7/25/2022, Single Blind Randomized Controlled Trial, Mexico, peer-reviewed, median age 12.0, 7 authors, study period 24 March, 2020 - 31 March, 2021, dosage 2,000IU daily, daily, 1,000IU for children <1 year, trial NCT04502667 (history), excluded in exclusion analyses: randomization resulted in significant baseline differences that were not adjusted for. risk of death, 79.2% lower, RR 0.21, p = 0.11, treatment 1 of 20 (5.0%), control 6 of 25 (24.0%), NNT 5.3.
risk of mechanical ventilation, 72.2% lower, RR 0.28, p = 0.08, treatment 2 of 20 (10.0%), control 9 of 25 (36.0%), NNT 3.8.
risk of ICU admission, 73.2% lower, RR 0.27, p = 0.006, treatment 3 of 20 (15.0%), control 14 of 25 (56.0%), NNT 2.4.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. Only the first (most serious) outcome is used in pooled analysis, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
Abdulateef, 4/8/2021, retrospective, Iraq, peer-reviewed, 7 authors, study period July 2020 - August 2020, dosage varies, excluded in exclusion analyses: unadjusted results with no group details. risk of hospitalization, 40.9% lower, RR 0.59, p = 0.30, treatment 6 of 127 (4.7%), control 24 of 300 (8.0%), NNT 31, unadjusted.
Ahmed, 11/21/2021, retrospective, USA, preprint, 5 authors, dosage not specified. risk of death, 10.5% lower, RR 0.90, p = 0.28.
Akbar, 11/7/2023, retrospective, Qatar, peer-reviewed, mean age 40.3, 9 authors, study period March 2020 - September 2020, dosage not specified. risk of case, 19.0% lower, OR 0.81, p = 0.02, treatment 2,402, control 7,598, adjusted per study, multivariable, model 2, RR approximated with OR.
Aldwihi, 5/11/2021, retrospective, Saudi Arabia, peer-reviewed, survey, mean age 36.5, 8 authors, study period August 2020 - October 2020, dosage not specified. risk of hospitalization, 49.3% higher, RR 1.49, p = 0.002, treatment 94 of 259 (36.3%), control 143 of 479 (29.9%), adjusted per study, odds ratio converted to relative risk, multivariable.
Annweiler (C), 11/2/2020, retrospective, France, peer-reviewed, mean age 88.0, 7 authors, dosage 50,000IU monthly, dose varies - 50,000 IU/month, or 80,000IU/100,000IU every 2–3 months. risk of death, 93.0% lower, RR 0.07, p = 0.02, treatment 2 of 29 (6.9%), control 10 of 32 (31.2%), NNT 4.1, adjusted per study, regular bolus supplementation.
Arboleda, 3/13/2024, prospective, Colombia, peer-reviewed, 4 authors, dosage 5,000IU daily, this trial uses multiple treatments in the treatment arm (combined with vitamin C) - results of individual treatments may vary, excluded in exclusion analyses: unadjusted results with no group details. risk of case, 35.7% lower, RR 0.64, p = 0.03, treatment 26 of 214 (12.1%), control 115 of 609 (18.9%), NNT 15.
Arroyo-Díaz, 9/24/2021, retrospective, Spain, peer-reviewed, 11 authors, dosage not specified. risk of death, 12.4% higher, RR 1.12, p = 0.59, treatment 50 of 189 (26.5%), control 167 of 1,078 (15.5%), adjusted per study, odds ratio converted to relative risk.
risk of mechanical ventilation, 43.3% lower, RR 0.57, p = 0.22, treatment 11 of 189 (5.8%), control 113 of 1,078 (10.5%), NNT 21, adjusted per study, odds ratio converted to relative risk.
risk of ICU admission, 44.2% lower, RR 0.56, p = 0.03, treatment 13 of 189 (6.9%), control 133 of 1,078 (12.3%), NNT 18, unadjusted.
hospitalization time, 11.8% lower, relative time 0.88, p = 0.20, treatment 189, control 1,078, unadjusted.
Aweimer, 3/29/2023, retrospective, Germany, peer-reviewed, median age 67.0, 19 authors, study period 1 March, 2020 - 31 August, 2021, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 20.9% lower, RR 0.79, p = 0.31, treatment 7 of 12 (58.3%), control 101 of 137 (73.7%), NNT 6.5.
Bagheri, 9/1/2021, retrospective, Iran, peer-reviewed, 6 authors, dosage not specified. risk of severe case, 70.9% lower, OR 0.29, p = 0.02, treatment 131, control 379, adjusted per study, multinomial logistic regression, RR approximated with OR.
risk of hospitalization, 37.9% lower, RR 0.62, p = 0.11, treatment 28 of 131 (21.4%), control 143 of 379 (37.7%), NNT 6.1, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, binary logistic regression.
Baralić, 4/24/2023, prospective, France, peer-reviewed, 15 authors, study period March 2020 - September 2022, dosage not specified. risk of death, 66.8% lower, HR 0.33, p = 0.02, treatment 7 of 31 (22.6%), control 11 of 21 (52.4%), NNT 3.4, Cox proportional hazards.
Bhat, 3/6/2023, prospective, placebo-controlled, India, peer-reviewed, 13 authors, dosage calcifediol 50μg days 1-180, trial CTRI/2021/08/035709. risk of symptomatic case, 34.2% lower, RR 0.66, p = 0.01, treatment 59 of 262 (22.5%), control 52 of 152 (34.2%), NNT 8.6.
Blanch-Rubió, 10/20/2020, retrospective, Spain, peer-reviewed, mean age 66.4, 11 authors, dosage not specified. risk of case, 8.0% lower, RR 0.92, p = 0.68, treatment 62 of 1,303 (4.8%), control 47 of 799 (5.9%), adjusted per study.
Brunvoll, 9/7/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Norway, peer-reviewed, mean age 44.9, 15 authors, study period 10 November, 2020 - 2 June, 2021, dosage 400IU daily, this trial uses multiple treatments in the treatment arm (combined with cod liver oil) - results of individual treatments may vary, trial NCT04609423 (history). risk of ICU admission, 0.3% higher, RR 1.00, p = 1.00, treatment 4 of 17,278 (0.0%), control 4 of 17,323 (0.0%).
risk of hospitalization, 10.9% lower, RR 0.89, p = 1.00, treatment 8 of 17,278 (0.0%), control 9 of 17,323 (0.1%), NNT 17692.
risk of severe case, 20.0% higher, RR 1.20, p = 0.17, treatment 121 of 17,278 (0.7%), control 101 of 17,323 (0.6%).
risk of case, no change, RR 1.00, p = 0.98, treatment 227 of 17,278 (1.3%), control 228 of 17,323 (1.3%), NNT 42377.
Campi, 6/14/2021, prospective, Italy, peer-reviewed, 21 authors, dosage not specified, excluded in exclusion analyses: significant unadjusted differences between groups. risk of severe case, 88.4% lower, OR 0.12, p < 0.001, treatment 31 of 103 (30.1%) cases, 41 of 52 (78.8%) controls, NNT 2.3, case control OR, vitamin D supplementation, hospitalized patients vs. controls.
Cangiano, 12/22/2020, retrospective, Italy, peer-reviewed, 14 authors, dosage 25,000IU 2x per month. risk of death, 70.0% lower, RR 0.30, p = 0.04, treatment 3 of 20 (15.0%), control 39 of 78 (50.0%), NNT 2.9.
Cereda, 11/11/2020, retrospective, Italy, peer-reviewed, mean age 68.8, 7 authors, dosage varies. risk of death, 73.0% higher, RR 1.73, p = 0.14, treatment 7 of 18 (38.9%), control 40 of 152 (26.3%), odds ratio converted to relative risk, >=25,000IU/month for at least 3 months.
risk of hospitalization, 17.3% higher, RR 1.17, p = 0.68, treatment 7 of 27 (25.9%), control 36 of 170 (21.2%), odds ratio converted to relative risk.
Comunale, 1/24/2024, retrospective, USA, peer-reviewed, 6 authors, study period November 2020 - May 2021, dosage not specified, trial NCT04639375 (history). risk of symptomatic case, 91.0% lower, OR 0.09, p < 0.001, treatment 100, control 182, adjusted per study, multivariable, RR approximated with OR.
risk of case, 88.0% lower, OR 0.12, p = 0.001, treatment 100, control 182, adjusted per study, multivariable, RR approximated with OR.
De Nicolò, 12/29/2022, prospective, Italy, peer-reviewed, 11 authors, study period January 2021 - April 2021, dosage not specified. risk of IgG positive, 88.4% lower, OR 0.12, p = 0.002, treatment 43, control 63, adjusted per study, multivariable, RR approximated with OR.
Dudley, 5/18/2021, retrospective, United Kingdom, peer-reviewed, 5 authors, dosage 800IU daily. risk of symptomatic case, 22.4% lower, RR 0.78, p = 0.65, treatment 15 of 58 (25.9%), control 2 of 6 (33.3%), NNT 13, positive test.
Fasano, 6/2/2021, retrospective, Italy, peer-reviewed, 7 authors, dosage not specified. risk of case, 42.0% lower, RR 0.58, p = 0.048, treatment 13 of 329 (4.0%), control 92 of 1,157 (8.0%), NNT 25, odds ratio converted to relative risk.
Gibbons, 11/12/2022, retrospective, USA, peer-reviewed, 7 authors, dosage varies. risk of death, 33.3% lower, HR 0.67, p < 0.001, treatment 5,315 of 199,498 (2.7%), control 6,591 of 199,498 (3.3%), D3, propensity score matching, Cox proportional hazards.
risk of death, 23.5% lower, HR 0.77, p = 0.10, treatment 716 of 33,216 (2.2%), control 987 of 33,216 (3.0%), NNT 123, D2, propensity score matching, Cox proportional hazards.
risk of case, 20.3% lower, HR 0.80, p < 0.001, treatment 462 of 199,498 (0.2%), control 689 of 199,498 (0.3%), D3, propensity score matching, Cox proportional hazards.
risk of case, 28.0% lower, HR 0.72, p < 0.001, treatment 65 of 33,216 (0.2%), control 86 of 33,216 (0.3%), NNT 1582, D2, propensity score matching, Cox proportional hazards.
Golabi (B), 8/26/2021, retrospective, Iran, peer-reviewed, 10 authors, dosage not specified. risk of case, 25.4% higher, OR 1.25, p = 0.56, treatment 28 of 53 (52.8%) cases, 25 of 53 (47.2%) controls, case control OR.
Guldemir, 11/16/2022, retrospective, Turkey, peer-reviewed, 3 authors, study period 30 March, 2020 - 23 September, 2020, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of hospitalization, 5.2% lower, RR 0.95, p = 0.89 (Fisher's exact test), treatment 19 of 81 (23.5%), control 98 of 396 (24.7%), NNT 77.
Hernández (B), 10/27/2020, retrospective, Spain, peer-reviewed, mean age 60.9, 12 authors, dosage varies. risk of death, 3.7% higher, RR 1.04, p = 1.00, treatment 2 of 19 (10.5%), control 20 of 197 (10.2%).
risk of mechanical ventilation, 75.9% lower, RR 0.24, p = 0.13, treatment 1 of 19 (5.3%), control 43 of 197 (21.8%), NNT 6.0.
risk of ICU admission, 79.3% lower, RR 0.21, p = 0.05, treatment 1 of 19 (5.3%), control 50 of 197 (25.4%), NNT 5.0.
hospitalization time, 33.3% lower, relative time 0.67, p = 0.11, treatment 19, control 197.
Holt, 3/30/2021, prospective, United Kingdom, peer-reviewed, 34 authors, study period 1 May, 2020 - 5 February, 2021, dosage not specified, trial NCT04330599 (history) (COVIDENCE UK), excluded in exclusion analyses: significant unadjusted confounding possible. risk of case, 6.8% lower, RR 0.93, p = 0.53, treatment 141 of 5,640 (2.5%), control 305 of 9,587 (3.2%), adjusted per study, odds ratio converted to relative risk, fully adjusted, group sizes approximated.
Hosseini (C), 7/19/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, preprint, mean age 39.5, 9 authors, study period 8 February, 2021 - 4 May, 2021, dosage 100,000IU day 1, 10,000IU day 7, 10,000IU day 14, 10,000IU day 21, 10,000IU day 28, 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks, trial NCT04483635 (history) (PROTECT). risk of case, 81.9% lower, RR 0.18, p = 0.19, treatment 0 of 19 (0.0%), control 2 of 15 (13.3%), NNT 7.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Israel (B), 7/27/2021, retrospective, Israel, peer-reviewed, 10 authors, dosage not specified. risk of hospitalization, 13.1% lower, OR 0.87, p = 0.003, treatment 737 of 6,953 (10.6%) cases, 1,669 of 13,906 (12.0%) controls, NNT 33, case control OR, PCR+, cohort 2.
Jabeen, 5/11/2022, prospective, Pakistan, peer-reviewed, 7 authors, dosage 200,000IU single dose. risk of symptomatic case, 88.9% lower, RR 0.11, p = 0.11, treatment 0 of 20 (0.0%), control 4 of 20 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Jimenez, 7/26/2021, retrospective, Spain, peer-reviewed, 21 authors, study period 12 March, 2020 - 21 May, 2020, dosage paricalcitol 0.9μg weekly. risk of death, 50.1% lower, HR 0.50, p = 0.02, treatment 16 of 94 (17.0%), control 65 of 191 (34.0%), NNT 5.9, adjusted per study, paricalcitol treatment, multivariate Cox regression.
risk of death, 50.7% lower, HR 0.49, p = 0.003, all vitamin D derivatives, univariate.
Jolliffe, 3/23/2022, Randomized Controlled Trial, United Kingdom, peer-reviewed, median age 60.2, 25 authors, study period December 2020 - June 2021, dosage 3,200IU daily, daily, trial NCT04579640 (history) (CORONAVIT). risk of mechanical ventilation, 94.7% higher, RR 1.95, p = 1.00, treatment 1 of 1,515 (0.1%), control 1 of 2,949 (0.0%), 3200IU/day.
risk of mechanical ventilation, 94.7% higher, RR 1.95, p = 1.00, treatment 1 of 1,515 (0.1%), control 1 of 2,949 (0.0%), 800IU/day.
risk of hospitalization, 41.1% higher, RR 1.41, p = 0.16, treatment 29 of 1,515 (1.9%), control 40 of 2,949 (1.4%), 3200IU/day.
risk of hospitalization, 16.8% higher, RR 1.17, p = 0.60, treatment 24 of 1,515 (1.6%), control 40 of 2,949 (1.4%), 800IU/day.
risk of case, 8.8% higher, RR 1.09, p = 0.55, treatment 76 of 1,515 (5.0%), control 136 of 2,949 (4.6%), 3200IU/day.
risk of case, 24.5% higher, RR 1.25, p = 0.11, treatment 87 of 1,515 (5.7%), control 136 of 2,949 (4.6%), 800IU/day.
risk of case, 12.3% higher, RR 1.12, p = 0.56, treatment 45 of 1,515 (3.0%), control 78 of 2,949 (2.6%), confirmed, 3200IU/day.
risk of case, 37.3% higher, RR 1.37, p = 0.08, treatment 55 of 1,515 (3.6%), control 78 of 2,949 (2.6%), confirmed, 800IU/day.
Junior, 2/17/2022, prospective, Brazil, peer-reviewed, 6 authors, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 22.1% lower, RR 0.78, p = 0.61, treatment 8 of 113 (7.1%), control 8 of 88 (9.1%), NNT 50.
risk of progression, 30.8% lower, RR 0.69, p = 0.26, treatment 16 of 113 (14.2%), control 18 of 88 (20.5%), NNT 16, respiratory failure.
Levitus, 5/3/2021, retrospective, USA, peer-reviewed, 9 authors, dosage varies. risk of severe case, 30.8% lower, RR 0.69, p = 0.25, treatment 65, control 64, odds ratio converted to relative risk, ≥1,000IU, control prevalence approximated with overall prevalence.
risk of severe case, 40.0% lower, RR 0.60, p = 0.15, treatment 65, control 64, odds ratio converted to relative risk, ≥5,000IU, control prevalence approximated with overall prevalence.
risk of severe case, no change, RR 1.00, p = 0.92, treatment 65, control 64, odds ratio converted to relative risk, ≥50,000IU, control prevalence approximated with overall prevalence.
Levy, 1/31/2022, retrospective, Israel, peer-reviewed, 10 authors, dosage not specified. risk of death/hospitalization, 30.0% lower, HR 0.70, p = 0.05, treatment 39 of 208 (18.8%), control 168 of 641 (26.2%), NNT 13, adjusted per study, multivariable, Cox proportional hazards, day 40.
Louca, 11/30/2020, retrospective, population-based cohort, United Kingdom, peer-reviewed, mean age 49.6, 26 authors, dosage not specified. risk of case, 7.5% lower, RR 0.92, p < 0.001, odds ratio converted to relative risk, United Kingdom, all adjustment model.
Loucera, 4/29/2021, retrospective, propensity score matching, Spain, peer-reviewed, 11 authors, dosage varies (calcifediol). risk of death, 33.0% lower, HR 0.67, p = 0.009, treatment 374, control 374, calcifediol, <15 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 27.0% lower, HR 0.73, p = 0.02, treatment 439, control 439, calcifediol, <30 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 25.0% lower, HR 0.75, p = 0.005, treatment 570, control 570, cholecalciferol, <15 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 12.0% lower, HR 0.88, p = 0.11, treatment 802, control 802, cholecalciferol, <30 days before hospitalization, Cox model with inverse propensity weighting.
Lázaro, 9/5/2021, retrospective, Spain, preprint, 9 authors, dosage not specified, excluded in exclusion analyses: very few events; unadjusted results with no group details; minimal details provided. risk of case, 26.8% lower, RR 0.73, p = 1.00, treatment 1 of 97 (1.0%), control 2 of 142 (1.4%), NNT 265.
Ma, 12/3/2021, retrospective, USA, peer-reviewed, 16 authors, study period May 2020 - March 2021, dosage varies. risk of hospitalization, 49.0% lower, OR 0.51, p = 0.04, treatment 26,605, control 12,710, adjusted per study, supplementation ≥400 IU/day, model 3, supplemental table 3, multivariable, RR approximated with OR.
risk of symptomatic case, 7.0% higher, OR 1.07, p = 0.25, treatment 7,895, control 31,420, adjusted per study, supplementation ≥2000 IU/day vs. <400 IU/day, model 3, supplemental table 3, multivariable, RR approximated with OR.
risk of case, 17.0% lower, OR 0.83, p = 0.07, treatment 7,895, control 31,420, adjusted per study, supplementation ≥2000 IU/day vs. <400 IU/day, model 3, supplemental table 3, multivariable, RR approximated with OR.
Ma (B), 1/29/2021, retrospective, United Kingdom, peer-reviewed, 4 authors, dosage not specified. risk of case, 30.0% lower, RR 0.70, p = 0.03, treatment 49 of 363 (13.5%), control 1,329 of 7,934 (16.8%), adjusted per study, odds ratio converted to relative risk.
Mahmood, 12/29/2021, retrospective, United Kingdom, peer-reviewed, 4 authors, study period 23 March, 2020 - 31 December, 2020, dosage varies, excluded in exclusion analyses: unadjusted results with no group details; substantial unadjusted confounding by indication likely. risk of death, 9.4% lower, RR 0.91, p = 0.67, treatment 34 of 138 (24.6%), control 31 of 114 (27.2%), NNT 39, prescribed by GP.
Meltzer (C), 3/19/2021, retrospective, database analysis, USA, peer-reviewed, 6 authors, dosage not specified. risk of case, 36.0% lower, RR 0.64, p = 0.38, treatment 6 of 131 (4.6%), control 239 of 3,338 (7.2%), NNT 39, >=2,000IU/d.
risk of case, 31.1% lower, RR 0.69, p = 0.16, treatment 15 of 304 (4.9%), control 239 of 3,338 (7.2%), NNT 45, >=1,001IU/d.
risk of case, 8.9% lower, RR 0.91, p = 0.56, treatment 60 of 920 (6.5%), control 239 of 3,338 (7.2%), NNT 157, >=1IU/d.
Mohseni, 8/4/2021, retrospective, Iran, peer-reviewed, 4 authors, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of case, 12.4% lower, RR 0.88, p = 0.09, treatment 99 of 192 (51.6%), control 242 of 411 (58.9%), NNT 14.
Nimer, 2/28/2022, retrospective, Jordan, peer-reviewed, survey, 4 authors, study period March 2021 - July 2021, dosage not specified. risk of hospitalization, 33.3% lower, RR 0.67, p = 0.001, treatment 66 of 796 (8.3%), control 153 of 1,352 (11.3%), NNT 33, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of severe case, 29.0% lower, RR 0.71, p = 0.01, treatment 81 of 796 (10.2%), control 179 of 1,352 (13.2%), NNT 33, adjusted per study, odds ratio converted to relative risk, multivariable.
Oristrell, 7/17/2021, retrospective, population-based cohort, Spain, peer-reviewed, 8 authors, dosage varies (calcifediol). risk of death, 1.0% higher, RR 1.01, p = 0.91, calcifediol, univariate.
risk of death, 4.0% lower, RR 0.96, p = 0.37, cholecalciferol, univariate.
risk of case, 1.0% lower, RR 0.99, p = 0.65, NNT 3499, calcifediol, univariate.
risk of case, 5.0% lower, RR 0.95, p = 0.004, cholecalciferol, multivariate.
Oristrell (B), 4/6/2021, retrospective, Spain, peer-reviewed, 10 authors, dosage calcitriol 0.3μg daily, mean daily dose. risk of death, 43.0% lower, HR 0.57, p = 0.001, treatment 2,296, control 3,407, multivariate, patients with CKD stages 4-5.
risk of severe case, 43.0% lower, HR 0.57, p < 0.001, treatment 2,296, control 3,407, multivariate, patients with CKD stages 4-5.
risk of case, 22.0% lower, HR 0.78, p = 0.01, treatment 163 of 2,296 (7.1%), control 326 of 3,407 (9.6%), NNT 40, multivariate, patients with CKD stages 4-5.
Parant, 4/14/2022, retrospective, France, peer-reviewed, median age 78.0, 12 authors, study period 1 March, 2020 - 30 June, 2020, dosage varies, trial NCT04877509 (history). risk of death, 50.5% lower, RR 0.50, p = 0.11, treatment 7 of 66 (10.6%), control 28 of 162 (17.3%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of ICU admission, 51.2% lower, RR 0.49, p = 0.008, treatment 10 of 66 (15.2%), control 74 of 162 (45.7%), NNT 3.3, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of severe case, 38.7% lower, RR 0.61, p = 0.01, treatment 19 of 66 (28.8%), control 86 of 162 (53.1%), NNT 4.1, adjusted per study, odds ratio converted to relative risk, multivariable.
Pecina, 8/27/2021, retrospective, USA, peer-reviewed, 4 authors, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of death, 70.0% higher, OR 1.70, p = 0.52, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR.
risk of mechanical ventilation, 10.0% higher, OR 1.10, p = 0.89, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR.
risk of ICU admission, 30.0% higher, OR 1.30, p = 0.61, treatment 29, control 63, supplementation, unadjusted, RR approximated with OR.
Regalia, 1/13/2022, retrospective, Italy, peer-reviewed, 10 authors, dosage varies. risk of case, 33.0% lower, OR 0.67, p = 0.21, treatment 32 of 60 (53.3%) cases, 75 of 119 (63.0%) controls, NNT 11, case control OR, vitamin D supplementation for ≥3 months in the last year.
Sainz-Amo, 10/24/2020, retrospective, Spain, peer-reviewed, mean age 74.5, 13 authors, dosage not specified. risk of severe case, 32.7% lower, OR 0.67, p = 0.45, treatment 5 of 29 (17.2%) cases, 43 of 182 (23.6%) controls, NNT 23, case control OR.
risk of case, 43.7% lower, OR 0.56, p = 0.23, treatment 6 of 39 (15.4%) cases, 42 of 172 (24.4%) controls, NNT 13, case control OR.
Sharif, 11/26/2022, retrospective, Bangladesh, peer-reviewed, 14 authors, study period 13 December, 2020 - 4 February, 2021, dosage 2,000IU daily. risk of severe case, 28.0% lower, OR 0.72, p = 0.001, adjusted per study, multivariable, RR approximated with OR.
risk of severe case, 97.0% lower, OR 0.03, p = 0.005, adjusted per study, combined use of vitamin C, vitamin D, and zinc, multivariable, RR approximated with OR.
Shehab, 2/28/2022, retrospective, multiple countries, peer-reviewed, survey, 7 authors, study period September 2020 - March 2021, dosage not specified, excluded in exclusion analyses: unadjusted results with no group details. risk of severe case, 45.7% lower, RR 0.54, p = 0.20, treatment 6 of 90 (6.7%), control 20 of 163 (12.3%), NNT 18, unadjusted, severe vs. mild cases.
Sinaci, 8/11/2021, retrospective, Turkey, peer-reviewed, 10 authors, dosage not specified. risk of severe case, 90.0% lower, RR 0.10, p = 0.35, treatment 0 of 36 (0.0%), control 7 of 123 (5.7%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), supplementation.
risk of moderate/severe case, 18.8% higher, RR 1.19, p = 0.64, treatment 8 of 36 (22.2%), control 23 of 123 (18.7%), supplementation.
Subramanian, 1/31/2022, prospective, United Kingdom, peer-reviewed, 16 authors, dosage not specified. risk of death, 27.3% lower, RR 0.73, p = 0.12, treatment 31 of 131 (23.7%), control 80 of 336 (23.8%), adjusted per study, odds ratio converted to relative risk, prescribed supplement use, multivariable.
Sulli, 2/24/2021, retrospective, Italy, peer-reviewed, 10 authors, dosage not specified. risk of case, 75.6% lower, OR 0.24, p < 0.001, treatment 22 of 65 (33.8%) cases, 44 of 65 (67.7%) controls, NNT 3.0, case control OR, vitamin D supplementation.
Tylicki, 1/6/2022, retrospective, Poland, peer-reviewed, 10 authors, study period 6 October, 2020 - 28 February, 2021, dosage not specified. risk of death, 14.4% lower, RR 0.86, p = 0.61, treatment 28 of 85 (32.9%), control 25 of 48 (52.1%), NNT 5.2, adjusted per study, odds ratio converted to relative risk, multivariable.
Ullah, 3/4/2021, retrospective, United Kingdom, peer-reviewed, 3 authors, dosage not specified, excluded in exclusion analyses: significant unadjusted confounding possible. risk of death, 42.1% higher, RR 1.42, p = 0.34, treatment 21 of 64 (32.8%), control 26 of 135 (19.3%), adjusted per study, odds ratio converted to relative risk.
risk of case, 146.0% higher, RR 2.46, p < 0.001, treatment 69 of 2,168 (3.2%), control 139 of 12,681 (1.1%), adjusted per study, odds ratio converted to relative risk.
van Helmond, 9/17/2022, prospective, USA, peer-reviewed, 14 authors, study period 27 October, 2020 - 31 January, 2021, dosage 5,000IU daily, trial NCT04596657 (history). risk of case, 97.5% lower, RR 0.02, p = 0.07, treatment 0 of 255 (0.0%), control 36 of 2,827 (1.3%), NNT 79, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Vasheghani, 1/18/2021, retrospective, Iran, preprint, 6 authors, dosage not specified. risk of death, 30.4% lower, RR 0.70, p = 0.45, treatment 7 of 88 (8.0%), control 48 of 420 (11.4%), NNT 29, vitamin D supplementation.
risk of ICU admission, 63.8% lower, RR 0.36, p = 0.009, treatment 13 of 185 (7.0%), control 53 of 323 (16.4%), NNT 11, adjusted per study, inverted to make RR<1 favor treatment, vitamin D levels >30ng/mL.
Villasis-Keever, 4/18/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, 16 authors, study period 15 July, 2020 - 30 December, 2020, dosage 4,000IU daily. risk of hospitalization, 66.5% lower, RR 0.33, p = 1.00, treatment 0 of 150 (0.0%), control 1 of 152 (0.7%), NNT 152, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), ITT.
risk of case, 78.0% lower, RR 0.22, p = 0.001, treatment 7 of 150 (4.7%), control 26 of 152 (17.1%), NNT 8.0, adjusted per study, multivariable, Table 3.
Wang (C), 3/29/2023, Randomized Controlled Trial, China, peer-reviewed, median age 36.5, 23 authors, study period 18 December, 2022 - 20 February, 2023, dosage 200,000IU days 1, 14, trial NCT05673980 (history). risk of progression, 25.2% lower, RR 0.75, p = 0.15, treatment 99, control 103, combined symptoms.
risk of progression, 4.0% higher, RR 1.04, p = 1.00, treatment 5 of 99 (5.1%), control 5 of 103 (4.9%), risk of severe case, fever.
risk of progression, 7.5% lower, RR 0.92, p = 1.00, treatment 8 of 99 (8.1%), control 9 of 103 (8.7%), NNT 152, risk of severe case, sore throat.
risk of progression, 42.2% lower, RR 0.58, p = 0.41, treatment 5 of 99 (5.1%), control 9 of 103 (8.7%), NNT 27, risk of severe case, rhinorrhea or congestion.
risk of progression, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 99 (0.0%), control 1 of 103 (1.0%), NNT 103, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), risk of severe case, diarrhea.
risk of progression, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 99 (0.0%), control 1 of 103 (1.0%), NNT 103, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), risk of severe case, vomiting.
risk of progression, 13.3% lower, RR 0.87, p = 0.82, treatment 10 of 99 (10.1%), control 12 of 103 (11.7%), NNT 65, risk of severe case, cough.
risk of progression, 48.0% lower, RR 0.52, p = 0.13, treatment 8 of 99 (8.1%), control 16 of 103 (15.5%), NNT 13, risk of severe case, muscle/joint aches.
risk of progression, 56.1% higher, RR 1.56, p = 0.68, treatment 3 of 99 (3.0%), control 2 of 103 (1.9%), risk of severe case, taste/smell.
risk of case, 3.7% lower, RR 0.96, p = 0.89, treatment 50 of 99 (50.5%), control 54 of 103 (52.4%), NNT 52.
risk of case, 15.0% higher, RR 1.15, p = 0.47, treatment 42 of 99 (42.4%), control 38 of 103 (36.9%), first two weeks.
risk of case, 48.0% lower, RR 0.52, p = 0.13, treatment 8 of 99 (8.1%), control 16 of 103 (15.5%), NNT 13, last two weeks.
Ünsal (B), 4/5/2021, retrospective, Turkey, peer-reviewed, 10 authors, dosage varies. risk of pneumonia, 71.4% lower, RR 0.29, p = 0.009, treatment 4 of 28 (14.3%), control 14 of 28 (50.0%), NNT 2.8, average 800-1000IU/day cholecalciferol.
Şengül, 12/31/2022, retrospective, Turkey, peer-reviewed, 4 authors, study period March 2020 - December 2021, dosage not specified. risk of case, 68.5% lower, OR 0.31, p = 0.004, treatment 8 of 54 (14.8%) cases, 94 of 264 (35.6%) controls, NNT 7.4, case control OR.